<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/228089-pyrazolo-3-4-b-pyridine-compounds-and-their-use-as-phosphodiesterase-inhibitors by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 08:39:29 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 228089:PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS .</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS .</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention relates to a compound of formula (I) or a salt thereof: Formula (I) wherein: Rl is C1-4alkyl, C1-3fluo- roalkyl or -(CH2)2OH; R2 is a hydrogen atom (H), methyl or C1fluoroalkyl; R3a is a hydrogen atom (H) or C1-3alkyl; R3 is optionally substituted branched C3-6alkyl, optionally substituted C3-8cycloalkyl, optionally substituted mono-unsaturated-C5-7cycloalkenyl, op tionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), or (bb) or (cc) in which nl and n2 independently are 1 or 2; and Y is O, S, SO2, or NR4; and wherein Het is of sub-formula (i), or (ii), or (iii), or (iv) or (v). The com- pounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase<br>
inhibitors<br>
The present invention relates to pyrazolopyridine compounds, processes for their<br>
preparation, intermediates usable in these processes, and pharmaceutical compositions<br>
containing the compounds. The invention also relates to the use of the pyrazolopyridine<br>
compounds in therapy, for example as inhibitors of phosphodiesterases (PDE) and/or for<br>
the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic<br>
obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis.<br>
US 3,979,399, US 3,840,546, and US 3,966,746 (E.R.Squibb &amp; Sons) disclose 4-amino<br>
derivatives of pyrazolo[3,4-b]pyridine-5-carboxamides wherein the 4-amino group<br>
NR3R4 can be an acyclic amino group wherein R3 and R4 may each be hydrogen, lower<br>
alkyl (e.g. butyl), phenyl, etc.; NR3R4 can alternatively be a 3-6-membered heterocyclic<br>
group such as pyrrolidino, piperidino and piperazino. The compounds are disclosed as<br>
central nervous system depressants useful as ataractic, analgesic and hypotensive agents.<br>
US 3,925,388, US 3,856,799, US 3,833,594 and US 3,755,340 (E.R.Squibb &amp; Sons)<br>
disclose 4-amino derivatives of pyrazolo[3,4-b]pyridine-5-carboxylic acids and esters.<br>
The 4-amino group NR3R4 can be an acyclic amino group wherein R3 and R4 may each<br>
be hydrogen, lower alkyl (e.g. butyl), phenyl, etc.; NR3R4 can alternatively be a 5-6-<br>
mernbered heterocyclic group in which an additional nitrogen is present such as<br>
pyrrolidino, piperidino, pyrazolyl, pyrimidinyl, pyridazinyl or piperazinyl. The<br>
compounds are mentioned as being central nervous system depressants useful as ataractic<br>
agents or tranquilisers, as having antiinflammatory and analgesic properties. The<br>
compounds are mentioned as increasing the intracellular concentration of adenosine-3',5'-<br>
cyclic monophosphate and for alleviating the symptoms of asthma.<br>
H. Hoehn et al., J. Heterocycl. Chem., 1972, 9(2), 235-253 discloses a series of 1H-<br>
pyrazolo[3,4-b]pyridine-5-carboxylic acid derivatives with 4-hydroxy, 4-chloro,<br>
4-alkoxy, 4-hydrazino, and 4-amino substituents.<br>
CA 1003419, CH 553 799 and T.Denzel, Archiv der Pharmazie, 1974, 307(3), 177-186<br>
disclose 4,5-disubstituted 1H-pyrazolo[3,4-b]pyridines unsubstituted at the 1-position.<br>
US 3,833,598 and GB 1,417,489 (E.R.Squibb &amp; Sons) disclose 4-amino derivatives of<br>
pyrazolo[3,4-b]pyridine-6-carboxylic acids and esters. The 4-amino group NR3R4 can<br>
be an acyclic amino group wherein R3 and R4 may each be hydrogen, lower alkyl,<br>
R6,R7-phenyl, etc.; or NR3R4 can be a 5-6-membered heterocyclic group in which an<br>
additional nitrogen is present, namely optionally substituted pyrrolidino, piperidino,<br>
pyrazolyl, dihydropyridazinyl or piperazinyl. At the 5-position of the pyrazolo[3,4-<br>
b]pyridine is group R5 which is hydrogen, lower alkyl, phenyl, phenyl-lower-alkyl or<br><br>
halogen; R5 is preferably hydrogen, methyl or chlorine. The compounds are mentioned as<br>
being central nervous system depressants useful as tranquilizers or ataractic agents for the<br>
relief of anxiety and tension states. The compounds are also mentioned as increasing the<br>
intracellular concentration of adenosine-3',5'-cyclic monophosphate and for alleviating<br>
the symptoms of asthma. The compounds are also mentioned as having anti-<br>
inflammatory properties and as being useful as anti-inflammatory agents, for example, to<br>
reduce local inflammatory conditions such as those of an edematous nature or resulting<br>
from proliferation of connective tissue in various mammalian species such as rats and<br>
dogs.<br>
US 4,115,394 and GB 1,511,006 (E.R.Squibb &amp; Sons) disclose 4-amino derivatives of 6-<br>
phenyl-pyrazolo[3,4-b]pyridines. The 4-amino group NR3R4 is an acyclic amino group<br>
wherein R3 and R4 may each be hydrogen, lower alkyl, phenyl, phenyl-lower-alkyl or<br>
substituted phenyl. At the 5-position of the pyrazolo[3,4-b]pyridine is group R5 which is<br>
hydrogen, lower alkyl, phenyl or phenyl-lower-alkyl; R5 is preferably hydrogen. The<br>
compounds are mentioned as having anti-inflammatory properties and as being useful as<br>
anti-inflammatory agents, for example, to reduce local inflammatory conditions such as<br>
those of an edematous nature or resulting from proliferation of connective tissue in<br>
various mammalian species such as rats and dogs. The compounds are also mentioned<br>
(a) as having diuretic activity, and (b) as increasing the intracellular concentration of<br>
adenosme-3',5'-cyclic monophosphate and for alleviating the symptoms of asthma.<br>
Japanese laid-open patent application JP-2002-20386-A (Ono Yakuhin Kogyo KK)<br>
published on 23 January 2002 discloses pyrazoiopyridine compounds of the following<br>
formula: <br>
wherein R1 denotes 1) a group -OR6, 2) a group -SR7,3) a C2-8 alkynyl group, 4) a nitro<br>
group, 5) a cyano group, 6) a C1-8 alkyl group substituted by a hydroxy group or a C1-8<br>
alkoxy group, 7) a phenyl group, 8) a group -C(O)R8,9) a group -SO2NR9R10 10) a<br>
group -KR11 SO2Rl2 11) a group -NR13C(O)RM or 12) a group -CH=NR15 R6 and R7<br>
denote,) a hydrogen atom, ii) a C1-8 alkyl group, iii) a C1-8 alkyl group substituted by a<br>
C1-8 alkoxy group, iv) a trihalomethyl group, y) a C3-7 cycloalkyl group, vi) a C1-8<br>
alkyl group substituted by a phenyl group or vii) a 3-15 membered mono-, di- or tricyclic<br>
hetero ring containing 1-4 nitrogen atoms, 1-3 oxygen atoms and/or 1-3 sulphur atoms<br>
R denotes 1) a hydrogen atom or 2) a C1-8 alkoxy group. R3 denotes 1) a hydrogen<br><br>
atom or 2) a C1-8 alkyl group. R4 denotes 1) a hydrogen atom, 2) a C1-8 alkyl group, 3)<br>
a C3-7 cycloalkyl group, 4) a C1-8 alkyl group substituted by a C3-7 cycloalkyl group, 5)<br>
a phenyl group which may be substituted by 1-3 halogen atoms or 6) a 3-15 membered<br>
mono-, di- or tricyclic hetero ring containing 1-4 nitrogen atoms, 1-3 oxygen atoms<br>
and/or 1-3 sulphur atoms. R5 denotes 1) a hydrogen atom, 2) a C1-8 alkyl group, 3) a C3-<br>
7 cycloalkyl group, 4) a C1-8 alkyl group substituted by a C3-7 cycloalkyl group or 5) a<br>
phenyl group which maybe substituted by 1-3 substituents. In group R3, a hydrogen<br>
atom is preferred. In group R4, methyl, ethyl, cyclopropyl, cyclobutyl or cyclopentyl are<br>
preferred. The compounds of JP-2002-203 86-A are stated as having PDE4 inhibitory<br>
activity and as being useful in the prevention and/or treatment of inflammatory diseases<br>
and many other diseases.<br>
EP 0 076 035 A1 (ICI Americas) discloses pyrazolo[3,4-b]pyridine derivatives as central<br>
nervous system depressants useful as tranquilisers or ataractic agents for the relief of<br>
anxiety and tension states.<br>
The compound cartazolate, ethyl 1-ethyl-4-n-butylamiao-1H-pyrazolo[3,4-b]-pyridine-5-<br>
carboxylate, is known. J.W. Daly et al., Med. Chem. Res., 1994,4,293-306 and D. Shi<br>
et al., Drug Development Research, 1997,42,41-56 disclose a series of<br>
4-(amino)substituted 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid derivatives, including<br>
ethyl 4-cyclopentylammo-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate, and their<br>
affinities and antagonist activities at A1- and A2A-adenosine receptors, and the latter<br>
paper discloses their affinities at various binding sites of the GABAA-receptor channel.<br>
S. Schenone et al, Bioorg. Med. Chem. Lett., 2001,11, 2529-2531, and F. Bondavalli et<br>
al., J. Med. Chem., 2002, vol. 45 (Issue 22, 24 October 2002, allegedly published on the<br>
Web on 09/24/2002), pp. 4875-4887, disclose a series of 4-amino-1-(2-chloro-2-<br>
phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters as A1-adenosine<br>
receptor ligands.<br>
WO 02/060900 A2 appears to disclose, as MCP-1 antagonists for treatment of allergic,<br>
inflammatory or autoimmune disorders or diseases, a series of bicyclic heterocyclic<br>
compounds with a -C(O)-NR4-C(O)-NR5R6 substituent, including isoxazolo[5,4-<br>
hjpyridines and 1H-pyrazolo[3,4-b]pyridines (named as pyrazolo[5,4-b]pyridines) with<br>
the -C(O)-NR4-C(O)-NR5R6 group as the 5-substituent and optionally substituted at the<br>
1-, 3-, 4-, and/or 6-positions. Bicyclic heterocyclic compounds with a -C(O)NH2<br>
substituent instead of the -C(O)-NR4-C(O)-NR5R6 substituent are alleged to be disclosed<br>
in WO 02/060900 as intermediates in the synthesis of the -C(O)-NR4-C(O)-NR5R6<br>
substituted compounds.<br>
S.S.Chakravorti et al., Indian J. Chem., 1978,16B(2), 161-3 discloses the compounds<br>
4-hydroxy-l,3-diphenyl-5-(3',4'-dihydroisoqumo1-1'-yl)-pyrazolo[3,4-b]pyridineand<br>
l,3-diphenyl-4-hydroxy-5-(3'-methyl-3',4'-dihydroisoquino1-l'-yl)-<br><br>
pyrazolo[3,4-b]pyridine. These two compounds were tested for antifilarial activity but<br>
were found to have no significant microfilaricidal activity.<br>
G. Sabitha et al., Synthetic Commun., 1999,29(4), 655-665 discloses a synthetic route to<br>
5-substituted-6-ammo-1-phenyl-3-(me1hyl or phenyl)-pvrazolo[3,4-b]pyridines wherein<br>
the 5-substituent of the pyrazolo[3,4-b]pyridine is benzimidazo1-2-yl,<br>
5-chloro-benzoxazo1-2-yl, or benzothiazo1-2-yl. Though declared to be "biologically<br>
interesting molecules", there is however no disclosure that these compounds had been<br>
tested in any pharmacological tests and there is no disclosure of any general or specific<br>
biological activity of these compounds.<br>
On 8th April 2003, Chemical Abstracts (CAS) registered on their database a compound<br>
with the CAS Registry Number 502143-17-1, with the chemical name "1H-Pyrazolo[3,4-<br>
b]pyridin-4-amine, N-butyl-5-(4,5-dihydro-1H-imidazol-2- yl)-1-ethyl-" and bearing the<br>
laboratory code NSC 235755. As at 5th November 2003, the CAS entry for this<br>
compound had no associated literature references and therefore it appears that no<br>
chemical synthesis and no uses of the compound have been disclosed as at 5th November<br>
2003. The structure of the compound from the CAS database is as follows:<br><br>
It is desirable to find new compounds which bind to, and preferably inhibit,<br>
phosphodiesterase type TV (PDE4).<br>
The present invention provides a compound of formula (I) or a salt thereof (in particular,<br>
apharmaceutically acceptable salt thereof):<br><br>
wherein:<br>
R1 is C1-4alkyl, C1-3fluoroalkyl or -(CH2)2OH;<br>
R2 is a hydrogen atom (H), methyl or C1fluoroalkyl;<br><br>
R3 is optionally substituted branched C3-6alkyl, optionally substituted C3-8cycloalkyl,<br>
optionally substituted mono-unsaturated-C5-7cycloalkenyl, optionally substituted phenyl,<br>
or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc):<br>
in which n1 and n2 independently are 1 or 2; and Y is O, S, SO2, or NR4; where R4 is a<br>
hydrogen atom (H), C1-2alkyl, C1-2fluoroalkyl, CH2C(O)NH2, C(O)NH2,<br>
C(O)-C1-2alkyl, or C(O)-C1fluoroalkyl;<br>
wherein in R3 the optionally substituted branched Cs.galkyl is optionally substituted with<br>
one or two substituents being oxo (=O), OH, C1-2alkoxy or C1-2fluoroalkoxy; and<br>
wherein any such substituent is not substituted at the R3 carbon atom attached (bonded)<br>
to the -NH- group of formula (I);<br>
wherein in R3 the phenyl is optionally substituted with one substituent being fluoro,<br>
chloro, C1-2alkyl, C1-2fluoroalkyl, C1-2alkoxy, C1-2fluoroalkoxy or cyano, or with two<br>
or three fluoro substituents;<br>
wherein in R3 the C3-8cycloalkyl or the heterocyclic group of sub-formula (aa), (bb) or<br>
(cc) is optionally substituted with one or two substituents independently being (e.g.<br>
being) oxo (=O); OH; C1-2alkoxy; C1-2fluoroalkoxy; NHR21 wherein R21 is a<br>
hydrogen atom (H) or C1-4 straight-chain alkyi; C1-2alkyl; C1-2fluroalkyl (e.g.<br>
C1fluoroalkyl such as -CH2F or -CHF2); -CH2OH; -CH2CH2OH; -CH2NHR22 wherein<br>
R22 is H or C1-2alkyl; -C(O)OR23 wherein R23 is H or C1-2alkyl; -C(O)NHR24<br>
wherein R24 is H or C1-2alkyl; -C(O)R25 wherein R25 is C1-2alkyl; fluoro;<br>
hydroxyimino (=N-OH); or (C1-4alkoxy)imino (=N-OR26 where R26 is C1-4alkyl); and<br>
wherein any OH, alkoxy, fluoroalkoxy or NHR21 substituent is not substituted at the R3<br>
ring carbon attached (bonded) to the -NH- group of formula (I) and is not substituted at<br>
either R3 ring carbon bonded to the Y group of the heterocyclic group (aa), (bb) or (cc);<br>
and wherein, when R3 is optionally substituted mono-unsaturated-C5-7cycloalkenyl, then<br>
the cycloalkenyl is optionally substituted with one or two substituents independently<br>
being fluoro or C1-2alkyl provided that if there are two substituents then they are not<br>
both C2alkyl, and the R3 ring carbon bonded to the -NH- group of formula (I) does not<br>
partake in the cycloalkenyl double bond;<br><br>
and R3a is a hydrogen atom (H) or straight-chain C1-3alkyl;<br>
provided that when R3a is C1-3alkyl then R3 is tetrahydro-2H-pyran-4-yl, cyclohexyl<br>
(i.e. unsubstituted), 3-hydroxy-cyclohexyl, 4-oxo-cyclohexyl or<br>
4-(hydroxyimino)cyclohexyl;<br>
and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v):<br><br>
wherein:<br>
W1, W2, W4 and W5 is N; and W3 is NR.W ;<br>
X1, X3 and X4 is N or CRX; X2 is O, S or NRX ; and X5 is CRX1RX2 or CRX3RX4;<br>
Yl, Y2 and Y3 is CRY or N; Y4 is O, S or NRY ; and Y5 is CRY1RY2;<br>
Z1 and Z5 is O, S or NRZ; and Z2, Z3 and Z4 is N or CRZ;<br>
wherein:<br>
RW is a hydrogen atom (H) or C1-2alkyl;<br>
Rx, RX2, RY and RY2 independently are:<br>
a hydrogen atom (H);<br>
C1-8alkyl;<br>
C3-6cycloalkyl optionally substituted by one or two C1-2alkyl groups and/or by one<br>
oxo (=O) group;<br>
-(CH2)n2a-C3-6cycloalkyl optionally substituted, in the -(CH2)n2a- moiety or in<br>
the C3-6cycloalkyl moiety, by a C1-2alkyl group, or optionally substituted in<br>
the C3-6cycloalkyl moiety by a -CH2C(O)NHC1-2alkyl group, wherein n2a is<br>
1, 2 or 3;<br><br>
-(CH2)n3-S(O)2-R5, -CH(C1-2a]kyl)-S(O)2-R5, -CMe2-S(O)2-R5, or<br>
C~3-5cycloalkyl substituted at the connecting carbon atom by -S(O)2-R5,<br>
wherein n3 is 1 or 2;<br>
and R5 is C1-4alkyl (e.g. C1-3alkyl), -NR15R16, phenyl, carbon-linked-<br>
pyridinyl or benzyl (wherein the phenyl and benzyl are independently<br>
optionally substituted on the aromatic ring by one or two substituents<br>
independently being fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy,<br>
C1fluoroalkoxy or OH, and wherein the pyridinyl is optionally substituted by<br>
one methyl, methoxy or OH (including any tautomer thereof));<br>
wherein R15 is H, C1-4alkyl (e.g. C1-2alkyl), phenyl, benzyl (wherein the<br>
phenyl and benzyl are independently optionally substituted on the aromatic<br>
ring by one or two substituents independently being fluoro, chloro, C1-2alkyl,<br>
C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy), CH(Me)Ph, or carbon-linked-<br>
pyridinyl optionally substituted by one methyl, methoxy or OH (including any<br>
tautomer thereof);<br>
and R16 is H or C1-2alkyl;<br>
or wherein R15 and R16 together are -(CH2)n3a-X3a-(CH2)n3b- in which<br>
n3a and n3b independently are 2 or 3andX3a is a bond, -CH2-, O, orNR8a<br>
wherein R8a is H or C1-2alkyl, acetyl, -S(O)2Me or phenyl, and wherein the<br>
ring formed by NR15R16 is optionally substituted on a ring carbon by one or<br>
two substituents independently being methyl or oxo (=O);<br>
-(CH2)n4-NR6R7, -CH(C1-2alkyl)-NR6R7, -CMe2-NR6R7 or C~3-5cycloalkyl<br>
substituted at the connecting carbon atom by -NR6R7, wherein n4 is 0,1, 2 or<br>
3;<br>
and R6 and R7 independently are H, C1-6alkyl (e.g. C1-4alkyl),<br>
C3-6cycloalkyl, -CH2-C3-6cycloalkyl, -C(O)R17, -S(O)2R18, phenyl, benzyl<br>
(wherein the phenyl and benzyl are independently optionally substituted on<br>
the aromatic ring by one or two substituents independently being fluoro,<br>
chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy), or carbon-<br>
linked-pyridinyl optionally substituted by one methyl, methoxy or OH<br>
(including any tautomer thereof);<br>
and wherein R17 and Rl8 independently are C1-6alkyl (e.g. C1-4alkyl or<br>
C1-2alkyl or isopropyl or n-propyl), C3-6cycloalkyl, optionally substituted 5-<br>
membered heteroaryl being furyl (furanyl, e.g. 2-furyl) or 1,3-oxazolyl or<br>
isoxazolyl or oxadiazolyl or thienyl (e.g. 2- or 3- thienyl) or 1,3-thiazolyl or<br>
isothiazolyl or pyrrolyl or imidazolyl or pyrazolyl (all independently<br>
optionally substituted by one oxo and/or one or two methyl), or phenyl or<br>
benzyl (wherein the phenyl and benzyl are independently optionally<br>
substituted on the aromatic ring by one or two substituents independently<br><br>
being fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy, C1fluoroalkoxy<br>
or OH), or carbon-linked-pyridinyl optionally substituted, by one methyl,<br>
methoxy or OH (including any tautomer thereof);<br>
or R6 and R7 together are -(CH2)n5-X5-(CH2)n6- in which n5 and n6<br>
independently are 2 or 3 and X5 is a bond, -CH2-, O, or NR8 wherein R8 is H,<br>
C1-2alkyl, acetyl, -S(O)2Me or phenyl, and wherein the ring formed by<br>
NR^R7 is optionally substituted on a ring carbon by one or two substituents<br>
independently being methyl or oxo (=O);<br>
-(CH2)n7-0-R9; wherein n7 is 0,1,2 or 3 and R9 is H, C1-6alkyl, C3-6cycloalkyl,<br>
-CH2-C3-6cycloalkyl, -C(O)R17, phenyl, or benzyl (wherein the phenyl and<br>
benzyl are independently optionally substituted on the aromatic ring by one or<br>
two of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or<br>
C1fluoroalkoxy); wherein n7 is 0 only when the -(CH2)n7-O-R9 is bonded to<br>
a carbon atom in the Het ring; and wherein n7 is not 0 when Het is of sub-<br>
formula (v) (i.e. n7 is not 0 for RX2 and for RY2);<br>
-(CH2)n11-C(O)-NR10R11, -CHC1-2alkyl)-C(O)NR10R11,<br>
-CMe2-C(O)-NR10R11, or C~3-5cycloalkyl substituted at the connecting<br>
carbon atom by -C(O)-NR10R11, wherein n11 is 0,1 or 2;<br>
and wherein R10 and R11 independently are: H; C1-6alkyl;<br>
C1fluoroalkyl; C2-4alkyl substituted by one OH or -OC1-2alkyl other than<br>
at the connection point; C3-6cycloalkyl optionally substituted by one or two<br>
methyl groups; -CH2-C3-6cycloalkyl optionally substituted by one methyl,<br>
NH2 or NHMe group; -(CH2)n17-Het2; carbon-linked-pyridinyl optionally<br>
substituted by one methyl, methoxy or OH (including any tautomer thereof);<br>
phenyl; benzyl; or -CH(C1-2alkyl)Ph [wherein the phenyl, benzyl, and<br>
-CH(C1-2alkyl)Ph are independently optionally substituted on the aromatic<br>
ring by one or two substituents independently being: fluoro, chloro,<br>
C1-2alkyl, C1fluoroalkyl, C1-2alkoxy, C1fluoroalkoxy, OH, -NRl0aRl0b<br>
(wherein R10a is H or C1-2alkyl and Rl0b is H, C1-2alkyl, -C(O)-C1-2alkyl<br>
or -S(O)2-C1-2alkyl), -C(O)-NR10cR10d (wherein R10c andR10d<br>
independently are H or C1-2alkyl), or -S(O)2-R10e (wherein Rl0e is<br>
C1-2alkyl, NH2, NHMe or NMe2)],<br>
wherein n17 is 0,1 or 2 and wherein Het2 is a 4-, 5- or 6- membered<br>
saturated heterocyclic ring containing one O or S ring atom or one NR27 ring<br>
group wherein R27 is H, C1-2alkyl, -C(O)Me, or -S(O)2Me, wherein the Het2<br>
ring is optionally substituted on a ring carbon by one or two substituents<br>
independently being methyl or oxo (=O);<br><br>
and wherein when n17 is 2 then the Het2 ring can optionally contain one<br>
additional ring N atom at the Het2 ring position bonded to the -(CH2)n17-<br>
moiety; provided that, when Het2 contains one O or S or NR27 ring<br>
atom/group and one additional ring N atom, then the O/S/NR27 ring<br>
atom/group and the one additional ring N atom are not directly bonded to each<br>
other, and are separated by more than one carbon atom;<br>
or R10 and R11 together are -(CH2)n8-X6-(CH2)n9- in which n8 and n9<br>
independently are 2 or 3 and X6 is a bond, -CH2-, O, or NR12 wherein R12 is<br>
H, C1-2alkyl, acetyl, -S(O)2Me or phenyl, and wherein the ring formed by<br>
NR10R11 is optionally substituted on a ring carbon by one or two substitaents<br>
independently being methyl or oxo (=O);<br>
-(CH2)n12-C(O)-OR13 wherein n12 is 0,1 or 2; and wherein R13 is H, C1-6alkyl,<br>
C3-6cycloalkyl, -CH2-C3-6cycloalkyl, phenyl, or benzyl (wherein the phenyl<br>
and benzyl are independently optionally substituted on the aromatic ring by<br>
one or two of (independently) fluoro, chloro, C1-2alkyl, C1fluoroalkyl,<br>
C1-2alkoxy or C1fluoroalkoxy);<br>
-(CH2)n13-C(O)-R13a wherein n13 is 0,1 or 2; and wherein R13a is a hydrogen<br>
atom (H), C1-6alkyl, C1fluoroalkyl, C3-6cycloalkyl, -CH2-C3-6cycloalkyl,<br>
benzyl, or phenyl; wherein the phenyl and benzyl are independently optionally<br>
substituted on the aromatic ring by one or two of (independently) fluoro,<br>
chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy;<br>
-(CH2)n14-Het1,-CH(C1-2alkyl)-Het1, -CMe2-Het1, or C~3-5cycloalkyl<br>
substituted at the connecting carbon atom by Het1, wherein n14 is 0,1 or 2<br>
and wherein Het1 is a 4-, 5-, 6- or 7-membered saturated heterocyclic ring;<br>
wherein said heterocyclic ring Het1 contains one O or S ring atom and/or<br>
oneNR14 ring group whereinR14 is H, C1-4alkyl, C3-6cycloalkyl, benzyl,<br>
phenyl, -C(O)Rl9, or -S(O)2R19;<br>
wherein R19, independent of any other R19, is C1-6alkyl (e.g. C1-4alkyl<br>
or C1-3alkyl), C3-6cycloalkyl, thienyl (e.g. 2-thienyl), furyl (furanyl, e.g.<br>
furan-2-yl), or phenyl or benzyl; wherein the phenyl and benzyl are<br>
independently optionally substituted by one or two of (independently) fluoro,<br>
methyl or methoxy;<br>
and wherein said heterocyclic ring Het1 is optionally substituted (at a<br>
position or positions other than any NR14 position) by one or two oxo (=O)<br>
and/or one C1-4alkyl substituents;<br>
provided that, when the heterocyclic ring Het1 contains one O or S ring<br>
atom and one NR14 ring group then: (a) the O/S ring atom and the NR14 ring<br>
group are not directly bonded to each other, and (b) the O/S ring atom and the<br><br>
NR14 ring group are separated by more than one carbon atom unless Het1<br>
contains an -NR14-C(O)-O- or -NR14-C(O)-S- moiety as part of the ring; or<br>
-(CH2)n10-Ar, -CH(C1-2alkyl)-Ar, -CMe2-Ar, or C~3-5cycloalkyl substituted at the<br>
connecting carbon atom by Ar, wherein n10 is 0,1 or 2 and<br>
(i) Ar is phenyl optionally substituted by one or two substituents<br>
independently being fluoro, chloro, bromo, C1-2alkyl, C1-2fluoroalkyl,<br>
C1-2alkoxy, C1-2fluoroalkoxy, OH, -NR11aR11b (wherein R11a is H or<br>
C1-2alkyl and R11b is H, C1-2alkyl, -C(O)-C1-2alkyl or -S(O)2-C1-2alkyl),<br>
cyano, -C(O)-NR11CR11d (wherein R11c and R11d independently are H or<br>
C1-2alkyl), -C(O)-OR11e wherein R11e is H or C1-2alkyl, or -S(O)2-R1lf<br>
(wherein R11f is C1-2alkyl, NH2, NHMe or NMe2); or the phenyl Ar is<br>
optionally substituted at two adjacent Ar ring atoms by the two ends of a chain<br>
which is: -(CH2)4-, -(CH2)3-, or -CH=CH-CH=CH-; or<br>
(ii) Ar is an optionally substituted 5- or 6-membered heterocyclic aromatic<br>
ring containing 1,2, 3 or 4 heteroatoms (e.g. 1,2 or 3 heteroatoms) selected<br>
from O, N or S; and wherein when the heterocyclic aromatic ring Ar contains<br>
2, 3 or 4 heteroatoms (e.g. 2 or 3 heteroatoms), one is selected from O, N and<br>
S and the remaining heteroatom(s) are N; and wherein the heterocyclic<br>
aromatic ring Ar is optionally substituted by one or two groups independently<br>
being C1-4alkyl (e.g. C1-2alkyl) or OH (including any keto tautomer of an<br>
OH-substituted aromatic ring), or the heterocyclic aromatic ring Ar is<br>
optionally substituted at two adjacent Ar ring atoms by the two ends of a chain<br>
which is: -(CH2)4-, -(CH2)3-, or -CH=CH-CH=CH-;<br>
RX1 and RY1 independently are a hydrogen atom (H), C1-2alkyl or C1fluoroalkyl;<br>
RX3 and RX4 together are -(CH2)n15-X7-(CH2)n16- wherein n15 and n16<br>
independently are 1 or 2 and X7 is a bond, -CH2-, O, or NRX5 wherein RX5 is H,<br>
C1-2alkyl, acetyl or -S(O)2Me; and<br>
RZ is a hydrogen atom (H) or C1-2alkyl,<br>
provided that:<br>
when R3 is the heterocyclic group of sub-formula (bb), n1 is 1, and Y is NR4, then R4 is<br>
not C1-2alkyl, C1-2fluoroalkyl or CH2C(O)NH2-<br>
Preferably, R3a is a hydrogen atom (H) or methyl.<br>
It is particularly preferred that R3a is a hydrogen atom (H).<br><br>
In one optional embodiment of the invention, R3 is optionally substituted branched<br>
C3-6alkyl, optionally substituted C3-8cycloalkyl, optionally substituted phenyl, or an<br>
optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc):<br><br>
in which n1 and n2 are 1 or 2; and Y is O, S, SO2, or NR4; where R4 is a hydrogen atom,<br>
C1-2alkyl, C1-2fluoroalkyl, C(O)MH2, C(O)-C1-2alkyl, or C(O)-C1fluoroalkyl; provided<br>
that Y is not NR4 when the heterocyclic group is of sub-formula (aa).<br>
Alternatively or additionally, in one optional embodiment of the invention, in R3 the<br>
branched C3-6alkyl is optionally substituted with one or two substituents being oxo (=O),<br>
OH, C1-2alkoxy or C1-2fluoroalkoxy; and wherein any such substituent is not substituted<br>
at the R3 carbon atom attached to the -NH- group of formula (I).<br>
Alternatively or additionally, in one optional embodiment of the invention, in R3 the<br>
phenyl is optionally substituted with one substituent being fluoro, chloro, C1-2alkyl, C1-<br>
2fluoroalkyl, C1-2alkoxy, C1-2fluoroalkoxy or cyano.<br>
Alternatively or additionally, in one optional embodiment of the invention, in R3 the C3.<br>
8cycloalkyl or the heterocyclic group of sub-formula (aa), (bb) or (cc) is optionally<br>
substituted with one or two substituents being oxo (=O), OH, C1-2alkoxy,<br>
C1-2fluoroalkoxy, or C1-2alkyl; and wherein any OH, alkoxy or fluoroalkoxy substituent<br>
is not substituted at the R3 ring carbon attached to the -NH- group of formula (I) and is<br>
not substituted at either R3 ring carbon bonded to the Y group of the heterocyclic group<br>
(aa), (bb) or (cc).<br>
Alternatively or additionally, in one optional embodiment of the invention, Het is of sub-<br>
formula (i), (ii), (iii) or (iv):<br><br><br>
wherein:<br>
W1, W2 and W4 is N; and W3 is NRW;<br>
Xl, X3 and X4 is N or CRX; and X2 is O, S or NRX ;<br>
Y1, Y2 and Y3 is CRY or N; and Y4 is O, S or NRY ;<br>
Z1 is O, S or NRZ; and Z2, Z3 and Z4 is N or CRZ;<br>
and wherein:<br>
RW is a hydrogen atom (H) or C1-2alkyl; and<br>
RZ is a hydrogen atom (H) or C1-2alkyl.<br>
Alternatively or additionally, in one optional embodiment of the invention, RX and RY<br>
independently are:<br>
a hydrogen atom (H);<br>
C1-8alkyl;<br>
C3-6cycloalkyl;<br>
-(CH2)n3-SO2-R5 wherein n3 is 1 or 2 andR5 is C1-3alkyl or -NH-C1-2alkyl;<br>
-(CH2)n4-NR6R7 wherein n4 is 0,1 or 2, and R6 and R7 independently are H,<br>
C1-6alkyl e.g. C1-4alkyl, -C(O)-C1-2alkyl or -SO2-C1-2alkyl; or R6 and R7<br>
together are -(CH2)n5-X5-(CH2)n6- in which n5 and n6 independently are 2<br>
or 3 and X5 is a bond, -CH2-, O, or NR8 wherein R8 is H or C1-2alkyl;<br>
-(CH2)n7-0-R9 wherein n7 is 1 or 2 and R9 is H or C1-6alkyl;<br>
-C(O)-NR10R11 wherein R10 and R11 independently are H or C1-6alkyl; or R10<br>
and R11 together are -(CH2)n8-X6-(CH2)n9- in which n8 and n9<br>
independently are 2 or 3 and X6 is a bond, -CH2-, O, or NR12 wherein R12 is<br>
H or C1-2alkyl;<br>
-C(O)-OR13 wherein R13 is H or C1-6alkyl;<br>
a 4-, 5-, 6- or 7-membered saturated heterocyclic ring containing one O ring atom or<br>
one NR14 ring group wherein R14 is H or C1-4alkyl, said heterocyclic ring<br>
being optionally substituted (at a position or positions other than any NR14<br>
position) by one oxo (=O) and/or one C1-4alkyl substituent; or<br>
-(CH2)n10-Ar wherein n10 is 0,1 or 2 and<br>
(i) Ar is phenyl optionally substituted by one or two substituents being fluoro,<br>
chloro, C1-2alkyl, C1-2fluoroalkyl, C1-2alkoxy, C1-2fluoroalkoxy or cyano;<br>
or<br>
(ii) Ar is an optionally substituted 5- or 6-membered heterocyclic aromatic<br>
ring containing 1,2 or 3 heteroatoms selected from O, N or S; and wherein<br>
when the heterocyclic aromatic ring Ar contains 2 or 3 heteroatoms, one is<br>
selected from O, N and S and the remaining heteroatom(s) are N; and wherein<br><br>
the heterocyclic aromatic ring Ar is optionally substituted by one or two<br>
C1-4alkyl groups.<br>
Alternatively or additionally, in one optional embodiment of the invention, Het is of sub-<br>
formula (i), (ii), (iii), (iv) or (v):<br><br>
wherein:<br>
W1, W2, W4 and W5 is N; and W3 is NRW ;<br>
X1, X3 and X4 is N or CRX; X2 is O, S or NRX; and X5 is CRX1RX2;<br>
Y1, Y2 and Y3 is CRY or N; Y4 is O, S or NRY ; and Y5 is CRY1RY2;<br>
Z1 and Z5 is O, S or NRZ; and Z2, Z3 and Z4 is N or CRZ;<br>
and wherein:<br>
RW is a hydrogen atom (H) or C1-2alkyl; and<br>
RZ is a hydrogen atom (H) or C1-2alkyl.<br>
In one optional embodiment of the invention, RX, RX2, RY and RY2 independently are,<br>
or RX and RY independently are:<br>
a hydrogen atom (H);<br>
C1-8alkyl;<br>
C3-6cycloalkyl optionally substituted by a C1-2alkyl group;<br>
-(CH2)n2a-C3-6cycloalkyl optionally substituted, in the -(CH2)n2a- moiety or in<br>
the C3-6cycloalkyl moiety, by a C1-2alkyl group, wherein n2a is 1, 2 or 3;<br>
-(CH2)n3-SO2-R5 whereinn3 is 1 or 2 and R5 is C1-2alkyl or -NH-C1-2alkyl or<br>
phenyl;<br>
-(CH2)n4-NR6R7 wherein n4 is 0, 1, 2 or 3, and RÂ°" and R7 independently are H,<br>
C1-2galkyl e.g. C1-4alkyl, C3_6cycloalkyl, -CH2-C3_6cycloalkyl,<br>
-C(O)-Cj.2alkyl, -S02-C1-2alkyl, phenyl, or benzyl (wherein the phenyl or<br>
benzyl are independently optionally substituted on the aromatic ring by one of<br>
fluoro, chloro, C1-2alkyl, Cifiuoroalkyl, Cx_2alkoxy or C1fluoroalkoxy); or<br>
R6 and R7 together are -(CH2)n5-X5-(CH2)n6- in which n$ and n6<br>
independently are 2 or 3 and X^ is a bond, -CH2-, O, or NR8 wherein R8 is H<br>
orC1-2alkyl;<br><br>
-(CH2)n7-0-R9; wherein rP is 0,1, 2 or 3 and R9 is H or C1-2alkyl; wherein n? is<br>
0 only when the -(CH2)n7-0-R9 is bonded to a carbon atom in the Het ring;<br>
and wherein n7 is not 0 when Het is of sub-formula (v) (i.e. n7 is not 0 for<br>
RX2 and for RY2);<br>
-C(O)-NR10R11 whereinR10 andR11 independently are H, C1-6alkyl,<br>
C3-6cycloalkyl, -CH2-C3-6cycloalkyl, phenyl, or benzyl (wherein the phenyl<br>
or benzyl are independently optionally substituted on the aromatic ring by one<br>
of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy);<br>
or R10 and R11 together are -(CH2)n8-X6-(CH2)n9- in which n8 and n9<br>
independently are 2 or 3 and X6 is a bond, -CH2-, O, or NR12 wherein R12 is<br>
HorC1-2alkyl;<br>
-C(O)-OR13 wherein R13 is H, C1-2alkyl, C3-6cycloalkyl, -CH2-C3gcycloalkyl,<br>
phenyl, or benzyl (wherein the phenyl or benzyl are independently optionally<br>
substituted on the aromatic ring by one of fluoro, chloro, C1-2alkyl,<br>
C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy);<br>
-C(O)-R13a wherein R13a is a hydrogen atom (H), C1-6alkyl, C1-2fluoroalkyl,<br>
C3-8cycloalkyl, -CH2-C3-6cycloalkyl, benzyl, or phenyl; wherein the phenyl<br>
or benzyl are independently optionally substituted on the aromatic ring by one<br>
of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy;<br>
a 4-, 5-, 6- or 7-membered saturated heterocyclic ring containing one O ring atom or<br>
one NR14 ring group wherein R14 is H or C1-4alkyl, said heterocyclic ring<br>
being optionally substituted (at a position or positions other than any NR14<br>
position) by one oxo (=O) and/or one C1-4alkyl substituent; or<br>
-(CH2)n10-Ar wherein n10 is 0,1 or 2 and<br>
(i) Ar is phenyl optionally substituted by one or two substituents being fluoro,<br>
chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy, C1fluoroalkoxy or cyano;<br>
or<br>
(ii) Ar is an optionally substituted 5- or 6-membered heterocyclic aromatic<br>
ring containing 1,2 or 3 heteroatoms selected from O, N or S; and wherein<br>
when the heterocyclic aromatic ring Ar contains 2 or 3 heteroatoms, one is<br>
selected from 0, N and S and the remaining heteroatom(s) are N; and wherein<br>
the heterocyclic aromatic ring Ar is optionally substituted by one or two<br>
C1-4alkyl groups; and<br>
RXI and RYI independently are a hydrogen atom (H), C1-2alkyl or C1fluoroalkyl.<br>
In compounds, for example in the compounds of formula (I), an "alkyl" group or<br>
moiety may be straight-chain or branched. Alkyl groups, for example C1-8alkyl or<br><br>
C1-6alkyl or C1-4alkyl or C1-3alkyl or C1-2alkyl, which maybe employed include<br>
C1-6alkyl or C1-4alkyl or Chalkyl or C1-2alkyl such as methyl, ethyl, n-propyl, n-<br>
butyl, n-pentyl, or n-hexyl, or any branched isomers thereof such as isopropyl, t-butyl,<br>
sec-butyl, isobutyl, 3-methylbutan-2-yl, 2-ethylbutan-1-yl, or the like.<br>
A corresponding meaning is intended for "alkoxy", "alkylene", and like terms<br>
derived from alkyl. For example, "alkoxy" such as C1-6alkoxy or C1-4alkoxy or<br>
C1-2alkoxy includes methoxy, ethoxy, propyloxy, and oxy derivatives of the alkyls listed<br>
above. "Alkylsulfonyl" such as C1-4alkylsulfonyl includes methylsulfonyl<br>
(methanesulfonyl), etibylsulfonyl, and others derived from the alkyls listed above,<br>
"Alkylsulfonyloxy" such as C1-4alkylsulfonyloxy includes methanesulfonyloxy<br>
(methylsulfonyloxy), ethanesulfonyloxy, et al.<br>
"Cycloalkyl", for example C3-8cycloalkyl, includes cyclopropyl, cyclobutyl,<br>
cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like. Preferably, a<br>
C3-8 cycloalkyl group is C3-6gcycloalkyl or C5-6cycloalkyl, that is the cycloalkyl group<br>
contains a 3-6 membered or 5-6 membered carbocyclic ring respectively.<br>
"Fluoroalkyl" includes alkyl groups with one, two, three, four, five or more<br>
fluorine substituents, for example C1-2fluoroalkyi or C1-2fluoroalkyl or C1-2fluoroalkyl<br>
such as monofluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-<br>
trifluoroethyl (CF3CH2-), 2,2-difluoroethyl (CHF2-CH2-), or 2-fluoroethyl<br>
(CH2F-CH2-), etc. "Fluoroalkoxy" includes C1-4fluoroalkoxy or C1-2fluoroalkoxy such<br>
as trifiuoromemoxy, pentafluoroethoxy, monofluoromethoxy, difluoTorhethoxy, etc.<br>
"Fluoroalkylsulfonyl" such as C1-4fluoroalkylsulfonyl includes<br>
trifluoromethanesulfonyl, pentafluoroethylsulfonyl, etc.<br>
A halogen atom ("halo") present in compounds, for example in the compounds of<br>
formula (I), can be a fluorine, chlorine, bromine or iodine atom ("fluoro", "chloro",<br>
"bromo" or "iodo").<br>
When the specification states that atom or moiety A is "bonded" or "attached" to<br>
atom or moiety B, it means that atom/moiety A is directly bonded to atom/moiety B<br>
usually by means of one or more covalent bonds, and excludes A being indirectly<br>
attached to B via one or more intermediate atoms/moieties (e.g. excludes A-C-B); unless<br>
it is clear from the context that another meaning is intended.<br>
By "carbon-linked-pyridinyl" is meant pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl.<br>
Preferably, R1 is C1-2alkyl, C1-3fluoroalkyl or -(CH2)2OH; more preferably C1-3alkyl,<br>
C1-2fluoroalkyl or -(CH2)20H; still more preferably C2-3alkyl, C2fluoroalkyl or<br>
-(CH2)2OH; and yet more preferably C2alkyl or C2fluoroalkyl. When R1 is C1-4alkyl<br>
or C1-3fluoroalkyl, it can be straight-chained or branched. R1 can for example be<br>
methyl, trifluoromethyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, C2fluoroalkyl or<br>
-(CH2)2OH; and more preferably R1 is ethyl, n-propyl, C2fhioroalkyl (e.g.<br>
C1fluoroalkyl-CH2- such as CF3-CH2-) or -(CH2)2OH. R1 is most preferably ethyl.<br><br>
Preferably, R2 is a hydrogen atom (H) or methyl, more preferably a hydrogen atom (H).<br>
Where R3 optionally substituted phenyl, preferably the phenyl is optionally substituted<br>
with one substituent being fluoro, chloro, C1-2alkyl, C1-2fluoroalkyl, C1-2alkoxy,<br>
C1-2fluoroalkoxy or cyano. Where R3 is optionally substituted phenyl, the optional<br>
substituent can be at the 2-, 3- or 4-position of the phenyl ring, e.g. at the 4-position. For<br>
example, R3 can be phenyl or fluorophenyl; in particular 4-fluorophenyl.<br>
R3 is preferably optionally substituted branched C3-6alkyl, optionally substituted<br>
C3-8cycloalkyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb)<br>
or (cc). R3 is more preferably optionally substituted C1-2gcycloalkyl, or an optionally<br>
substituted heterocyclic group of sub-formula (aa), (bb) or (cc).<br>
Preferably, in R3 there is one substituent or no substituent.<br>
Where R3 is optionally substituted branched C3-6alkyl, then preferably R3 is optionally<br>
substituted branched C1-2alkyl and/or unsubstituted C3-6alkyl such as isopropyl,<br>
isobutyl, sec-butyl, t-butyl, 3-methylbutan-2-yl, or 2-ethylbutan-1-yl. Where R3 is<br>
optionally substituted branched C3-6alkyl, it is most preferably isobutyl, sec-butyl,<br>
t-butyl or 3-methylbutan-2-yl (for example (R)-3-methylbutan-2-yl or (S)-3-methylbutan-<br>
2-yl).<br>
In one optional embodiment, where R3 is optionally substituted C3-8cycloalkyl, it is not<br>
optionally substituted C5cycloalkyl, i.e. not optionally substituted cyclopentyl. In this<br>
case, more preferably, R3 is optionally substituted C6-8cycloalkyl or optionally<br>
substituted C6-7cycloalkyl.<br>
Where R3 is optionally substituted C3-8gcycloalkyl, it is more preferably optionally<br>
substituted C6cycloalkyl (i.e. optionally substituted cyclohexyl); for example<br>
C6cycloalkyl optionally substituted with one or two substituents independently being<br>
(e.g. being) oxo (=O), OH, C1-2alkoxy, C1-2fluoroalkoxy (e.g. trifluoromethoxy), or<br>
C1-2alkyl, and wherein any OH, alkoxy or fluoroalkoxy substituent is not substituted at<br>
theR3 ring carbon attached (bonded) to the -NH- group of formula (I).<br>
Where R3 is optionally substituted C3-8gcycloalkyl, the one or two optional substituents<br>
preferably comprise (e.g. is or independently are (e.g. is or are)) oxo (=O); OH;<br>
Cjalkoxy; C1fluoroalkoxy (e.g. trifluoromethoxy); NHR21 wherein R21 is a hydrogen<br>
atom (H) or C1-2 straight-chain alkyl; C1-2alkyl such as methyl; C1fluoroalkyl such as<br><br>
-CH2F or -CHF2; -CH2OH; -CH2NHR22 wherein R22 is H; -C(O)OR23 wherein R23 is<br>
H or methyl; -C(O)NHR24 wherein R24 is H or methyl; -C(O)R25 wherein R25 is<br>
methyl; fluoro; hydxoxyimino (=N-OH); or (C1-2alkoxy)imino (=N-OR26 where R26 is<br>
C1-2alkyl); and wherein any OH, alkoxy, fluoroalkoxy or NHR21 substituent is not<br>
substituted at the R3 ring carbon attached (bonded) to the -NH- group of formula (I) and<br>
is not substituted at either R3 ring carbon bonded to the Y group of the heterocyclic group<br>
(aa), (bb) or (cc).<br>
More preferably, where R3 is optionally substituted C3-8cycloalkyl, the one or two<br>
optional substituents comprise (e.g. is or independently are (e.g. is or are)) oxo (=O); OH;<br>
NHR21 wherein R21 is a hydrogen atom (H); C1-2alkyl such as methyl; Cifiuoroalkyl<br>
such as -CH2F or -CHF2; -C(O)OR23 wherein R23 is H or methyl; -C(O)NHR24<br>
wherein R24 is H or methyl; fluoro; hydroxyimino (=N-OH); or (C1-2aIkoxy)irnino<br>
(=N-OR26 where R26 is C1-2alkyl).<br>
Still more preferably, where R3 is optionally substituted C3-8gcycloalkyl, the one or two<br>
optional substituents comprise (e.g. is or independently are (e.g. is or are)) oxo (=O); OH;<br>
NHR21 wherein R21 is a hydrogen atom (H); methyl; -CH2F; -CHF2; -C(O)OR23<br>
wherein R23 is H; fluoro; hydroxyimino (=N-OH); or (C1-2alkoxy)imino (=N-OR26<br>
where R26 is C1-2alkyl). Yet more preferably, where R3 is optionally substituted<br>
C3-8cycloalkyl, the one or two optional substituents comprise (e.g. is or independently<br>
are (e.g. is or are)) oxo (=O); OH; methyl; fluoro; hydroxyimino (==N-OH); or<br>
(C1-2alkoxy)imino (=N-OR26 where R26 is C1-2aLkyl).<br>
Most preferably, where R3 is optionally substituted C3-8cycloalkyl, the one or two<br>
optional substituents comprise (e.g. is or independently are (e.g. is or are)) OH, oxo (=O)<br>
or hydroxyimino (=N-OH). For example, where R3 is optionally substituted<br>
C3-8cycloalkyl, the one or two optional substituents preferably comprise (e.g. is or are)<br>
OH and/or oxo (=O).<br>
Optionally, in R3, the C3-8cycloalkyl is unsubstituted.<br>
Where R3 is optionally substituted C3-8cycloalkyl, e.g. optionally substituted<br>
C1-2gcycloalkyl such as optionally substituted C6cycloalkyl (optionally substituted<br>
cyclohexyl), the one or two optional substituents if present preferably comprise a<br>
substituent (for example is or are substituent(s)) at the 3-, 4- or 5- position(s) of the R3<br>
cycloalkyl ring. (In this connection, the 1-position of the R3 cycloalkyl ring is deemed to<br>
be the connection point to the -NH- in formula (I)).<br><br>
Where R3 is optionally substituted C3-8cycloalkyl, any OH, alkoxy, fluoroalkoxy,<br>
-CH2OH, -CH2CH2OH, -CH2NHR22, -C(O)OR23, -C(O)NHR24 -C(O)R25 or fluoro<br>
substituent (particularly any OH substituent) is more preferably at the 3-, 4- or 5-position,<br>
e.g. the 3- or 5-position, of the R3 cycloalkyl (e.g. C6-8cycloalkyl) ring. For example,<br>
any OH, alkoxy, fluoroalkoxy, -CH2OH, -CH2CH2OH, -CH2NH22, -C(O)OR23,<br>
-C(O)NHR24, -C(O)R25 or fluoro substituent (particularly any OH substituent) can be at<br>
the 3-position of a R3 Cscycloalkyl (cyclopentyl) ring or at the 3-, 4- or 5- position, e.g.<br>
3- or 5-position, of a R3 Cgcycloalkyl (cyclohexyl) ring. (In this connection, and also<br>
below, the 1-position of the R3 cycloalkyl ring is deemed to be the connection point to<br>
the -NH- in formula (I)).<br>
Where R3 is optionally substituted C3-8cycloalkyl, any NHR21 substituent is preferably<br>
at the 2-, 3-, 4- or 5- position, preferably the 2- or 3-position or more preferably the<br>
3-position, of the R3 cycloalkyl (e.g. C6-8gcycloalkyl e.g. cyclohexyl) ring.<br>
Where R3 is optionally substituted C3-8cycloalkyl, any alkyl or fluoroalkyl substituent is<br>
preferably at the 1-, 2-, 3-, 4- or 5- position, more preferably the 1-, 2-, 3- or 5-position,<br>
still more preferably the 1- or 3-position, of the R3 cycloalkyl (e.g. C6-8cycloalkyl e.g.<br>
cyclohexyl) ring.<br>
Where R3 is optionally substituted C3-8cycloalkyl, any oxo (=O), hydroxyimino<br>
(=N-OH); or (C1-4alkoxy)imino (=N-OR26) substituent is preferably at the 3- or<br>
4-position, preferably at the 4-position, of the R3 cycloalkyl (e.g. C1-2cycloalkyl e.g.<br>
cyclohexyl) ring.<br>
Where R3 is optionally substituted C3-8cycloalkyl, R3 is preferably cyclohexyl (i.e.<br>
unsubstituted) or cyclohexyl substituted by one oxo (=O), OH, NHR21, C1-2alkyl,<br>
C1-2fiuoroalkyl, -CH2OH, -C(O)OR23, -C(O)NHR24, -C(O)R25, fluoro, hydroxyimino<br>
(=N-OH) or (C1-4alkoxy)imino (=N-OR26) substituent, or cyclohexyl substituted by two<br>
fluoro substituents. More preferably, R3 is cyclohexyl (i.e. unsubstituted), or cyclohexyl<br>
substituted by one oxo (=O), OH, NHR21, C1-2alkyl, C1-2fluoroalkyl, -C(O)OR23,<br>
fluoro, hydroxyimino (=N-OH) or (C1-4alkoxy)imino (=N-OR26) substituent, or<br>
cyclohexyl substituted by two fluoro substituents. Still more preferably R3 is cyclohexyl<br>
(i.e. unsubstituted) or cyclohexyl substituted by one oxo (=O), hydroxyimino (=N-OH),<br>
C1-2alkyl or OH substituent, for example R3 can be cyclohexyl (i.e. unsubstituted) or<br>
cyclohexyl substituted by one oxo (=O) or OH substituent. The optional substituent can<br><br>
be at the 3- or 4- position, e.g. 3-position, of the R3 cyclohexyl ring; more preferably any<br>
OH substituent is preferably at the 3-position of the R3 cyclohexyl ring, and/or any oxo<br>
(=O), hydWyimino (=N-OH) or (C1-4alkoxy)imino (=N-OR26) substituent is preferably<br>
at the 4-position of the R3 cyclohexyl ring.<br>
Where R3 is optionally substituted Cgcycloalkyl, R3 can for example be 4-hydroxy-<br>
cyclohexyl (i.e. 4-hydroxycyclohexan-1-yl) or 3-oxo-cyclohexyl, but R3 is more<br>
preferably cyclohexyl (i.e. unsubstituted), 3-hydroxy-cyclohexyl (i.e. 3-<br>
hydroxycyclohexan-1-yl), 4-oxo-cyclohexyl (i.e. 4-oxocyclohexan-1-yl), 4-<br>
(hydroxyimino)cyclohexyl (i.e. 4-(hy&amp;oxyimino)cyclohexan-1-yl),<br>
4-(C1-2alkoxyimino)cyclohexyl, 1-methylcyclohexyl or 3-methylcyclohexyl. In one<br>
embodiment, R3 can optionally be cyclohexyl (i.e. unsubstituted) or 3-hydroxy-<br>
cyclohexyl or 4-oxo-cyclohexyl. Where R3 is optionally substituted Cgcycloalkyl, R3 is<br>
most preferably cyclohexyl (i.e. unsubstituted), 4-oxo-cyclohexyl (i.e. 4-oxocyclohexan-<br>
1-yl) or 4-(hydroxyimino)cyclohexyl (i.e. 4-(hydroxyimino)cyclohexan-1-yl).<br>
Where R3 is optionally substituted Cscycloalkyl (optionally substituted cyclopentyl), R3<br>
can for example be cyclopentyl (i.e. unsubstituted) or 3-hydroxy-cyclopentyl.<br>
Where R3 is optionally substituted mono-unsaturated-C5-7cycloalkenyl, preferably it is<br>
optionally substituted mono-unsaturated-C5-6cycloalkenyl, more preferably optionally<br>
substituted mono-unsaturated-C6cycloalkenyl (i.e. optionally substituted<br>
mono-unsaturated-cyclohexenyl = optionally substituted cyclohexenyl). Still more<br>
preferably, the R3 cyclohexenyl is optionally substituted cyclohex-3-en-1-yl.<br>
Where R3 is optionally substituted mono-unsaturated-C5-7cycloalkenyl, preferably the<br>
R3 cycloalkenyl is optionally substituted with one or two substituents independently<br>
being fluoro or methyl; preferably if there are two substituents then they are not both<br>
methyl. Preferably, the R3 cycloalkenyl is optionally substituted with one substituent<br>
being fluoro or C1-2alkyl (e.g. methyl); more preferably the R3 cycloalkenyl is<br>
substituted with one fluoro substituent or is unsubstituted. For R3 cycloalkenyl, the<br>
optional substituent(s) can be at the 1-, 2-, 3-, 4- or 5- positions) of the cycloalkenyl ring.<br>
Where R3 is the heterocyclic group of sub-formula (aa), (bb) or (cc), then Y is preferably<br>
O, S, SO2, NH or N-C(O)-Me (for example O, S, SO2 or N-C(O)-Me), more preferably<br>
O, NH or N-C(O)-Me, still more preferably O or N-C(O)-Me, most preferably O. (When<br>
Y is NH or N-C(O)-Me, then R4 is H or -C(O)-Me).<br><br>
Preferably, R4 is a hydrogen atom (H), C1-2alkyl, C(O)NH2, C(O)-Me or C(O)-CF3.<br>
Optionally, R4 can be a hydrogen atom (H), C1-2alkyl, C(O)-Me or C(O)-CF3, more<br>
preferably H, C(O)-Me or C(O)-CF3, still more preferably H or C(O)-Me.<br>
Preferably, Y is not N-C(O)-Me when the heterocyclic group is of sub-formula (aa).<br>
Where R3 is the heterocyclic group of sub-formula (aa), (bb) or (cc), then it is preferable<br>
that R3 is the heterocyclic group of sub-formula (aa) or (bb). More preferably, in R3, the<br>
heterocyclic group is of sub-formula (bb).<br>
In sub-formula (bb), n1 is preferably 1. In sub-formula (cc), n2 is preferably 1. That is,<br>
six-membered rings are preferred in the R3 heterocyclic group.<br>
Preferably, in R3, the heterocyclic group of sub-formula (aa), (bb) or (cc) is<br>
unsubstituted. (In this connection, where Y is NR4, R4 is not classified as a substituent).<br>
In the R3 heterocyclic group of sub-formula (aa), (bb) or (cc), the one or two optional<br>
substituents preferably comprise (e.g. is or independently are (e.g. is or are)): OH; oxo<br>
(=O); C1-2alkyl (e.g. methyl) or C1-2fluoroalkyl (e.g. C1fluoroalkyl such as -CH2F or<br>
-CHF2)- More preferably, in the R3 heterocyclic group of sub-formula (aa), (bb) or (cc),<br>
the one or two optional substituents comprise (e.g. is or independently are ((e.g. is or<br>
are)) OH and/or oxo; most preferably the one or two optional substituents comprise (e.g.<br>
is or are) oxo (=O). In the R3 heterocyclic group of sub-formula (aa), (bb) or (cc), any<br>
oxo (=O) substituents are preferably on a carbon atom bonded (adjacent) to X, and/or can<br>
be at the 2-, 3-, 4- or 5- positions) of the R3 heterocyclic ring. (In this connection, the 1-<br>
position of the R3 heterocyclic ring is deemed to be the connection point to the -NH- in<br>
formula (I)). Preferably, only C1-2alkyl, C1fluoroalkyl, fluoro or oxo (=O) substitution<br>
or no substitution is allowed at each of the 2- and 6-positions of the R3 heterocyclic ring.<br>
When R3 is the heterocyclic group of sub-formula (aa) and Y is NR4, then preferably R4<br>
is not C(O)-Me. More preferably, when R3 is the heterocyclic group of sub-formula (aa)<br>
and Y is NR4, then R4 is preferably not C(O)R, i.e. or e.g. R4 is preferably not<br>
C(O)NH2, C(O)-C1-2alkyl or C(O)-C1fluoroalkyl. In one embodiment, Y is O, S, SO2<br>
or NH when R3 is the heterocyclic group of sub-formula (aa).<br>
When R3 is the heterocyclic group of sub-formula (aa), preferably Y is not NR4.<br>
Optionally, according to one embodiment of the invention, NHR3 or NR3R3a is not<br>
  . More preferably, when R3 is the heterocyclic group of sub-formula (bb)<br><br>
and Y is NR4, and optionally when n1 is 1, then preferably R4 is not methyl. More<br>
preferably, when R^ is the heterocyclic group of sub-formula (bb) and Y is NR4, and<br>
optionally when n1 is 1, then R4 is preferably not alkyl or substituted alkyl, i.e. or e.g. R4<br>
is preferably not C1-2alkyl, C1-2fluoroalkyl or CH2C(O)NH2. In one embodiment,<br>
when R3 is the heterocyclic group of sub-formula (bb), Y is preferably O, S, SO2 or<br>
NR4, wherein R4 is H, C(O)NH2, C(O)-C1-2alkyl or C(O)-C1fluoroalkyl or more<br>
preferably Y is H or C(O)-Me. More preferably, for sub-formula (bb), Y is O or NR4.<br>
Preferably, NHR3 or NR3R3a is of sub-formula (a), (al), (b), (c), (c 1), (c 2), (c 3), (c 4),<br>
(c 5), (d), (e), (f), (g), (gl), (g2), (g3), (g4), (h), (hi), (i), (j), (k), (kl), (L), (m), (ml), '<br>
(m2), (m3), (m5), (n), (o), (ol), (o2), (o3), (o4), (o5), (p), (p2), (p3), (p5), (p6), (p7), (p8),<br>
(q), (r), (s), (t), (tl) or (t2):<br><br><br><br>
In the sub-formulae (a) to (t2) etc above, the -NH- connection point of the NHR3 or<br>
NR3R3a group to the 4-position of the pyrazolopyridine of formula (I) is underlined.<br>
Generally, in this specification, for a group or radical, where NH or N are underlined,<br>
then this indicates the connection point.<br><br>
When NHR.3 or NR3R3a is of sub-formula (n), then preferably it is a cis-(3-<br>
hy&amp;oxycyclohex-1-yl)amino group, eg in any enantiomeric form or mixture of forms but<br>
it can be racemic.<br>
Preferably, Het is of sub-formula (i), (ii), (iii) or (v); more preferably Het is of sub-<br>
formula (i), (ii), or (v); still more preferably Het is of sub-formula (i).<br>
Xl, X3 and/or X4 independently is/are often N (a nitrogen atom).<br>
yl, Y2 and/or Y3 independently is/are often CRT.<br>
Suitably, Z1 and/or Z5 independently is/are O or S. Preferably, Z1 and/or Z5 is O.<br><br><br><br>
Alternatively, when Het is of sub-formula (v), Het can for example be of sub-formula<br>
(va) or (vb), more preferably of sub-formula (va):<br><br><br><br>
Alternatively, when Het is of sub-formula (ii), Het can for example be of sub-formula<br>
(iia):<br><br><br><br><br>
For the Het group in general, preferably, one of Rx and RY (or RX2 and RY2) is as<br>
defined herein and the other of Rx and RY (or RX2 and RY2) is as hydrogen atom (H) or<br>
C1-2alkyl. More preferably, one of RX and RY (or RX2 and RY2) is as defined herein<br>
and the other of RX and RY (or RX2 and RY2) is as hydrogen atom (H).<br>
Overall, for the Het group in general, it is preferred that one of Rx and RY, and for Het<br>
of sub-formula (v) one of RX2 and RY2, is:<br>
C1-8alkyl;<br>
optionally substituted C3-6cycloalkyl;<br>
-(CH2)n3-S(O)2-R5, -CH(C1.2alkyl)-S(O)2-R5, -CMe2-S(O)2-R5, or<br>
C3.5cycloalkyl substituted at the connecting carbon atom by -S(O)2-R^;<br>
preferably -(CH2)n3-S(O)2-R5;<br>
-(CH2)n4-NR6R7, -CH(C1-2alkyl)-NR6R7, -CMe2-NR6R7, or C3.5cycloalkyl<br>
substituted at the connecting carbon atom by -NR^R7; preferably<br>
-(CH2)n4-NR6R7 or -CH(Me)-NR%7;<br>
-(CH2)n11-C(O)-NR10R11, -CH(C1-2alkyl)-C(O&gt;NR10R1!,<br>
-CME2-C(O)-NR10R11, or C~3-5cycloalkyl substituted at the connecting<br>
carbon atom by -C(O)-NR10R11; preferably -(CH2)n1 1-C(O)-NR10R11;<br>
-(CH2)n14-Hetl, -CH(C1-2alkyl)-Het1, -CMe2-Hetl, or C~3-5cycloalkyl substituted<br>
at the connecting carbon atom by Het1; preferably -(CH2)n14-Hetl;<br>
-(CH2)n10-Ar, -CH(C1-2alkyl)-Ar, -CMe2-Ar, or C~3-5cycloalkyl substituted at the<br>
connecting carbon atom by Ar; preferably -(CH2)n10-Ar;<br>
(i) wherein Ar is optionally substituted phenyl, or more preferably (ii) wherein<br>
Ar is an optionally substituted 5- or 6-membered heterocyclic aromatic ring .<br>
Overall, for the Het group in general, it is more preferred that one of RX and RY, and for<br>
Het of sub-formula (v) one of RX2 and RY2, is:<br>
-(CH2)n4-NR6R7, -CH(C1-2alkyl)-NR6R7, -CMe2-NR6R7, or C3.5cycloalkyl<br>
substituted at the connecting carbon atom by -NR6R7; preferably<br>
-(CH2)n4-NR6R7 or -CH(Me)-NR6R7;<br>
-(CH2)n11-C(O)-NR10Rl!, -CH(C1.2alkyl)-C(O)-NR10R11,<br>
-CMe2-C(O)-NR10R11, or C~3-5cycloalkyl substituted at the connecting<br>
carbon atom by -C(O)-NR10R11; preferably -(CH2)n11-C(O)-NR10R11;<br>
-(CH2)n14-Hetl, -CH(C1-2alkyl)-Hetl, -CMe2-Het1, or C~3-5cycloalkyl substituted<br>
at the connecting carbon atom by Het1; preferably -(CH2)n14-Het1; or<br><br>
-(CH2)n10-Ar, -CH(C1-2alkyl)-Ar, -CMe2-Ar, or C~3-5cycloalkyl substituted at the<br>
connecting carbon atom by Ar; preferably -(CH2)n10-Ar;<br>
(i) wherein Ar is optionally substituted phenyl, or or more preferably (ii)<br>
wherein Ar is an optionally substituted 5- or 6-membered heterocyclic<br>
aromatic ring.<br>
Optionally, one of Rx and RY can be: C1-2alkyl; C3-6cycloalkyl; -(CH2)n3-SO2-R5;<br>
-(CH2)n4-NR6R7; -(CH2)n7-O-R9; -C(O)-NR10R11; -C(O)-OR13; or the 4-, 5-, 6- or<br>
7-membered optionally substituted saturated heterocyclic ring Het1. More preferably,<br>
one of Rx andRY is: C1-2alkyl; -(CH2)n3-SO2-R5; or the 4-, 5-, 6- or 7-membered<br>
optionally substituted saturated heterocyclic ring Het1. In these cases, as mentioned<br>
above, it is preferred that the other of Rx and RY is a hydrogen atom (H) or C1-2alkyl.<br>
When Rx, RX2, RY and/or RY2 is C1-8galkyl, then preferably it/they independently<br>
is/are C1-2galkyl, e.g. C3-6alkyl and/or C1-2alkyl such as methyl, isopropyl, isobutyl or t-<br>
butyl.<br>
When Rx, Rx2, RY and/or RY2 is optionally substituted C3-6cycloalkyl, then optionally<br>
it/they independently can be C3-6cycloalkyl optionally substituted by a C1-2alkyl group.<br>
When Rx, RX2, RY and/or RY2 is optionally substituted C3-6cycloalkyl, then preferably<br>
it/they independently is/are C3-6cycloalkyl (i.e. unsubstituted), for example cyclopropyl<br>
or cyclobutyl.<br>
When Rx, RX2, RY and/or RY2 is optionally substituted -(CH2)n2a-C3-6cycloalkyl,<br>
then preferably it/they independently is/are -(CH2)n2a-C3-6cycloalkyl optionally<br>
substituted, in the -(CH2)n2a- moiety or in the C3-6cycloalkyl moiety, by a C1-2alkyl<br>
group, wherein n2a is 1,2 or 3.<br>
When Rx, Rx2, RY and/or RY2 is optionally substituted -(CH2)n2a-C3-6cycloalkyl;<br>
then n2a is preferably 1 or 2 or more preferably 1; and/or preferably Rx, RX2, RY and/or<br>
RY2 independently is/are optionally substituted -(CH2)n2a-C5.6cycloalkyl or optionally<br>
substituted -(CH2)n2a-C6cycloalkyl. When Rx, RX2, RY and/or RY2 is optionally<br>
substituted -(CH2)n2a-C3-6cycloalkyl, then preferably it/they independently is/are<br>
-(CH2)n2a-C3-6cycloalkyl (i.e. not substituted). More preferably Rx, R^, RY and/or<br>
RY2 independently is/are (cyclohexyl)methyl-, that is -CH2-cyclohexyl.When Rx, Rx2,<br>
RY and/or RY2 is -(CH2)n3-S(O)2-R5, -CH(C1-2alkyl)-S(O)2-R5 (e.g.<br><br>
-CH(Me)-S(O)2-R5), -CMe2-S(O)2-R5, or C~3-5cycloalleyl substituted at the connecting<br>
carbon atom by -S(O)2-R5, then preferably it/they independently is/are<br>
-(CH2)n3-S(O)2-R5.<br>
When Rx, RX2, RY and/or RY2 is C~3-5cycloalkyl substituted at the connecting carbon<br>
atom by -S(O)2-R5, then preferably it/they independently is/are C3cycloalkyl<br>
(cyclopropyl) substituted at the connecting carbon atom by -S(O)2-R5, for example<br>
  (see for example Example 178).<br>
When Rx, RX2, RY and/or RY2 is -(CH2)n3-S(O)2-R5, then preferably n3 is 1.<br>
Preferably, R5 is C1-2alkyl (e.g. C1-2alkyl), -NR15R16, or optionally substituted phenyl.<br>
R5 is more preferably C1-3alkyl or -NH-C1-2alkyl or phenyl; still more preferably R5 is<br>
C1-3alkyl or C1-2alkyl such as methyl. Most preferably, -(CH2)n3-S(O)2-R5 is<br>
-CH2SO2Me.<br>
Preferably, R15 is H, C1-2alkyl (e.g. C1-2alkyl), optionally substituted phenyl or<br>
optionally substituted benzyl; and/or preferably R^ is H or methyl, e.g. H.<br>
When R15 and R16 together are -(CH2)n3a-X3a-(CH2)n3b-, then: preferably n3a and/or<br>
n3b independently are 2; and/or preferably X3a is a bond, -CH2-, O, or NR8a wherein<br>
R8a is C1-2alkyl or acetyl; and/or preferably the ring formed by NR15R16 is not<br>
substituted on a ring carbon or is substituted on a ring carbon by one methyl or oxo (=O)<br>
substituent.<br>
When RX, RX2, RY and/or RY2 is -(CH2)n4-NR6R7, -CH(C1-2alkyl)-NR6R7 (e.g.<br>
-CH(Me)-NR6R7), -CMe2-NR6R7, or C~3-5cycloalkyl (e.g. C3cycloalkyl) substituted at<br>
the connecting carbon atom by -NR6R7, then preferably it/they independently is/are<br>
-(CH2)n4-NR6R7, -CH(C1-2alkyl)-NR6R7 (e.g. -CH(Me)-NR6R7), or -CMe2-NR6R7;<br>
more preferably it/they independently is/are -CH(Me)-NR6R7 or still more preferably<br>
-(CH2)n4-NR6R7<br>
When Rx, RX2, RY and/or RY2 is -(CH2)n4-NR6R7, then preferably n4 is 0 only when<br>
the -(CH2)n4_NR6R7 is bonded to a carbon atom in the Het ring.<br><br>
When RX, RX2, RY and/or RY2 is -(CH2)n4-NR6R7 , then preferably n4 is 0,1 or 2;<br>
more preferably n4 is 0 or 1, still more preferably n4 is I.<br>
In one optional embodiment of the invention, R6 and R7 independently are H, Chalkyl<br>
e.g. C1-4alkyl, C3-6cycloalkyl, -CH2-C3-6cycloalkyl, -C(O)-C1-2alkyl, -SO2-C1-2alkyl,<br>
phenyl, or benzyl (wherein the phenyl and benzyl are independently optionally<br>
substituted on the aromatic ring by one of fluoro, chloro, C1-2alkyl, C1fluoroalkyl,<br>
C1-2aIkoxy or C1fluoroalkoxy); or R6 and R7 together are -(CH2)n5-X5-(CH2)n6- in<br>
which n5 and n6 independently are 2 or 3 and X5 is a bond, -CH2-, O, or NR8 wherein<br>
R8 is H or C1-2alkyl, and wherein the ring formed by NR6R7 is not substituted on a ring<br>
carbon.<br>
In one optional embodiment of the invention, R6 and R7 independently are H, C1-6alkyl<br>
e.g. C1-4alkyl, -C(O)-C1-2alkyl or -SO2-C1-2alkyl; or R6 and R7 together are<br>
-(CH2)n5-X5-(CH2)n6- in which n5 and n^ independently are 2 or 3 and X5 is a bond,<br>
-CH2-, O, or NR8 wherein R8 is H or C1-2alkyl, and wherein the ring formed by NR6R7<br>
is not substituted on a ring carbon.<br>
R6 is preferably H or C1-2alkyl. R7 is preferably C1-6alkyl, -C(O)R17 or -S(O)2R18,<br>
for example C1-6alkyl. Where R6 and/or R7 is Chalkyl, then it/they independently<br>
is/are preferably C1-2alkyl e.g. methyl.<br>
Preferably, R17 and R18 independently are C1-6alkyl (e.g. C1-4alkyl or C1-2alkyl or<br>
isopropyl or n-propyl), C3-6cycloalkyl, optionally substituted 5-membered heteroaryl<br>
being furyl (furanyl, e.g. 2-furyl) or thienyl (e.g. 2- or 3- thienyl) (the furyl or thienyl<br>
being independently optionally substituted by one oxo and/or one or two methyl), or<br>
phenyl or benzyl (wherein the phenyl and benzyl are independently optionally substituted<br>
on the aromatic ring by one or two substituents independently being fluoro, chloro,<br>
C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy).<br>
In an alternative preferable embodiment, R6 and R7 together are -(CH2)n5-X5-(CH2)n6-,<br>
in which case it is preferable that n5 is 2 and/or n6 is 2. Preferably, when R6 and R7<br>
together are -(CH2)n5-X5-(CH2)n6-, and when the ring formed by NR6R7 is substituted<br>
on a ring carbon by one or two substituents being oxo (=O), then the one or two oxo<br>
substituents are substituted on a ring carbon atom adjacent to (bonded to) the connecting<br>
nitrogen N of NR6R7. When R6 and R7 together are -(CH2)n5-X5-(CH2)n6-, then<br>
preferably the ring formed by NR6R7 is optionally substituted on a ring carbon by one or<br><br>
two substituents independently being methyl or oxo (=O) only when X5 is a bond or<br>
-CH2-.<br>
When R6 and R7 together are -(CH2)n5-X5-(CH2)n6-, it is preferable that the ring<br>
formed by NR^R7 is not substituted on a ring carbon or is substituted on a ring carbon by<br>
one methyl or oxo (=O) substituent.<br>
Preferably, R8 is Chalkyl or phenyl.<br><br>
When Rx, RX2, RY and/or RY2 is -(CH2)n7-O-R9, then in one embodiment n7 is 1,2 or<br>
3 and/or R9 is H, C1-2galkyl or phenyl, or more preferably R9 is H or C1-2galkyl. n7 is<br>
preferably 1 or 2, more preferably 1. R9 is preferably C1-4alkyl such as methyl or t-butyl.<br>
For example, -(CH2)n7-O-R9 can be -CE^-O-tBu or -CH2-O-Me.<br>
When Rx, RX2, RY and/or RY2 is (CH2)n11-C(O)-NR10R11,<br>
-CH(C1-2alkyl)-C(O)-NR10R11 (e.g. -CH(Me)-C(O)-NR10R11),<br>
-CMe2-C(O)-NR10R11, or C~3-5cycloalkyl (e.g. C3cycloalkyl) substituted at the<br>
connecting carbon atom by -C(O)-NR10R11, then: preferably it/they independently is/are<br>
-(CH2)n11-C(O)-NR10R11, -CH(C1-2alkyl)-C(O)-NR10R11 (e.g.<br>
-CH(Me)-C(O)-NR10R11, or -CMe2-C(O)-NR10R11; more preferably<br>
-(CH2)n11-C(O)-NR10R11; still more preferably -CH2-C(O)-NR10R11 or<br>
-C(O)-NR10R11.<br><br>
When Rx, R*2, RY and/or RY2 is -(CH2)nl 1-C(O&gt;NR10Rl l, then n11 is preferably 0<br>
or 1, more preferably 1.<br>
Preferably R10 is H or C1-6alkyl (e.g. C1-2alkyl or C1-2aUcyl or methyl), or R10 and<br>
Rll together are -(CH2)n8-X6-(CH2)n9-.<br>
Preferably, R10 and R11 independently are, and more preferably R11 is:<br>
H; C1-2galkyl; C1-2fluoroalkyl; C2-3alkyl substituted by one OH or -OC1-2alkyl other<br>
than at the connection point; C3-6cycloalkyl optionally substituted by one or two methyl<br>
groups; -CH2-C3-6cycloalkyl optionally substituted by one NHMe group (preferably<br>
unsubstituted); -(CH2)n17-Het2; optionally substituted carbon-linked-pyridinyl,<br>
optionally substituted phenyl; optionally substituted benzyl; or optionally substituted<br>
-CH(C1-2alkyl)Ph.<br>
More, preferably, R10 and R11 independently are, and still more preferably R11 is: H;<br>
C1-6alkyl; C3-6cycloalkyl optionally substituted by one or two methyl groups;<br>
-CH2-C3-6cycloalkyl (unsubstituted); -(CH2)1117-Het2; optionally substituted carbon-<br>
linked-pyridinyl; optionally substituted phenyl, optionally substituted benzyl; or<br>
optionally substituted -CH(C1-2alkyl)Ph (e.g. optionally substituted -CH(Me)Ph).<br>
Preferably, in R10 and/or R11, the phenyl, the benzyl and the -CH(C1-2alkyl)Ph (e.g.<br>
-CH(Me)Ph) are independently optionally substituted on the aromatic ring by one or two<br>
substituents independently being: fluoro, chloro, C1.2alkyl (e.g. methyl), C1fluoroalkyl<br>
(e.g. CF3), C1-2alkoxy (e.g. methoxy), C1fluoroalkoxy (e.g. CF3O- or CHF2O-),<br>
-NR10aR10b (wherein R10a is H or methyl and R10b is H, C1-2alkyl (e.g. methyl),<br>
-C(O)Me or -S(O)2Me), -C(O)-NR10cR10d (wherein R10c and R10d independently are<br>
H or C1-2alkyl, e.g. H or Me), or -S(O)2-R10e (wherein R10e is C1-2alkyl (e.g. methyl),<br>
NH2, NHMe or NMe2). One substituent is preferred.<br>
In RlO and/or R* 1, and/or (independently) in R^, and/or (independently) in R\$, and/or<br>
(independently) in R^ and/or R?, and/or (independently) in R*?, and/or (independently)<br>
in Rl 8; the carbon-linked-pyridinyl is preferably optionally substituted by one OH<br>
(including any keto tautomer thereof), and more preferably is not substituted.<br>
In RlÂ° andVor R11, for -(CH2)n17-Het2, preferably n*? is 0 or 1; and/or preferably Het2<br>
is a 5- or 6- membered saturated optionally substituted heterocyclic ring containing one O<br>
or S (preferably O) ring atom or one NR27 ring group. Preferably, R27 is C1-2alkyl or<br>
-C(O)Me. Preferably, the Het2 ring is substituted on a ring carbon by one or two<br>
substituents being methyl or is not substituted on a ring carbon.<br><br>
In one embodiment when RX, RX2, RY and/or RY2 is -(CH2)n11C(O)-NR10R11,<br>
-CH(C1-2alkyl)-C1-2-NR10R11 or -CMe2-C(O)-NR10R11, then optionally: R10 and<br>
R11 independently are H of C1-2alkyl; or R10 and R11 together are<br>
-(CH2)n8-X6-(CH2)n9- in which n8 and n9 independently are 2 or 3 and X6 is a bond,<br>
-CH2-, O, or NR12 wherein R12 is H or C1-2alkyl, and wherein the ring formed by<br>
NR10R11 is not substituted on a ring carbon.<br>
Preferably R10 is H and/or optionally R11 is C1-6alkyl e.g. C1-4alkyl such as isopropyl.<br>
For example, -(CH2)n11-C(O)NR10R11 such as -C(O)-NR10R11 can be <br>
In an alternative preferable embodiment, when R10 and R11 together are<br>
-(CH2)n8-X6-(CH2)n9-, then preferably n8 is 2 and/or n9 is 2. When R10 and R11<br>
together are -(CH2)n8-X6-(CH2)n9-, which is a preferable feature of the invention, then<br>
preferably X^ is a bond, -CH2-, O, or NR12 wherein R12 is H or C1-2alkyl, and wherein<br>
the ring formed by NR10R11 1 is not substituted on a ring carbon.<br>
When R10 and R11 together are -(CH2)n8-X6-(CH2)ri9-, it is preferable that the ring<br>
formed by NR10R11 is not substituted on a ring carbon or is substituted on a ring carbon<br>
by one methyl or oxo (=O) substituent.<br><br><br><br>
. (In the above-illustrated most preferred groups, and generally in this<br>
specification for a group or radical, where NH or N are underlined, then this indicates the<br>
connection point.)<br>
Still more preferably, When Rx, RX2, RY and/or RY2 is -(CH2)n11(CO-NR10R11,<br>
-CH(C1-2alkyl)-C(O)-NR10R11, -CMe2-C(O)-NRl0R11, or C~3-5cycloalkyl substituted<br>
at the connecting carbon atom by -C(O)-NR10R11, then preferably it/they independently<br>
is/are-(CH2)n11-C(O)-NR10R11 (more preferably-CH2-C(O)-NR10R11 or<br>
-C1-2-NR10R11) wherein NR10R11 is one of the above-illustrated most preferred<br>
groups.<br>
The -(CH2)n11-C(O)-NR10R11 group is preferably as defined in any of Examples 36,<br>
58, 84, 85-90, 95-96,126-147 or 148-155. These Examples illustrate some of the above-<br>
illustrated preferred NR10R11 groups, and some of these Examples give literature<br>
references and/or commercial sources for amines R10R11NH, Which may be used to<br>
prepare the compounds of Formula (I) containing the -(CH2)n11-C(O)-NR10R11 group<br>
as RX, RX2, RY and/or- RY2.<br>
When RX, RX2, RY and/or RY2 is -(CH2)n12-C(O)-ORl3 , n12 is preferably 0 or 1,<br>
more preferably 1. In one preferred embodiment when RX, RX2, RY and/or RY2 is<br>
-(CH2)n12-C(O)-OR13 R13 is H or C1-6alkyl. When R13 is C1-6alkyl, then R13 is<br>
preferably C1-4alkyl or C1-3alkyl such as methyl (e.g. RX, RY and/or RX2 can be<br>
-CO2Me) or ethyl.<br>
When RX, RX2, RY and/or RY2 is -(CH2)n13-C(O)-Rl3a, n13 is preferably 0 or 1,<br>
more preferably 1. When Rx, RX2, RY and/or RY2 is -(CH2)n13-C(O)-R13a, then<br>
suitably R13a is C1-2galkyl, C1-2fiuoroalkyl, C3-6cycloalkyl, -CH2-C3-6cycloalkyl,<br>
benzyl, or phenyl (wherein the phenyl and benzyl are independently optionally<br>
substituted on the aromatic ring by one or two of (independently) (e.g. one of) fluoro,<br><br>
chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy). More preferably R13a<br>
is C1-6alkyl or C1-4alkyl or C1-2alkyl.<br>
When Rx, RX2, RY and/or RY2 is -(CH2)n14-Het1, -CH(C1-2alkyl)-Het1 (e.g.<br>
-CH(Me)-Het1), -CMe2-Het1, or C~3-5cycloalkyl (e.g. C3cycloalkyl) substituted at the<br>
connecting carbon atom by Het1, wherein n14 is 0,1 or 2, then: (a) n14 is preferably 0 or<br>
1, and/or (b) -(CH2)n14-Het1 is more preferred than -CH(Me)-Het1 or -CMe2-Het1, or<br>
C~3-5cycloalkyl substituted at the connecting carbon atom by Ar.<br>
When Rx, RX2, RY and/or RY2 is -(CH2)n14-Hetl, -CH(C1-2alkyl)-Hetl (e.g.<br>
-CHOleJ-Het1), -CMe2-Het1, or C~3-5cycloalkyl (e.g. C3cycloallcyl) substituted at the<br>
connecting carbon atom by Het1, wherein n14 is 0,1 or 2 and wherein Het1 is the 4-, 5-,<br>
6- or 7-membered optionally substituted saturated heterocyclic ring containing one O or S<br>
ring atom and/or one NR14 ring group, then the optionally substituted saturated<br>
heterocyclic ring Het1 is preferably 4-, 5- or 6-membered, more preferably preferably 5-<br>
or 6-membered. When Het1 is 6-membered, then any O or S ring atom and/or any NR14<br>
ring group independently can be present at the 2-, 3- or 4- ring position, preferably at the<br>
4- ring position, with respect to the connecting ring-atom in Het1. When the optionally<br>
substituted saturated heterocyclic ring Het1 is 4-membered, then preferably the<br>
heterocyclic ring Het1 is not optionally substituted by oxo (=O).<br>
When R14 and/or a or the optional ring substituent is C1-4alkyl, it is suitably C1-2a&amp;yl<br>
such as methyl. Preferably, R14 is C1-4alkyl (e.g. C1-2alkyl), C(O)R19 or S(O)2R19.<br>
Preferably, Rl9 is C1-4alkyl (e.g. methyl or isobutyl), C3-6cycloalkyl such as<br>
cyclopropyl or cyclohexyl, 2-thienyl, furan-2-yl, phenyl (unsubstituted), or benzyl<br>
(unsubstituted); more preferably R14 is C1-4alkyl (e.g. methyl or isobutyl).<br>
When Rx R^, RY and/or RY2 is -(CH2)n14-Het1 and n14 is 0, and when the saturated<br>
heterocyclic ring Het1 is optionally substituted (at a position other than any NR14<br>
position) by C1-2alkyl, then preferably the optional Cj.4alkyl is substituted at the carbon<br>
atom directly attached to the 5-membered ring in sub-formula (i), (ii), (iii), (iv) or (v) of<br>
Het.<br>
The heterocyclic ring Het1 is preferably optionally substituted (at a position or positions<br>
other than any NR14 position) by one oxo (=O) and/or one C1-4alkyl substituent;<br>
preferably by one oxo (=O) substituent. Any oxo (=O) substituent is preferably<br>
substituted on a ring carbon adjacent to (bonded to) any NR14 ring group present.<br>
Preferably, in Het1, the one or two oxo (=O) substituents are only present when there is a<br>
NR14 ring group present.<br><br><br>
foregoing wherein the connection point [which connects to the -(CH2)n14-,<br>
-CH(C1-2alkyl)- or -CHMe2- or connecting-C~3-5cycloalkyl moiety or connects to the<br>
5-membered ring of sub-formula (i), (ii), (iii), (iv) or (v) in Het] is at a different ring<br>
carbon atom of Het1.<br>
When RX, RX2, RY and/or RY2 is -(CH2)n10-Ar, -CH(C1-2alkyl)-Ar (e.g.<br>
-CH(Me)-Ar), -CMe2-Ar, or C~3-5cycloalkyl (e.g. C3cycloalkyl) substituted at the<br>
connecting carbon atom by Ar, then preferably it/they independently is/are -(CH2)n10-Ar<br>
or -CH(Me)-Ar, preferably -(CH2)n10-Ar such as -CH2~Ar.<br>
When Rx, RX2, RY and/or RY2 is -(CH2)n10-Ar then preferably n10 is 0 or 1; more<br>
preferably n10 is 1.<br>
When Ar is optionally substituted phenyl, preferably the phenyl is optionally substituted<br>
by one or two substituents (preferably one) independently being fluoro, chloro, bromo,<br>
C1-2alkyl, Cifiuoroalkyl, C1-2alkoxy, C1fluoroalkoxy, -NRllaRllb (wherein R1 la is H<br>
or methyl and R1lb is H, C1-2alkyl, -C(O)Me or -S(O)2Me), -C1-2-NR1lcR1ld<br>
(wherein R1lc and R1ld independently are H or methyl), -C1-2-OR1le wherein R11e is<br>
H, or -S(O)2-R11f (wherein R11f is methyl, NH2, NHMe or NMe2). When Ar is<br>
optionally substituted phenyl, more preferably -(CH2)n10-Ar can be as defined for RX,<br>
RX2, RY and/or RY2 in any of Examples 49-55, 83,103,107,120-125,179,181-184,<br>
189 or 190.<br><br>
When Ar is phenyl optionally substituted at two adjacent Ar ring atoms by the two ends<br>
of a chain which is: -(CH2)4-, -(012)3-, or -CH=CH-CH=CH-, then it can be for<br>
example naphthyl e.g. 1-naphthyl or 2-naphthyl.<br>
When Ar is the optionally substituted 5- or 6-membered heterocyclic aromatic ring<br>
containing 1,2,3 or 4 heteroatoms (e.g. 1, 2 or 3 heteroatoms) selected from O, N or S ,<br>
then Ar can be optionally substituted: furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl,<br>
imidazolyl, oxadiazolyl (e.g. 1,3,4- or 1,2,4- or 1,2,5- oxadiazolyl), thiadiazolyl (e.g.<br>
1,3,4- or 1,2,4-), pyridyl, triazolyl (e.g. 1,2,3- or 1,2,4- triazolyl), tetrazolyl, triazinyl,<br>
pyridazyl, pyrimidinyl, pyrazolyl, isothiazolyl (1,2-thiazolyl), or isoxazolyl (1,2-<br>
oxazolyl). When Ar is the optionally substituted 5- or 6-membered heterocyclic aromatic<br>
ring, the ring is preferably optionally substituted by one or two independent C1-2alkyl<br>
groups or by one OH group (including any keto tautomer thereof); more preferably the<br>
ring is optionally substituted by one or two independent C1-2alkyl (e.g. methyl) groups;<br>
and still more preferably there is/are one or no substituents. When Ar is the optionally<br>
substituted 5- or 6-membered heterocyclic aromatic ring, preferably it is 5-membered.<br>
When Ar is the 5- or 6-membered heterocyclic aromatic ring, more preferably<br>
-(CH2)n10-Ar can be as defined for Rx, RX2, RY and/or RY2 in any of Examples 71,<br>
79, 80, 97-100,104-106,108,112-114,117,158 or 186.<br>
When the heterocyclic aromatic ring Ar is substituted at two adjacent Ar ring atoms by<br>
the two ends of a chain which is: -(CH2)4-, -(CH2)3-, or -CH=CH-CH=CH-, then e.g. Ar<br><br>
(see for example Example 186). Preferably, in these cases -(CH2)n10-Ar is -CH2-Ar.<br>
In R5, R15, R6, R7, R17, R18, R9, Rl3, R13a, and/or Rl9, independent of each other,<br>
the phenyl and/or benzyl is/are preferably independently optionally substituted by one<br>
substituent; or more preferably the phenyl and/or benzyl is/are not substituted. In R*0<br>
and/or R11, independent of each other, the phenyl, benzyl and/or -CH(C1-2alkyl)Ph<br>
is/are preferably independently optionally substituted by one substituent; or more<br>
preferably the the phenyl, benzyl and/or -CH(C1-2alkyl)Ph is/are not substituted. In Ar,<br>
the phenyl and/or the heterocyclic aromatic ring is/are preferably independently<br>
optionally substituted by one substituent; or more preferably the phenyl and/or the<br>
heterocyclic aromatic ring is/are not substituted. In Het1 and/or Het2, independent of<br>
each other, the saturated heterocyclic ring is/are preferably independently optionally<br>
substituted on a ring carbon by one substituent; or more preferably the saturated<br>
heterocyclic ring is/are not substituted on a ring carbon.<br><br>
When Het is of sub-formula (v), then suitably R^2 and/or R.Y2 independently is/are: a<br>
hydrogen atom (H), C1-2alkyl (e.g. C1-2alkyl such as methyl), C3-6cycloalkyl,<br>
-C(O)-NR10R11, -C(O)-ORl3, or -(CH2)nl0-Ar, more preferably H, C1-6alkyl,<br>
-C(O)-NR10R11, -C(O)-ORl3, or-(CH2)n10-Ar; still more preferably H, C1-6alkyl (e.g.<br>
C1-4alkyl such as methyl), -C(O)-NR10Rl 1, or -(CH2)n10-Ar. In this instance, i.e.<br>
when Het is of sub-formula (v), then Ar is preferably optionally substituted phenyl and/or<br>
n^ is preferably 0 or 1.<br>
Preferably, RX1 and/or RY1 independently is/are a hydrogen atom (H) or C1-2alkyl,<br>
more preferably H or methyl, still more preferably H.<br>
Suitably, Y$ can be CH2 or CMe2- More preferably, Y5 is CH2, i.e. CRY1RY2 wherein<br>
RYl = RY2 = a hydrogen atom (H).<br>
X5 can suitably be CHRX2 or CMe2, for example CHMe, CH-CO2Me or CMe2-<br>
It is particularly preferred that the compound of formula (I) or the salt thereof is:<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
A second aspect of the present invention provides a compound of formula (IA) or a salt<br>
thereof (in particular, a pharmaceutically acceptable salt thereof):<br>
wherein:<br>
R1 is C1-4alkyl, C1-2fluoroalkyl or -(CH2)2OH;<br>
R2 is a hydrogen atom (H), methyl or C1fluoroalkyl;<br>
R3 is optionally substituted branched C3-6alkyl, optionally substituted C3-8cycloalkyl,<br>
optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-<br>
formula (aa). (bb) or (cc):<br><br>
in which n1 and n2 independently are 1 or 2; and Y is O, S, SO2, or NR4; where R4 is a<br>
hydrogen atom (H), C1-2alkyl, C1-2fluoroalkyl, CH2C(O)NH2, C(O)NH2,<br>
C(O)-C1-2alkyl, or C1-2-C1fluoroalkyl;<br>
wherein in H? the optionally substituted branched C1-2galkyl is optionally substituted with<br>
one or two substituents being oxo (=O), OH, C1-2alkoxy or C1-2fluoroalkoxy; and<br>
wherein any such substituent is not substituted at the R3 carbon atom attached (bonded)<br>
to the -NH- group of formula (IA);<br>
wherein in R3 the phenyl is optionally substituted with one substituent being fluoro,<br>
chloro, C1-2alkyl, C1-2fluoroalkyl, C1-2alkoxy, C1-2fluoroalkoxy or cyano;<br>
wherein in R3 the C3-8cycloalkyl or the heterocyclic group of sub-formula (aa), (bb) or<br>
(cc) is optionally substituted with one or two substituents being oxo (=O), OH,<br>
C1-2alkoxy, C1-2fluoroalkoxy, or C1-2alkyl; and wherein any OH, alkoxy or<br><br>
fluoroalkoxy substituent is not substituted at the R3 ring carbon attached (bonded) to the<br>
-NH- group of formula (IA) and is not substituted at either R3 ring carbon bonded to the<br>
Y group of the heterocyclic group (aa), (bb) or (cc);<br>
and wherein Het is of sub-formula (i), (ii), (in), (iv) or (v):<br><br>
wherein:<br>
W1, W2, W4 and W5 is N; and W3 is NRW;<br>
X1, X3 and X4 is N or CRX; X2 is O, S or NRX; and X5 is CRX1RX2;<br>
Yl, Y2 and Y3 is CRY or N; Y4 is O, S or NRY ; and Y5 is CRY1RY2;<br>
Z1 and Z5 is O, S or NRZ; and Z2, Z3 and Z4 is N or CRZ;<br>
wherein:<br>
RW is a hydrogen atom (H) or C1-2alkyl;<br>
Rx, RX2, RY and RY2 independently are:<br>
a hydrogen atom (H);<br>
C1-2alkyl;<br>
C3-6cycloalkyl optionally substituted by a C1-2alkyl group;<br>
-(CH2)n2a-C3-6cycloalkyl optionally substituted, in the -(CH2)n2a- moiety or in<br>
the C3-6cycloalkyl moiety, by a C1-2alkyl group, wherein n2a is 1,2 or 3;<br>
-(CH2)n3-SO2-R5 wherein n3 is 1 or 2 and R5 is C1-3alkyl or -NH-C1-2alkyl or<br>
phenyl;<br>
-(CH2)n4-NR6R7 wherein n4 is 0,1, 2 or 3, and R6 and R7 independently are H,<br>
C1-6alkyl e.g. C1-2alkyl, C3-6cycloalkyl, -CH2-C3-6cycloalkyl,<br>
-C(O)-C1-2alkyl, -SO2-C1-2alkyl, phenyl, or benzyl (wherein the phenyl or<br>
benzyl are independently optionally substituted on the aromatic ring by one of<br>
fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy); or<br>
R6 and R7 together are -(CH2)n5-X5-(CH2)n6- in which n5 and n6<br><br>
independently are 2 or 3 and X5 is a bond, -CH2-, O, or NR8 wherein R8 is H<br>
orC1-2alkyl;<br>
-(CH2)n7-0-R9; wherein n7 is 0,1, 2 or 3 and R9 is H or C1-2alkyl; wherein n7 is<br>
0 only when the -(CH2)n7-0-R9 is bonded to a carbon atom in the Het ring;<br>
and wherein n7 is not 0 when Het is of sub-formula (v) (i.e. n7 is not 0 for<br>
RX2andforRY2);<br>
-C(O)-NR10R11 wherein R10 and R11 independently are H, C1-6alkyl,<br>
C3-6cycloalkyl, -CH2-C3-6cycloalkyl, phenyl, or benzyl (wherein the phenyl<br>
or benzyl are independently optionally substituted on the aromatic ring by one<br>
of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy);<br>
or Rl 0 and R1! together are -(CH2)n8-X6-(CH2)n9- in which n8 and n9<br>
independently are 2 or 3 and X6 is a bond, -CH2-, O, or NR12 wherein R12 is<br>
HorC1-2alkyl;<br>
-C(O)-OR13 wherein R13 is H, C1-2galkyl, C3-6cycloalkyl, -CH2-C3-6cycloalkyl,<br>
phenyl, or benzyl (wherein the phenyl or benzyl are independently optionally<br>
substituted on the aromatic ring by one of fluoro, chloro, C1-2alkyl,<br>
C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy);<br>
-C(O)-Rl3a wherein R13a is a hydrogen atom (H), C1-6alkyl, C1fluoroalkyl,<br>
C3-6cycloalkyl, -CH2-C3-6cycloalkyl, benzyl, or phenyl; wherein the phenyl<br>
or benzyl are independently optionally substituted on the aromatic ring by one<br>
of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, Cj^alkoxy or C1fluoroalkoxy;<br>
a 4-, 5-, 6- or 7-membered saturated heterocyclic ring containing one O ring atom or<br>
one NR14 ring group wherein R14 is H or C1-4alkyl, said heterocyclic ring<br>
being optionally substituted (at a position or positions other than any NR14<br>
position) by one oxo (=O) and/or one C1-2alkyl substituent; or<br>
-(CH2)n10-Ar wherein n10 is 0,1 or 2 and<br>
(i) Ar is phenyl optionally substituted by one or two substituents being fluoro,<br>
chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy, C1fluoroalkoxy or cyano;<br>
or<br>
(ii) Ar is an optionally substituted 5- or 6-membered heterocyclic aromatic<br>
ring containing 1,2 or 3 heteroatoms selected from O, N or S; and wherein<br>
when the heterocyclic aromatic ring Ar contains 2 or 3 heteroatoms, one is<br>
selected from O, N and S and the remaining heteroatom(s) are N; and wherein<br>
the heterocyclic aromatic ring Ar is optionally substituted by one or two<br>
C1-4alkyl groups;<br>
RX1 and RY1 independently are a hydrogen atom (H), C1-2alkyl or C1fluoroalkyl; and<br>
RZ is a hydrogen atom (H) or C1-2alkyl.<br><br>
Preferably, in formula (IA), when R3 is the heterocyclic group of sub-formula (bb), n1 is<br>
1, and Y is NR4, then R4 is not C1-2alkyl, C1-2fluoroalkyl or CH2C(O)NH2.<br>
Examples 1-48 are examples of compounds or salts of the second aspect of the invention<br>
(Formula (IA)).<br>
The preferred or optional features for the compound of formula (IA) or salt thereof are<br>
the same as or similar to the preferred or optional features for the compound or salt of<br>
formula (I), with all necessary changes (for example to the formula, to the R groups<br>
and/or to substituents) having been made. Generally, whenever formula (I) is mentioned<br>
herein, then in alternative embodiments the statement mentioning formula (I) applies to<br>
formula (IA), with all necessary changes having been made.<br>
Salts, solvates, isomers, tautomeric forms, molecular weights, etc.<br>
Because of their potential use in medicine, the salts of the compounds of formula (I) are<br>
preferably pharmaceutically acceptable. Suitable pharmaceutically acceptable salts can<br>
include! acid or base addition salts.<br>
A pharmaceutically acceptable acid addition salt can be formed by reaction of a<br>
compound of formula (I) with a suitable inorganic or organic acid (such as hydrobromic,<br>
hydrochloric, sulfuric, nitric, phosphoric, succinic, maleic, formic, acetic, propionic,<br>
fumaric, citric, tartaric, lactic, benzoic, salicylic, glutamaic, aspartic, p-toluenesulfonic,<br>
benzenesulfonic, methanesulfonic, ethanesulfonic, naphthalenesulfonic such as 2-<br>
naphthalenesulfonic, or hexanoic acid), optionally in a suitable solvent such as an organic<br>
solvent, to give the salt which is usually isolated for example by crystallisation and<br>
filtration. A pharmaceutically acceptable acid addition salt of a compound of formula (I)<br>
can be for example a hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate,<br>
maleate, formate, acetate, propionate, fumarate, citrate, tartrate, lactate, benzoate,<br>
salicylate, glutamate, aspartate, p-toluenesulfonate, benzenesulfonate, methanesulfonate,<br>
ethanesulfonate, naphthalenesulfonate (e.g. 2- naphthalenesulfonate) or hexanoate salt.<br>
In one embodiment, the pharmaceutically acceptable acid addition salt can be a<br>
hydrobromide, hydrochloride, sulfate, nitrate, phosphate, succinate, maleate, acetate,<br>
fumarate, citrate, tartrate, benzoate, p-toluenesulfonate, methanesulfonate or<br>
naphthalenesulfonate salt.<br>
A pharmaceutically acceptable base addition salt can be formed by reaction of a<br>
compound of formula (I) with a suitable inorganic or organic base (e.g. triethylamine,<br>
ethanolamine, triethanolamine, choline, arginine, lysine or histidine), optionally in a<br>
suitable solvent such as an organic solvent, to give the base addition salt which is usually<br>
isolated for example by crystallisation and filtration.<br><br>
Other suitable pharmaceutically acceptable salts include pharmaceutically<br>
acceptable metal salts, for example pharmaceutically acceptable alkali-metal or alkaline-<br>
earth-metal salts such as sodium, potassium, calcium or magnesium salts; in particular<br>
pharmaceutically acceptable metal salts of one or more carboxylic acid moieties that may<br>
be present in the the compound of formula (I).<br>
Other non-pharmaceutically acceptable salts, eg. oxalates, may be used, for<br>
example in the isolation of compounds of the invention, and are included within the scope<br>
of this invention.<br>
The invention includes within its scope all possible stoichiometric and non-<br>
stoichiometric forms of the salts of the compounds of formula (I).<br>
Also included within the scope of the invention are all solvates, hydrates and<br>
complexes of compounds and salts of the invention.<br>
Certain groups, substituents, compounds or salts included in the present invention<br>
may be present as isomers. The present invention includes within its scope all such<br>
isomers, including racemates, enantiomers and mixtures thereof.<br>
Certain of the groups, e.g. heteroaromatic ring systems, included in compounds<br>
of formula (I) or their salts may exist in one or more tautomeric forms. The present<br>
invention includes within its scope all such tautomeric forms, including mixtures. For<br>
example, when Het is of sub-formula (i), Y1 is CRY, and X1 is CRX wherein RX is OH,<br>
then the compounds of formula (I) or their salts include the keto form (Kl), the enol form<br>
(El), and mixtures thereof, as shown below, unless otherwise indicated; and when Het is<br>
of sub-formula (i) and Y1 is CRY wherein RY is OH, then the compounds of formula (I)<br>
or their salts include the keto form (K2), the enol or hydroxy-imine form (E2), and<br>
mixtures thereof, as shown below, unless otherwise indicated:<br><br>
Especially when intended for oral medicinal use, the compound of formula (I) can<br>
optionally have a molecular weight of 1000 or less, for example 800 or less, in particular<br>
650 or less or 600 or less. Molecular weight here refers to that of the unsolvated "free<br>
base" compound, that is excluding any molecular weight contributed by any addition<br>
salts, solvent (e.g. water) molecules, etc.<br>
Synthetic Process Routes<br>
The following processes can be used to make the compounds of formula (I) The<br>
methods are sometimes illustrated for the circumstance where R2 is H or Me. However,<br><br>
some or all of these processes are thought to be usable with appropriate modification, e.g.<br>
of starting materials and reagents, for making compounds of Formula (I) wherein R2 is<br>
C1fluoroalkyl.<br>
Process A<br>
Compounds of formula (T) which are compounds of Formula I(ia) (that is, compounds of<br>
formula (I) wherein Het is of sub-formula (ia)) can be prepared by the cyclisation reaction<br>
of a compound of Formula II, for example in the presence of a dehydrating agent such as<br>
phosphorous oxychloride (POCl3) or Burgess reagent<br>
[(Methoxycarbonylsulphamoyl)triethylammonium hydroxide], and/or preferably in a<br>
suitable solvent (e.g. organic solvent, preferably anhydrous) such as acetonitrile (e.g. for<br>
POCl3) or THF and/or DMF (e.g. for Burgess reagent). The reaction may require heating,<br>
for example heating to from about 70 to about 150 Â°C or heating to from about 70 to<br>
about 120 Â°C or heating to from about 70 to about 90 Â°C:<br><br>
For the Formula II to Formula I(ia) cyclisation reaction, the conditions can for example<br>
be as described in (a) Examples 1-3 or 43 (POCl3 and acetonitrile), or (b) in Examples<br>
32, 34-37, 35 (alternative synthesis), 38-40,44, 66 or 97-125 (Burgess reagent, with THF<br>
and/or DMF).<br>
Compounds of Formula II may themselves be prepared by reacting a compound of<br>
Formula HI with a suitably substituted hydrazine derivative of formula RYCONHNH2,<br>
under standard coupling conditions. For example a coupling reagent such as<br>
1-(3-dimemylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) may be used e.g.<br>
in the presence of hydroxybenzotriazole (HOBT), for example in a suitable solvent such<br>
as DMF:<br><br><br>
Where the required hydrazine derivative RYCONHNH2 is not readily available,<br>
compounds of Formula II may alternatively be prepared by initially reacting a compound<br>
of Formula m with a carbazate ROCONHNH2 such as t-butylcarbazate tBuOCONHNH2<br>
under coupling conditions to form a compound of formula IV. For example a coupling<br>
reagent such as EDC may be used, e.g. in the presence of hydroxybenzotriazole, for<br>
example in a suitable solvent such as DMF:<br><br>
Subsequent Boc-deprotection of the resultant acid hydrazide derivative (compound of<br>
Formula IV) to afford a hydrazide derivative of Formula V, can be achieved using a<br>
dilute acid such as 2M hydrochloric acid in an organic solvent such as dioxane.<br>
The compound of Formula V can be converted to the compound of Formula II (the<br>
desired hydrazide derivative). This can be achieved by reaction of the compound of<br>
Formula V with an acid of formula RYCO2H under coupling conditions. For example a<br>
coupling agent such as EDC may be used e.g. in the presence of hydroxybenzotriazole<br><br>
(HOBT), for example in a suitable solvent such as DMF. Alternatively, an activated acid<br>
derivative of formula RYCO-X10 where X is a leaving group such as chloro (acid<br>
chloride) or -O-CO-R30 or -O-SO2-R30 (where R30 can e.g. be RY or alkyl or aryl such<br>
as methyl, t-butyl or p-methylphenyl) may be used to effect formation of a hydrazide of<br>
Formula II, through reaction with a hydrazide derivative of Formula V.<br>
Compounds of Formula EI can be prepared by hydrolysis of an ester of Formula VI (for<br>
example RA can be C1-2alkyl such as Et), for example according to the method<br>
described by Yu et. al. in J. Med Chem., 2001, 44,1025-1027. This hydrolysis procedure<br>
usually involves reaction with a base such as sodium hydroxide or potassium hydroxide<br>
in a solvent such as ethanol or dioxane (e.g. NaOH in EtOH), one or both solvents<br>
preferably containing some water:<br><br>
Compounds of Formula VI can be prepared, e.g. according to the method described by<br>
Yu et. al. in J. Med Chem., 2001,44,1025-1027, by reaction of a compound of Formula<br>
VII with an amine of Formula R3R3aNH. The reaction is best carried out in the presence<br>
of abase such as trieraylamine or diisopropylethyl amine in a solvent such as ethanol or<br>
dioxane (e.g. NEta in EtOH) and may require heating:<br><br>
Many amines of Formula R3R3aNH, e.g. those amines wherein R3R3aN are of sub-<br>
formulae (a) to (t2), are either commercially available, or syntheses therefor have been<br>
published and/or described herein, or they can be prepared from commercially available<br>
or synthesizable compounds e.g. from other amines of Formula R3R3aNH or derivatives<br>
thereof. For amines R3R3aNH whose preparations and/or specific commercial sources<br>
are described herein, see e.g. Intermediates 21,21A, 25, 50, 54-57, and 140-163.<br><br>
Compounds of Formula VII are also described in the above reference and can. be prepared<br>
first by reaction of a compound of Formula VIH with, for example, diethyl<br>
(ethoxymethylene)malonate (R2 = H, to afford RA = Et) or diethyl<br>
2-(1-ethoxyethylidene)malonate (R2 = Me, to afford RA = Et), e.g. with heating,<br>
followed by reaction with phosphorous oxychloride, again preferably with heating. See<br>
for example Intermediate 1 synthesis and G. Yu et. al., J. Med Chem., 2001,44,1025-<br>
1027 hereinafter, where R2 = H and R1 = ethyl; and see Intermediate 58 synthesis<br>
hereinafter where R2 = Me and R1 = ethyl:<br><br>
Where, for example, the desired amino pyrazole of Formula Vm is not commercially<br>
available, preparation of the Formula VIH pyrazole can be achieved, for example using<br>
methods described by Dorgan et. al. in J. Chem. Soc, Perkin Trans. 1980,1 (4), 938-42,<br>
involving reaction of cyanoethyl hydrazine with a suitable aldehyde R1aCHO in a solvent<br>
such as ethanol, with heating, followed by reduction, for example reduction with sodium<br>
in a solvent such as t-butanol. R1a should be chosen so as to contain one less carbon atom<br>
than R1, for example Rla= methyl will afford R1 = ethyl.<br><br>
Alternatively, e.g. where the desired amino pyrazole of Formula VIII is not commercially<br>
available, preparation of the compound of Formula VI can be achieved from the<br>
compound of Formula VII (e.g. Intermediate 1 wherein Rl = ethyl), using a generalised<br>
version of the reaction scheme shown in Example 43, especially that part relating to<br>
conversion of Intermediate 1 to Intermediate 38. In this method: the 4-chloro<br>
pyrazolopyridine of Formula VII (e.g. Intermediate 1) is optionally converted to the 4-<br>
alkoxy (e.g. C1-4alkoxy such as ethoxy) pyrazolopyridine (e.g. Intermediate 35); the R1<br>
group is removed (to e.g. Intermediate 36 wherein R^ is H rather than alkyl), the 4-amino<br>
R3R3aN group is inserted by displacing the 4-chloro or 4-alkoxy group by reaction with<br>
R3R3aNH (e.g. to Intermediate 37); and the pyrazolopyridine is alkylated at N-1 by<br>
reacting it with R1-X40 where X40 is a group displaceable by the N-1 nitrogen of the<br>
pyrazolopyridine in order to re-insert the desired R1 group (e.g. Intermediate 38<br><br>
synthesis). X40 can for example be a halogen, e.g. CI, Br or I; or X40 can be<br>
-O-SO2-R40 where R40 is C1-2alkyl, C1-2fluoroalkyl, or phenyl optionally substituted<br>
by C1-2alkyl.<br>
Process B<br>
Compounds of formula (I) which are compounds of Formula I(ia) (that is, compounds of<br>
formula (I) wherein Het is of sub-formula (ia)) can alternatively be prepared by reaction<br>
of a compound of Formula IX with an amine of formula R3R3 aNH, preferably in a<br>
solvent (e.g. organic solvent) such as ethanol or acetonitrile, and/or preferably in the<br>
presence of a base such as DIPEA. Heating may be required to effect the conversion:<br><br>
For the reaction of a compound of Formula DC with an amine of formula R3R3aNH to<br>
prepare the compound of Formula I(ia), the reaction conditions, e.g. solvents, mole ratios,<br>
temperatures and/or reaction times, can optionally be as described in Examples 9,10-11<br>
and/or 12-27.<br>
The reaction of Formula DC with R3R3aNH to give Formula I(ia) can be generalised for<br>
any compound of Formula (I), containing any Het group as defined herein, starting from a<br>
compound of Formula DCa:<br><br>
Compounds of Formula DC can themselves be prepared by cyclisation of a compound of<br>
Formula X, preferably in the presence of a dehydrating agent such asphosphorous<br>
oxychloride or Burgess reagent [(Methoxycarbonylsulphamoyl)triethylammonium<br>
hydroxide], in a suitable solvent (e.g. organic solvent, preferably anhydrous) such as<br><br>
acetonitrile (e.g. for POCl3) or THF and/or DMF (e.g. for Burgess reagent). The reaction<br>
may require heating, for example heating to from about 70 to about 150 Â°C or heating to<br>
from about 70 to about 120 Â°C or heating to from about 70 to about 90 Â°C:<br><br>
Compounds of Formula X can be prepared by initial activation of an acid of Formula XI,<br>
for example with an amide coupling reagent such as EDC/HOBT or with thionyl chloride,<br>
followed by reaction of the thus formed activated intermediate with an acid hydrazide of<br>
Formula RYCONHNH2:<br><br>
Examples of reactions of the compound of Formula XI to Formula X and of the<br>
compound of Formula X to Formula DC are presented in Intermediates 12 to 15.<br>
Acids of Formula XI can themselves be prepared by hydrolysis of an ester of Formula<br>
VII (e.g. as described in Process A) using a base such as potassium hydroxide in a solvent<br>
such as aqueous dioxane dioxane/water):<br><br>
Process C<br>
Compounds of Formula XII (that is, compounds of formula (I) wherein Het is of<br>
sub-formula (ib)) can be prepared by reaction of a compound of Formula II with a reagent<br><br>
capable of inserting sulfur, such as Lawesson's reagent, usually in a suitable solvent such<br>
as acetonitrile. The reaction may require heating:<br><br>
The reaction conditions, e.g. solvents, mole ratios, temperatures and/or reaction times,<br>
can optionally be as described in Examples 4, 5 or 6.<br>
Process D<br>
Compounds of Formula XIII [which are compounds of formula (I) wherein Het is of<br>
sub-formula (ic)] can be prepared by reaction of a compound of Formula VI (RA can be<br>
C1-2alkyl such as Et) with an amidoxime of formula RXC(=NOH)NH2 , preferably in the<br>
presence of a base such as sodium ethoxide and/or preferably in a suitable solvent (e.g.<br>
anhydrous and/or organic solvent) such as ethanol, and preferably in the presence of<br>
molecular sieves (e.g. 4 Angstrom and/or powdered molecular sieves) or under other<br>
conditions effective for removing water. The reaction mixture may optionally be heated,<br>
for example to reflux:<br><br>
The reaction conditions, e.g. solvents, mole ratios, temperatures and/or reaction times,<br>
can optionally be as described in Examples 7,28-29, 30, 31,48, 82-84, 92, 93 and/or<br>
178-187.<br>
Process E<br>
Compounds of Formula XTV (which are compounds of formula (I) wherein Het is of<br>
sub-formula (if)) can be prepared by reaction of a compound of Formula XV with a<br>
suitable acetimidate Rx-C(=NH)ORE, where RE is C1-6alkyl e.g. methyl, (such as<br><br>
methyl acetimidate (Rx = Me)), preferably in the presence of a base (such as<br>
triethylamine or sodium ethoxide) and/or in a suitable solvent (e.g. anhydrous and/or<br>
organic solvent) such as ethanol:<br><br>
Compounds of Formula XV may themselves be prepared by reaction of a compound of<br>
Formula m with a suitably substituted hydrazine derivative of Formula RZNHNH2, under<br>
coupling conditions. For example a coupling agent such as EDC may be used, e.g. in the<br>
presence of hydroxybenzotriazole (HOBT), in a suitable solvent such as DMF:<br><br>
Process F<br>
To make a compound of formula (I) wherein Het is of sub-formula (id) (optionally<br>
substituted l,3-oxazo1-2-yl), methods known to the skilled person can be used.<br>
For example, the 5-carboxylic acid compound of Formula HI can be converted directly or<br>
indirectly to a compound of formula (I) wherein Het is of sub-formula (id) (i.e. to a 5-<br>
(optionally-substituted l,3-oxazo1-2-yl)-pyrazolopyridine). Alternatively or additionally,<br>
a compound of formula (I), wherein Het is of sub-formula (va) in which RX1 and RY1<br>
are H and RX1 is RX and RY1 is RY [i.e. the corresponding 5-(optionally-substituted<br>
4,5-dihydro-l,3-oxazo1-2-yl)-pyrazolopyridine], can be dehydrogenated to a compound of<br>
formula (I) wherein Het is of sub-formula (id); e.g. by the method shown in Example 41<br>
(DBU, CCl4, CH3CN, Pyridine) or a modification of this method or by an analogous<br>
method for example using an oxidising agent.<br>
The dehydrogenation (oxidation) of the 4,5-dihydro-l,3-oxazo1-2-yl compound of<br>
formula (I) (wherein Het is of sub-formula (va) in which RX1 and RY1 are H and RX1 is<br>
RX and RY1 is RY) to the corresponding l,3-oxazo1-2-yl compound of formula (I)<br><br>
wherein Het is of sub-formula (id) can be carried out using reagents and conditions<br>
known to the skilled man (see for example the following reviews: T.G. Gant et al.,<br>
Tetrahedron, 1994, 50(8), 2297-2360; MLReuman et al., Tetrahedron, 1985,41(5), 837-<br>
860; and references cited therein). For this dehydrogenation reaction, preferably an<br>
oxidising agent is used such as nickel peroxide, manganese dioxide (MnO2), or 2,3-<br>
dichloro-5,6-dicyano-l ,4-benzoquinone (DDQ).<br>
A compound of formula (I) wherein Het is of sub-formula (va) can be prepared by<br>
cyclisation of a compound of Formula XXVIII, for example in the presence of Burgess<br>
reagent and/or preferably in a suitable solvent (e.g. organic solvent, preferably<br>
anhydrous) such as THF.<br><br>
The compound of Formula XXVH1 can be prepared from the compound of Formula III<br>
by reaction with the compound of Formula XXIX under coupling conditions (e.g. EDC<br>
with or without HOBT), optionally in the presence of a base such as Et3N, and preferably<br>
in a suitable solvent such as DMF.<br>
Process G<br>
Compounds of the invention of Formula XVI (1,2,4-oxadiazoles), which are compounds<br>
of formula (I) wherein Het is of sub-formula (ic) and Rx is -CH2C(O)NR10R11 can be<br>
prepared by reaction of a compound of the Formula XVII with an amine of Formula<br><br>
R10R11NH, under coupling conditions. Standard coupling conditions can be used<br>
known to the skilled person. For example a coupling agent such as TBTU may be used,<br>
preferably in the presence of hydroxybenzotriazole. However, it is more preferable that<br>
the coupling agent is oxalyl chloride, which in the reaction forms the corresponding acid<br>
chloride from the carboxylic acid of the compound of Formula XVII; in this embodiment<br>
it is preferable that the acid chloride is not isolated, i.e. the solvent in which it is formed<br>
is preferably not removed to a substantial extent. Preferably, whatever the coupling agent<br>
/ coupling conditions, the reaction is carried out in the presence of a base such as<br>
diisopropylethylamine, and/or in a suitable solvent (e.g. organic solvent, preferably<br>
anhydrous) such as DMF and/or dicloromethane.<br><br>
The reaction conditions for the Formula XVII to Formula XVI reaction, e.g. solvents,<br>
mole ratios, temperatures and/or reaction times, can optionally be as described in<br>
Examples 85-90, 95-96 and/or 148-155.<br>
Compounds of Formula XVII may themselves be prepared by reaction of a compound of<br>
Formula XVIII (RG is preferably tBu) with a hydrolysing agent (e.g. an acid such as<br>
trifluoroacetic acid) in a solvent such as dichloromethane:<br><br>
Compounds of Formula XVIII can be prepared by reaction of a compound of Formula VI<br>
(RA = H) with an amidoxime of formula RGOC(=O)CH2C(=NOH)NH2 and a coupling<br>
agent, for example TBTU, preferably in the presence of hydroxybenzotriazole, preferably<br>
in the presence of a base such as diisopropylemylamine and/or in a suitable solvent such<br>
as DMF, followed by reaction with l,l'-carbonyldiimidazole:<br><br><br>
Process H<br>
Compounds of Formula XIX, which are compounds of formula (I) wherein Het is of<br>
sub-formula (ic) and Rx is -CH2-NR6R7 wherein R7 is C(O)R17, may be prepared from<br>
compounds of Formula XX. For example, this can be by reaction of the compound of<br>
Formula XX with a carboxylic acid R17COOH in the presence of a coupling agent, for<br>
example TBTU, preferably with hydroxybenzotriazole, and preferably in the presence of<br>
a base such as diisopropylethylamine in a suitable solvent such as DMF. Alternatively or<br>
additionally, the compound of Formula XX can be reacted with an activated derivative of<br>
the carboxylic acid moiety of R17COOH (e.g. by reaction with an acid chloride<br>
R17C(O)Cl), preferably in the presence of a base such as diisopropylethylamine and/or in<br>
a suitable solvent (e.g. organic) such as dichloromethane and/or chloroform.<br><br>
The reaction conditions for the Formula XX to Formula XIX reaction, e.g. solvents, mole<br>
ratios, temperatures and/or reaction times, can optionally be as described in any of<br>
Examples 159-165.<br>
Compounds of Formula XX, which are compounds of formula (I) wherein Het is of<br>
sub-formula (ic) and RX is -CH2-NR6R7 wherein R7 is H, may be prepared by<br>
deprotecting compounds of Formula XXI wherein RH is benzyl or C1-6alkyl such as tBu<br>
e.g. by reaction with an acid such as trifluoroacetic acid (e.g. where RH is C1-2galkyl<br>
such as tBu) or by hydrogenation (e.g. where RH is benzyl), preferably in a suitable<br>
solvent such as dichloromethane:<br><br><br>
Compounds of Formula XXI can be prepared by reaction of a compound of Formula VI<br>
(but wherein RA is OH) with an amidoxime of formula<br>
RHOC(=O)N(R6)CH2C(=NOH)NH2 and a coupling agent, for example TBTU, preferably<br>
in the presence of hydroxybenzotriazole, and preferably in the presence of a base such as<br>
diisopropylethylarnine, and/or preferably in a suitable solvent such as DMF, followed by<br>
reaction with a base such as l,8-diazabicyclo[5.4.0]undec-7-ene:<br><br>
Process I<br>
Compounds of Formula XXII, which are compounds of formula (I) wherein Het is of<br>
sub-formula (ic) and RX is -CH2-NR6R7 wherein R7 is -S(O)2R18, may be prepared<br>
from compounds of Formula XX by reaction with a sulphonyl chloride Rl8S(O)2Cl,<br>
preferably in the presence of a base such as triethylamine and/or pyridine, and/or<br>
preferably in a suitable solvent (e.g. organic) such as dichloromethane and/or chloroform:<br><br>
The reaction conditions, e.g. solvents, mole ratios, temperatures and/or reaction times,<br>
can optionally be as described in any of Examples 166-172.<br><br>
Process J<br>
Compounds of Formula XXHI are compounds of formula (I) wherein Het is of<br>
sub-formula (ic) and Rx is -CH2-NR6R7, wherein R6 and R7 together are<br>
-(CH2)n5-X5-(CH2)n6- in which n5 and n6 independently are 2 or 3, and wherein the<br>
ring formed by NR6R7 is substituted by one oxo (=O) substituent at a carbon atom within<br>
(CH2)n6 which carbon atom is bonded to the nitrogen.<br>
Compounds of Formula XXIII can be prepared by reaction of a compound of the type<br>
Formula XX wherein R6 = H with acid chlorides of the type<br>
xJ-(CH2)n5-X5-(CH2)(n6-1)-COCl, where XJ is a leaving group, preferably in the<br>
presence of a base such as triemylamine and/or preferably in a suitable solvent, for<br>
example dichloromethane or tetrahydrofuran, preferably followed by treatment with a<br>
base such as sodium hydride in a suitable solvent such as DMF. The leaving group XJ<br>
can for example be a halogen atom such as CI, Br or I; or X^ can for example be<br>
-O-SO2-RJ where RJ is C1-4alkyl, C1-2fluoroalkyl, or phenyl optionally substituted by<br>
C1-2alkyl e.g. 4-methylphenyl.<br><br>
For examples of reaction conditions for the Formula XX to Formula XXIII reaction, see<br>
for example Intermediates 119 and/or 120 and/or subsequent Examples 173 and/or 174.<br>
Process K<br>
Compounds of the type Formula XXIV, which are compounds of formula (I) wherein Het<br>
is of sub-formula (iia), can be prepared from compounds of the type Formula XXV by<br>
reaction with R^C(O)X^ where X&amp; is a leaving group, preferably in a solvent such as<br>
acetic acid, pyridine, diglyme and/or dichloromethane. XK can for example be chloro;<br>
or RYC(O)XK can be an anhydride such as [RY(C=O)]2O; or RYC(O)XK can be an<br>
activated carboxylic acid derivative prepared from the reaction of RYC(O)OH with a<br>
coupling reagent such as EDC or TBTU with or without the presence of HOBT.<br><br><br>
For the Formula XXV to Formula XXW reaction, the reaction conditions can for<br>
example be as described in Examples 188,189 and/or 190.<br>
Compounds of the type Formula XXV can be prepared from compounds of the type<br>
Formula XXVI by reaction with hydroxylamine or a hydroxylamine salt, preferably in the<br>
presence of a base such as potassium carbonate, sodium alkoxide or a tertiary amine,<br>
and/or preferably in a suitable solvent such as ethanol or methanol:<br><br>
Compounds of the type Formula XXVI may themselves be prepared from compounds of<br>
Formula XXVII by reaction with a dehydrating agent such as Burgess Reagent,<br>
preferably in a solvent, for example tetrahydrofuran:<br><br>
Compounds of the type Formula XXVII can be prepared from carboxylic acid<br>
compounds of Formula IE, for example by reaction with thionyl chloride followed by<br>
ammonia in a suitable solvent such as dioxane:<br><br><br>
Process L - Conversion of a compound of formula (I) or a salt thereof into a<br>
different compound of formula (I) or a salt thereof<br>
One compound of formula (I) or salt thereof can be converted into another compound of<br>
formula (I) or salt thereof. This conversion preferably comprises or is one or more of the<br>
following processes LI to L10:<br>
LI. An oxidation process. For example, the oxidation process can comprise or be<br>
oxidation of an alcohol to a ketone (e.g. using Jones reagent) or oxidation of an alcohol or<br>
a ketone to a carboxylic acid.<br>
L2. A reduction process, for example reduction of a ketone or a carboxylic acid to an<br>
alcohol.<br>
L3. Acylation, for example acylation of an amine or of a hydroxy group.<br>
L4. Alkylation, for example alkylation of an amine or of a hydroxy group.<br>
L5. Hydrolysis, e.g. hydrolysis of an ester to the corresponding carboxylic acid or salt<br>
thereof, for example in the presence of base (e.g. alkali-metal hydroxide, preferably also<br>
in the presence of water) or in the presence of acid (e.g. aqueous HCl, or HCl in an<br>
anhydrous organic solvent such as dioxane).<br>
The hydrolysis can for example be hydrolysis of an ester compound, in which RX,<br>
RX2, RY or RY2 is -(CH2)n12-C(O)-OR13 wherein R13 is not a hydrogen atom (H), to<br>
the corresponding carboxylic acid wherein R13 is a hydrogen atom (H). See for example<br>
Example 57 and Intermediate 83.<br>
The hydrolysis can for example be hydrolysis of an ester compound, wherein R3<br>
is substituted by -C(O)OR23 in which R23 is C1-2alkyl (e.g. NHR3 or NR3R3a is of<br>
sub-formula (p8)), to the corresponding carboxylic acid or salt thereof wherein R23 is H<br>
(e.g. NHR3 or NR3R3a is of sub-formula (p7)).<br>
L6. Deprotection, e.g. deprotection (e.g. deacylation or t-butyloxycarbonyl (BOC)<br>
removal or benzyloxycarbonyl removal) of an amine group.<br><br>
L7. Formation of an ester or amide, for example from the corresponding carboxylic acid<br>
and/or an activated derivative of the carboxylic acid (e.g. acid chloride or acid anhydride<br>
or carboxylic acid activated by a coupling agent).<br>
The amide formation can be formation of an amide compound, in which one or<br>
more of Rx, RX2, RY and RY2 is -(CH2)n1 1-C(O)-NR10Rl 1,<br>
-CH(C1-2alkyl)-C(O)-NR10R11, -CMe2-C(O)-NR10R11 or cycloalkyl substituted by<br>
-C(O)-NR10R11, from the corresponding carboxylic acid and/or an activated derivative<br>
of the carboxylic acid. For examples of this amide formation, see Examples 58-59 and/or<br>
126-147 for Het = sub-formula (id), and/or Process G herein for Het = sub-formula (ic)<br>
(e.g. Examples 85-90, 95-96 and/or 148-155).<br>
The amide formation can alternatively be formation of an amide compound, in<br>
which one or more of Rx, RX2, RY and RY2 is -(CH2)n4-NR6R7,<br>
-CH(C1-2alkyl)-NR6R7, -CMe2-NR6R7 or cycloalkyl substituted by -NR6R7, wherein<br>
R6 is C(O)R17, from the corresponding carboxylic acid and/or an activated derivative of<br>
the carboxylic acid. For one example where Het is of sub-formula (ic) see Process H<br>
and/or Examples 159-165.<br>
L8. Conversion of a ketone into the corresponding oxime or oxime ether. This can for<br>
example include conversion of an oxo (=O) substituent within R3, e.g. within the NHR3<br>
or NR3R3a sub-formula (o), into anhydroxyimino (=N-OH) or (C1-4alkoxy)imino<br>
(=N-OR26) substituent within R3, e.g. within the NHR3 or NR3R3a sub-formula (o2),<br>
(o3), (o4) or (o5). This conversion can be carried out in the case of an oxime<br>
(hydroxyimino, =N-OH) by reacting hydroxylamine or a salt thereof (e.g. hydroxylamine<br>
hydrochloride) with the ketone, or in the case of an oxime ether (C1-4alkoxy)irmno,<br>
=N-OR26) by reacting C1-4alkoxylamine or a salt thereof (e.g. hydrochloride salt) with<br>
the ketone. The reaction is preferably carried out in the presence of a base such as<br>
anhydrous potassium carbonate or diisopropylethylarnine and/or in a suitable solvent such<br>
as acetonitrile. The mixture can be heated e.g. to reflux.<br>
L9. Sulfonylation, e.g. sulfonamide formation by reaction of an amine with a sulfonyl<br>
halide e.g. a sulfonyl chloride (e.g. see also Process I).<br>
and/or<br>
L10. Beckmann rearrangement of one compound of formula (I) into another compound<br>
of formula (I). Preferably, this uses cyanuric chloride (2,4,6-trichloro-l,3,5-triazine)<br>
together with a forrnamide such as DMF, e.g. at room temperature (see L.D. Luca, J. Org.<br>
Chem., 2002, 67, 6272-6274). The Beckmann rearrangement can for example comprise<br>
conversion of an (hydroxyimino)cycloalkyl compound of formula (I), e.g. wherein NHR3<br><br>
or NR.3R3 a is of sub-formula (o2) , into a single-atom-ring-expanded<br>
lactam compound of formula (I), e.g. wherein NHR3 or NR3R3a is of sub-formula (m3)<br>
The present invention therefore also provides a method of preparing a compound of<br>
formula (I) or a salt thereof, comprising:<br>
(a)	cyclisation of a compound of formula II to a compound of formula (I) wherein Het is<br>
of sub-formula (ia) (that is: to a compound of Formula I(ia), i.e. to an optionally<br>
substituted l,3,4-oxadiazo1-2-yl derivative at the 5-position of the pyrazolopyridine ring<br>
system), for example in the presence of a dehydrating agent such as phosphorus<br>
oxychloride or Burgess reagent, or<br>
(b)	reaction of a compound of formula IXa with an amine of formula R3R3aNH to form a<br>
compound of formula (I), preferably in a solvent (e.g. organic solvent) and/or preferably<br>
in the presence of a base, or<br>
(c)	cyclisation of a compound of formula II to a compound of formula (I) wherein Het is<br>
of sub-formula (ib) (i.e. to a compound of Formula XII i.e. to an optionally substituted<br>
l,3,4-thiadiazo1-2-yl derivative at the 5-position of the pyrazolopyridine ring system), for<br>
example in the presence of an agent capable of introducing sulfur such as Lawesson's<br>
reagent, or<br>
(d)	reaction of a compound of formula VI, wherein RA is C1-2alkyl such as Et, with an<br>
amidoxime of formula RXC(=NOH)NH2 or a salt thereof, preferably in the presence of a<br>
base such as sodium ethoxide and/or preferably in a suitable solvent (e.g. anhydrous<br>
and/or organic solvent) such as ethanol; or<br>
(e)	reaction of a compound of formula XV with an acetimidate RX-C(=NH)ORE, where<br>
RE is C1-6alkyl, to prepare a compound of formula (I) wherein Het is of sub-formula (if)<br>
(i.e. to a compound of Formula XIV, i.e. to an optionally substituted 1,2,4-triazo1- 3-yl or<br>
5-yl derivative at the 5-position of the pyrazolopyridine ring system), preferably in the<br>
presence of a base (such as Iriemylamine or sodium ethoxide) and/or in a suitable solvent<br>
(e.g. anhydrous and/or organic solvent) such as ethanol; or<br><br>
(f)(i) converting directly or indirectly a compound of Formula HI to a compound of<br>
formula (I) wherein Het is of sub-formula (id); and/or (f)(ii) dehydrogenating a<br>
compound of formula (I), wherein Het is of sub-formula (va) in which RXl and R^l are<br>
H and RX1 is RX and RY1 is RY<br>
to a compound of formula (T) wherein Het is of sub-<br>
formula (id); or<br>
(f)(iii) cyclisation of a compound of Formula XXVIII, for example in the presence of<br>
Burgess reagent and/or preferably in a suitable solvent, to prepare a compound of formula<br>
(I) wherein Het is of sub-formula (va); or<br>
(g) reaction of a compound of the Formula XVII with an amine of Formula R10R11NH<br>
under coupling conditions, to prepare a compound of formula (I) wherein Het is of<br>
sub-formula (ic) and RX is -CH2C(O)NR10R11 (i.e. to prepare a compound of Formula<br>
XVT), the reaction preferably being carried out in the presence of a base such as<br>
diisopropylethylamine, and/or preferably in a suitable solvent (e.g. organic solvent,<br>
preferably anhydrous) such as DMF and/or dicloromethane, and/or preferably in the<br>
presence of oxalyl chloride; or<br>
(h) conversion of a compound of Formula XX into a compound of formula (I) wherein<br>
Het is of sub-formula (ic) and Rx is -CH2-NR6R7 wherein R7 is C(O)R17 (i.e. into a<br>
compound of Formula XIX), preferably either by reaction of the compound of Formula<br>
XX with a carboxylic acid R17COOH in the presence of a coupling agent, and/or by<br>
reaction of the compound of Formula XX with an activated derivative of the carboxylic<br>
acid moiety of R17COOH (e.g. R17C(O)Cl), preferably in the presence of abase and/or a<br>
suitable solvent; or<br>
(i) reaction of a compound of Formula XX with a sulphonyl chloride R18S(O)2Cl to<br>
prepare a compound of formula (I) wherein Het is of sub-formula (ic) and RX is<br>
-CH2-NR6R7 wherein R7 is -S(O)2R18 (i.e. to prepare a compound of Formula XXII),<br>
preferably in the presence of a base such as triethylamine and/or pyridine, and/or<br>
preferably in a suitable solvent such as dichloromethane and/or chloroform; or<br>
(j) reaction of a compound of Formula XX wherein R6 = H with an acid chloride of<br>
formula XJ-(CH2)n5-X5-(CH2)(n6-1)-COCl, where XJ is a leaving group (XJ preferably<br>
being a halogen atom or -O-SO2-RJ where RJ is C1-4alkyl, C1-2fmoroalkyl, or phenyl<br>
optionally substituted by C1-2alkyl), to prepare a compound of formula (I) wherein Het is<br>
of sub-formula (ic) and RX is -CH2-MR6R7, wherein R6 and R7 together are<br>
-(CH2)n5-X5-(CH2)n6- in which n5 and n6 independently are 2 or 3, and wherein the<br>
ring formed by NR6R7 is substituted by one oxo (=O) substituent at a carbon atom within<br>
(CH2)n6 which carbon atom is bonded to the nitrogen (i.e. to prepare a compound of<br><br>
Formula XXIII); the reaction preferably being in the presence of a base and/or in a<br>
suitable solvent, and/or preferably being followed by treatment with a base; or<br>
(k) reaction of a compound of Formula XXV with RYC(O)XK where XK is a leaving<br>
group, to prepare a compound of formula (I) wherein Het is of sub-formula (iia) (i.e. to<br>
prepare a compound of Formula XXTV); or<br>
(L) conversion of a compound of formula (I) or a salt thereof into a different compound<br>
of formula (I) or a salt thereof;<br>
and optionally converting the compound, of formula (I) into a salt e.g. a pharmaceutically<br>
acceptable salt.<br>
Salt formation processes may optionally be as described elsewhere herein.<br>
Preferred features of methods (a), (b), (c), (d), (e), (f)(i), (f)(ii), (f)(iii), (g), (h), (i), Q),<br>
(k), and (L), independently of each other, are preferably as described above for Processes<br>
A, B, C, D, E, F, G, H, I, J, K, and L with all necessary changes being made. For<br>
example, the conversion process (L) preferably comprises or is one or more of processes<br>
LI to L10 described herein, e.g. hereinabove.<br>
In any of the methods which involve reaction of a carboxylic acid and/or an activated<br>
carboxylic acid derivative with an amine to form an amide, the activated carboxylic acid<br>
derivative preferably comprises a -C(O)X11 group in place of the COOH, wherein X11 is<br>
a leaving group substitutable by an amine. For example X11 can be C1 (wherein the<br>
activated derivative = the acid chloride) or -OC(O)R (wherein the activated derivative =<br>
an anhydride). Alternatively, the activated carboxylic acid derivative can be an activated<br>
ester wherein the leaving group X11 is<br><br>
The latter activated carboxylic acid derivative can be formed from the carboxylic acid<br>
(X11 = OH) either:<br>
(a) by reaction of the carboxylic acid with a carbodiimide such as EDC, which is 1-ethyl-<br>
3-(3'-dimethylaminopropyl)carbodiimide and is also 1-(3-dimethylaminopropyl)-3-<br>
ethylcarbodiimide, or a salt thereof e.g. hydrochloride salt,<br>
preferably followed by reaction of the resulting product with 1-hydroxybenzotriazole<br>
(HOBT); reaction (a) usually being carried out in the presence of a solvent (preferably<br><br>
anhydrous) such as dimethyl formamide (DMF) or acetonitrile and/or preferably under<br>
anhydrous conditions and/or usually at room temperature (e.g. about 20 to about 25 Â°C);<br>
or<br>
(b) by reaction with 2-(1H-benzotriazole-1-yl)-l,l,3,3-tetramethyluronium<br>
tetrafluoroborate (TBTU) or O-(7-Azaberizotriazo1-1-yl)-N,N,N',N'-tetramethyluromum<br>
hexafluorophosphate (HATU), preferably in the presence of abase such as<br>
dusopropylethylamine (iPr2NEt = D1PEA), and usually in the presence of a solvent such<br>
as dimethyl formamide (DMF) or acetonitrile and/or preferably under anhydrous<br>
conditions and/or usually at room temperature (e.g. about 20 to about 25 Â°C).<br>
The present invention also provides: (m) a method of preparing a pharmaceutically<br>
acceptable salt of a compound of formula (I) comprising conversion of the compound of<br>
formula (I) or a salt thereof into the desired pharmaceutically acceptable salt thereof.<br>
The present invention also provides a compound of formula (I) or a salt thereof, prepared<br>
by a method as defined herein.<br>
Medical uses<br>
The present invention also provides a compound of formula (I) or a pharmaceutically<br>
acceptable salt thereof for use as an active therapeutic substance in a mammal such as a<br>
human. The compound or salt can be for use in the treatment and/or prophylaxis of any<br>
of the diseases / conditions described herein (e.g. for use in the treatment and/or<br>
prophylaxis of an inflammatory and/or allergic disease in a mammal) and/or for use as a<br>
phosphodiesterase inhibitor e.g. for use as a phosphodiesterase 4 (PDE4) inhibitor.<br>
"Therapy" may include treatment and/or prophylaxis.<br>
Also provided is the use of a compound of formula (I) or a pharmaceutically acceptable<br>
salt thereof in the manufacture of a medicament (e.g. pharmaceutical composition) for the<br>
treatment and/or prophylaxis of any of the diseases / conditions described herein in a<br>
mammal such as a human, e.g. for the treatment and/or prophylaxis of an inflammatory<br>
and/or allergic disease in a mammal such as a human.<br>
Also provided is a method of treatment and/or prophylaxis of any of the diseases /<br>
conditions described herein in a mammal (e.g. human) in need thereof, e.g. a method of<br>
treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal<br>
(e.g. human) in need thereof, which method comprises administering to the mammal (e.g.<br>
human) a therapeutically effective amount of a compound of formula (I) as herein defined<br>
or a pharmaceutically acceptable salt thereof.<br><br>
Phosphodiesterase 4 inhibitors are thought to be useful in the treatment and/or<br>
prophylaxis of a variety of diseases / conditions, especially inflammatory and/or allergic<br>
diseases, in mammals such as humans, for example: asthma, chronic obstructive<br>
pulmonary disease (COPD) (e.g. chronic bronchitis and/or emphysema), atopic<br>
dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis,<br>
eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis,<br>
Crohn's disease, reperfusion injury of the myocardium and brain, chronic<br>
glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, multiple<br>
sclerosis, cognitive impairment (e.g. in a neurological disorder such as Alzheimer's<br>
disease), depression, or pain. Ulcerative colitis and/or Crohn's disease are collectively<br>
often referred to as inflammatory bowel disease.<br>
In the treatment and/or prophylaxis, the inflammatory and/or allergic disease is preferably<br>
chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic<br>
rhinitis in a mammal (e.g. human). More preferably, the treatment and/or prophylaxis is<br>
of COPD or asthma in a mammal (e.g. human).<br>
PDE4 inhibitors are thought to be effective in the treatment of asthma (e.g. see<br>
M.A.Giembycz, Drugs, Feb. 2000, 59(2), 193-212; Z. Huang et al., Current Opinion in<br>
Chemical Biology, 2001, 5: 432-438; H.J.Dyke et al., Expert Opinion on Investigational<br>
Drugs, January 2002, 11(1), 1-13; C.Burnouf etal., Current Pharmaceutical Design,<br>
2002, 8(14), 1255-1296; A.M.Doherty, Current Opinion Chem. Biol, 1999, 3(4), 466-<br>
473; and refs cited therein).<br>
PDE4 inhibitors are thought to be effective in the treatment of COPD (e.g. see S.L.<br>
Wolda, Emerging Drugs, 2000, 5(3), 309-319; Z. Huang et al., Current Opinion in<br>
Chemical Biology, 2001, 5: 432-438; H.J.Dyke et al., Expert Opinion on Investigational<br>
Drugs, January 2002, 11(1), 1-13; C.Burnouf et al., Current Pharmaceutical Design,<br>
2002, 8(14), 1255-1296; A.M.Doherty, Current Opinion Chem. Biol., 1999, 3(4), 466-<br>
473; and refs cited therein). COPD is often characterised by the presence of airflow<br>
obstruction due to chronic bronchitis and/or emphysema (SL Wolda, Emerging Drugs,<br>
2000, 5(3), 309-319).<br>
PDE4 inhibitors are thought to be effective in the treatment of allergic rhinitis (e.g. see<br>
B.M. Schmidt et al., J. Allergy &amp; Clinical Immunology, 108(4), 2001, 530-536).<br>
PDE4 inhibitors are thought to be effective in the treatment of rheumatoid arthritis and<br>
multiple sclerosis (e.g. see H.J.Dyke et al., Expert Opinion on Investigational Drugs,<br>
January 2002, 11(1), 1-13; CBurnouf etal., Current Pharmaceutical Design, 2002,<br>
8(14), 1255-1296; and A.M.Doherty, Current Opinion Chem. Biol, 1999, 3(4), 466-473;<br><br>
and refs cited therein). See e.g. A.M.Doherty, Current Opinion Chem. Biol, 1999, 3(4),<br>
466-473 and refs cited therein for atopic dermatitis use.<br>
PDE4 inhibitors have been suggested as having analgesic properties and thus being<br>
effective in the treatment of pain (A.Kumar et al., Indian J. Exp. Biol, 2000, 38(1), 26-<br>
30).<br>
In the invention, the treatment and/or prophylaxis can be of cognitive impairment e.g.<br>
cognitive impairment in a neurological disorder such as Alzheimer's disease. For<br>
example, the treatment and/or prophylaxis can comprise cognitive enhancement e.g. in a<br>
neurological disorder. See for example: H.T.Zhang et al. in: Psychopharmacology, June<br>
2000,150(3), 311-316 and Neuropsychopharmacology, 2000,23(2), 198-204; and T.<br>
Egawa et al., Japanese J. Pharmacol, 1997,75(3), 275-81.<br>
PDE4 inhibitors such as rolipram have been suggested as having antidepressant<br>
properties (e.g. J. Zhu et al., CNSDrug Reviews, 2001, 7(4), 387-398; O'Donnell, Expert<br>
Opinion on Investigational Drugs, 2000,9(3), 621-625; andH.T. Zhang et al.,<br>
Neuropsychopharmacology, October 2002,27(4), 587-595).<br>
Pharmaceutical compositions and dosing<br>
For use in medicine, the compounds of the present invention are usually<br>
administered as a pharmaceutical composition.<br>
The present invention therefore provides in a further aspect a pharmaceutical<br>
composition comprising a compound of formula (I) or a pharmaceutically acceptable salt<br>
thereof and one or more pharmaceutically acceptable carriers and/or excipients.<br>
The pharmaceutical composition can be for use in the treatment and/or<br>
prophylaxis of any of the conditions described herein.<br>
The invention also provides a method of preparing a pharmaceutical composition<br>
comprising a compound of formula (I), as herein defined, or a pharmaceutically<br>
acceptable salt thereof, and one or more pharmaceutically acceptable carriers and/or<br>
excipients,<br>
the method comprising mixing the compound or salt with the one or more<br>
pharmaceutically acceptable carriers and/or excipients.<br>
The invention also provides a pharmaceutical composition prepared by said<br>
method.<br>
The compounds of formula (I) and/or the pharmaceutical composition may be<br>
administered, for example, by oral, parenteral (e.g. intravenous, subcutaneous, or<br>
intramuscular), inhaled or nasal administration. Accordingly, the pharmaceutical<br>
composition is preferably suitable for oral, parenteral (e.g. intravenous, subcutaneous, or<br>
intramuscular), inhaled or nasal administration. More preferably, the pharmaceutical<br><br>
composition is suitable for inhaled or oral administration, e.g. to a mammal such as a<br>
human. Inhaled administration involves topical administration to the lung e.g. by aerosol<br>
or dry powder composition. Oral administration to a human is most preferred.<br>
A pharmaceutical composition suitable for oral administration can be liquid or<br>
solid; for example it can be a syrup, suspension or emulsion, a tablet, a capsule or a<br>
lozenge.<br>
A liquid formulation will generally consist of a suspension or solution of the<br>
compound or pharmaceutically acceptable salt in a suitable pharmaceutically acceptable<br>
liquid carrier(s), for example an aqueous solvent such as water, ethanol or glycerine, or a<br>
non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also<br>
contain a suspending agent, preservative, flavouring and/or colouring agent.<br>
In one preferable embodiment, the pharmaceutical composition is in unit dose<br>
form such as a tablet or capsule for oral administration, e.g. for oral administration to a<br>
human.<br>
A pharmaceutical composition suitable for oral administration being a<br>
tablet can comprise one or more pharmaceutically acceptable carriers and/or excipients<br>
suitable for preparing tablet formulations. The carrier can for example be or include<br>
lactose, cellulose (for example microcrystalline cellulose), or mannitol. The tablet can<br>
also or instead contain one or more pharmaceutically acceptable excipients, for example a<br>
binding agent such as hydroxypropylmethylcellulose or povidone (polyvinylpyrollidone),<br>
a lubricant e.g. an alkaline earth metal stearate such as magnesium stearate, and/or a<br>
tablet disintegrant such as sodium starch glycollate, croscarmellose sodium, or<br>
crospovidone (cross-linked polyvinylpyrollidone). The pharmaceutical composition<br>
being a tablet can be prepared by a method comprising the steps of: (i) mixing the<br>
compound of formula (I), as herein defined, or a pharmaceutically acceptable salt thereof,<br>
with the one or more pharmaceutically acceptable carriers and/or excipients, (ii)<br>
compressing the resulting mixture (which is usually in powder form) into tablets, and (iii)<br>
optionally coating the tablet with a tablet film-coating material.<br>
A pharmaceutical composition suitable for oral administration being a capsule can<br>
be prepared using encapsulation procedures. For example, pellets or powder containing<br>
the active ingredient can be prepared using a suitable pharmaceutically acceptable carrier<br>
and then filled into a hard gelatin capsule. Alternatively, a dispersion or suspension can<br>
be prepared using any suitable pharmaceutically acceptable carrier, for example an<br>
aqueous gum or an oil and the dispersion or suspension then filled into a soft gelatin<br>
capsule.<br>
A parenteral composition can comprise a solution or suspension of the compound<br>
or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable<br>
oil. Alternatively, the solution can be lyophilised; the lyophilised parenteral<br>
pharmaceutical composition can be reconstituted with a suitable solvent just prior to<br>
administration.<br>
Compositions for nasal or inhaled administration may conveniently be formulated<br>
as aerosols, drops, gels or dry powders.<br><br>
Aerosol formulations, e.g. for inhaled administration, can comprise a solution or<br>
fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-<br>
aqueous solvent. Aerosol formulations can be presented in single or multidose quantities<br>
in sterile form in a sealed container, which can take the form of a cartridge or refill for<br>
use with an atomising device or inhaler. Alternatively the sealed container may be a<br>
unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted<br>
with a metering valve (metered dose inhaler) which is intended for disposal once the<br>
contents of the container have been exhausted.<br>
Where the dosage form comprises an aerosol dispenser, it preferably contains a<br>
suitable propellant under pressure such as compressed air, carbon dioxide, or an organic<br>
propellant such as a chlorofluorocarbon (CFC) or hydrofluorocarbon (HFC). Suitable<br>
CFC propellants include dichlorodifluoromethane, trichlorofluoromethane and<br>
dichlorotetrafluoroethane. Suitable HFC propellants include 1,1,1,2,3,3,3-<br>
heptafluoropropane and 1,1,1,2-tetrafluoroethane. The aerosol dosage forms can also<br>
take the form of a pump-atomiser.<br>
Particle size reduction of compound of formula (I) or salt thereof<br>
For pharmaceutical compositions suitable and/or adapted for inhaled<br>
administration, it is preferred that the compound or salt of formula (I) is in a particle-size-<br>
reduced form, and more preferably the size-reduced form is obtained or obtainable by<br>
micronisation. Micronisation usually involves subjecting the compound/salt to collisional<br>
and abrasional forces in a fast-flowing circular or spiral/vortex-shaped airstream often<br>
including a cyclone component. The preferable particle size (e.g. D50 value) of the size-<br>
reduced (e.g. micronised) compound or salt is about 0.5 to about 10 microns, e.g. about 1<br>
to about 5 microns (e.g. as measured using laser diffraction). For example, it is<br>
preferable for the compound or salt of formula (I) to have a particle size defined by: a<br>
D10 of about 0.3 to about 3 microns (e.g. about 1 micron), and/or a D50 of about 1 to<br>
about 5 microns (e.g. about 2-5 or about 2-3 microns), and/or a D90 of about 2 to about<br>
20 microns or about 3 to about 10 microns (e.g. about 5-8 or about 5-6 microns); for<br>
example as measured using laser diffraction. The laser diffraction measurement can use a<br>
dry method (suspension of compound/salt in airflow crosses laser beam) or a wet method<br>
[suspension of compound/salt in liquid dispersing medium, such as isooctane or (e.g. if<br>
compound soluble in isooctane) 0.1% Tween 80 in water, crosses laser beam]. With laser<br>
diffraction, particle size is preferably calculated using the Fraunhofer calculation; and/or<br>
preferably a Malvern Mastersizer or Sympatec apparatus is used for measurement.<br>
An illustrative non-limiting example of a smal1-scale micronisation process is now given:<br>
Micronisation Example<br>
â¢ Purpose: To micronize a compound of formula (I) or a salt thereof- in particular one<br>
of the Examples of the invention (described hereinafter) - usually in an amount of<br>
approximately 600-1000 mg, using a JetpharmaMCl micronizer.<br><br>
â¢ The parent (unmicronised) and micronised materials are analyzed for particle size by<br>
laser diffraction and crystallinity by PXRD.<br><br>
The Jetpharma MCI Micronizer comprises a horizontal disc-shaped milling housing<br>
having: a tubular compound inlet (e.g. angled at ca. 30degrees to the horizontal) for entry<br>
of a suspension of unmicronised compound of formula (I) or salt in an gasflow, a separate<br>
gas inlet for entry of gases, a gas outlet for exit of gases, and a collection vessel for<br>
collecting micronised material. The milling housing has two chambers: an outer annular<br>
chamber in gaseous connection with the gas inlet the chamber being for receiving<br>
pressurised gas (e.g. air or nitrogen), an disc-shaped inner milling chamber within and<br>
coaxial with the outer chamber for micronising the input compound / salt, the two<br>
chambers being separated by an annular wall. The annular wall (ring R) has a plurality of<br>
narrow-bored holes connecting the inner and outer chambers and circurnferentially-<br>
spaced-apart around the annular wall. The holes open into the inner chamber directed at<br>
an angle (directed part-way between radially and tangentially), and in use act as nozzles<br>
directing pressurised gas at high velocity from the outer chamber into the inner chamber<br>
and in an inwardly-spiral path (vortex) around the inner chamber (cyclone). The<br>
compound inlet is is gaseous communication with the inner chamber via a nozzle directed<br>
tangentially to the inner chamber, within and near to the annular wall. Upper and lower<br>
broad-diameter exit vents in the central axis of the the inner milling chamber connect to<br>
(a) (lower exit) the collection vessel which has no air outlet, and (b) (upper exit) the gas<br>
outlet which leads to a collection bag, filter and a gas exhaust. Inside the tubular<br>
compound inlet and longitudinally-movable within it is positioned a venturi inlet (V) for<br>
entry of gases. The compound inlet also has a bifurcation connecting to an upwardly-<br>
directed material inlet port for inputting material.<br>
In use, the narrow head of the venturi inlet (V) is preferably positioned below and<br>
slightly forward of the material inlet port so that when the venturi delivers pressurised gas<br>
(eg air or nitrogen) the feed material is sucked into the gasstream thorough the compound<br>
inlet and accelerates it into the inner milling chamber tangentially at a subsonic speed.<br>
Inside the milling chamber the material is further accelerated to a supersonic speed by the<br>
hole/nozzle system around the ring (R) (annular wall) of the milling chamber. The<br>
nozzles are slightly angled so that the acceleration pattern of the material is in the form of<br><br>
an inwardly-directed vortex or cyclone. The material inside the milling chamber<br>
circulates rapidly and particle collisions occur during the process, causing larger particles<br>
to fracture into smaller ones. "Centrifugal" acceleration in the vortex causes the larger<br>
particles to remain at the periphery of the inner chamber while progressively smaller<br>
particles move closer to the center until they exit the milling chamber, generally through<br>
the lower exit, at low pressure and low velocity. The particles that exit the milling<br>
chamber are heavier than air and settle downward thorugh the lower exit into the<br>
collection vessel, while the exhaust gas rises (together with a miinority of small particles<br>
of micronised material) and escapes into the atmosphere at low pressure and low velocity.<br>
Procedure:<br>
The micronizer is assembled. The venturi protrusion distance from input port is<br>
adjusted to 1.0cm respectively (e.g. so that the narrow head of the venturi inlet is<br>
positioned below and slightly forward of the material inlet port) and is measured with a<br>
micro-caliper to make sure that it is inserted correctly. The ring (R) and venturi (V)<br>
pressures are adjusted according to the values specified in the experimental design (refer<br>
to experimental section below) by adjusting the valves on the pressure gauges on the<br>
micronizer. The setup is checked for leakage by observing if there is any fluctuation in<br>
the reading of the pressure gauges.<br>
Note that the venturi (V) pressure is kept at least 2 bars greater than the ring (R )<br>
pressure to prevent regurgitation of material, e.g. outwardly from the material inlet port.<br>
Balance performance is checked with calibration weights. Specified amount of<br>
the parent material (see section on experimental run) is weighed into a plastic weigh boat.<br>
The material is then fed into the micronizer using a vibrational spatula (e.g. V-shaped in<br>
cross-section) at a specified feed rate. The material feeding time and equipment pressures<br>
are monitored during the micronization process.<br>
Upon completion of the micronising run, the nitrogen supply is shut off and the<br>
collection bag is tapped to allow particles to settle into the recovery / collection vessel at<br>
the bottom of the micronizer. The collection bag is removed and set aside. The<br>
micronised powder in the recovery vessel (collection vessel) and the cyclone (above the<br>
recovery vessel) are collected separately into different weighed+labelled collection vials.<br>
The weight of the micronised material is recorded. The micronizer is disassembled and<br>
residual PDE4 compound on the micronizer inner surface is rinsed with 70/30 isopropyl<br>
alcohol / water and collected into a flask. The micronizer is then thoroughly cleaned by<br>
rinsing and wiping with suitable solvent and dried before subsequent runs are performed.<br>
Preferred Experimental Parameters<br>
Balance(s) Used: Sartorius analytical<br>
Venturi outlet insertion depth: 10.0 mm<br><br><br><br>
The above preferred or optional parameters can be varied using the skilled person's<br>
knowledge.<br>
Yield calculations<br>
% yield = [(Material from vessel + Material from cyclone)/Material input amount] x 100<br>
In general, very approximately 50-75 % yields are achievable using this method.<br>
Dry powder inhalable compositions<br>
For pharmaceutical compositions suitable and/or adapted for inhaled<br>
administration, it is preferred that the pharmaceutical composition is a dry powder<br>
inhalable composition. Such a composition can comprise a powder base such as lactose<br>
or starch, the compound of formula (I) or salt thereof (preferably in particle-size-reduced<br>
form, e.g. in micronised form), and optionally a performance modifier such as L-leucine,<br>
mannitol, trehalose and/or magnesium stearate. Preferably, the dry powder inhalable<br>
composition comprises a dry powder blend of lactose and the compound of formula (I) or<br>
salt thereof. The lactose is preferably lactose hydrate e.g. lactose monohydrate and/or is<br>
preferably inhalation-grade and/or fine-grade lactose. Preferably, the particle size of the<br>
lactose is defined by 90% or more (by weight or by volume) of the lactose particles being<br>
less than 1000 microns (micrometres) (e.g. 10-1000 microns e.g. 30-1000 microns) in<br>
diameter, and/or 50% or more of the lactose particles being less than 500 microns (e.g.<br>
10-500 microns) in diameter. More preferably, the particle size of the lactose is defined<br>
by 90% or more of the lactose particles being less than 300 microns (e.g. 10-300 microns<br>
e.g. 50-300 microns) in diameter, and/or 50% or more of the lactose particles being less<br>
than 100 microns in diameter. Optionally, the particle size of the lactose is defined by<br>
90% or more of the lactose particles being less than 100-200 microns in diameter, and/or<br>
50% or more of the lactose particles being less than 40-70 microns in diameter. Most<br>
importantly, it is preferable that about 3 to about 30% (e.g. about 10%) (by weight or by<br>
volume) of the particles are less than 50 microns or less than 20 microns in diameter. For<br>
example, without limitation, a suitable inhalation-grade lactose is E9334 lactose (10%<br>
fines) (Borculo Domo Ingredients, Hanzeplein 25, 8017 JD Zwolle, Netherlands).<br>
In the dry powder inhalable composition, preferably, the compound of formula (I)<br>
or salt thereof is present in about 0.1% to about 70% (e.g. about 1% to about 50%, e.g.<br>
about 5% to about 40%, e.g. about 20 to about 30%) by weight of the composition.<br><br>
An illustrative non-limiting example of a dry powder inhalable composition<br>
follows:<br>
Dry Powder Formulation Example - Dry powder Lactose Blend Preparation<br>
Using a size-reduced e.g. micronised form of the compound of formula (I) or salt thereof<br>
(e.g. as prepared in the Micronisatrion Example above), the dry powder blend is prepared<br>
by mixing the required amount of the compound/salt (e.g. 10 mg, 1% w/w) with<br>
inhalation-grade lactose containing 10% fines (e.g. 990 mg, 99% w/w) in a Teflonâ¢<br>
(polytetrafluoroethene) pot in a Mikro-dismembrator bal1-mill (but without a ball bearing)<br>
at % speed (ca. 2000-2500 rpm) for about 4 hours at each blend concentration. The<br>
Mikro-dismembrator (available from B. Braun Biotech International, Schwarzenberger<br>
Weg 73-79, D-34212 Melsungen, Germany; www.bbraunbiotech.com) comprises a base<br>
with an upwardly-projecting and sidewardly-vibratable arm to which is attached the<br>
Teflon TM pot. The vibration of the arm achieves blending.<br>
Other blends: 10% w/w compound/salt (50 mg) + 90% w/w lactose (450 mg,<br>
inhalation-grade lactose containing 10% fines).<br>
Serial dilution of the 1% w/w blend can achieve e.g. 0.1% and 0.3% w/w blends.<br>
Dry powder inhalation devices<br>
Optionally, in particular for dry powder inhalable compositions, a pharmaceutical<br>
composition for inhaled ad'ministration can be incorporated into a plurality of sealed dose<br>
containers (e.g. containing the dry powder composition) mounted longitudinally in a strip<br>
or ribbon inside a suitable inhalation device. The container is rupturable or pee1-openable<br>
on demand and the dose, e.g. of the dry powder composition, can be administered by<br>
inhalation via a device such as the DisKUS TM device, marketed by GlaxoSmithKline.<br>
The DisKUS â¢ inhalation device is usually substantially as described in GB 2,242,134<br>
A, and in such device at least one container for the pharmaceutical composition in<br>
powder form (the at least one container preferably being a plurality of sealed dose<br>
containers mounted longitudinally in a strip or ribbon) is defined between two members<br>
peelably secured to one another; the device comprises: means defining an opening station<br>
for the said at least one container; means for peeling the members apart at the opening<br>
station to open the container; and an outlet, communicating with the opened container,<br>
through which a user can inhale the pharmaceutical composition in powder form from the<br>
opened container.<br>
Unit dose form and dosing regimens<br>
Preferably the composition is in unit dose form such as a tablet or capsule for oral<br>
administration, e.g. for oral administration to a human.<br>
In the pharmaceutical composition, a or each dosage unit for oral or parenteral<br>
administration preferably contains from 0.01 to 3000 mg, more preferably 0.5 to 1000<br>
mg, of a compound of the formula (I) or a pharmaceutically acceptable salt thereof,<br>
calculated as the free base. A or each dosage unit for nasal or inhaled administration<br><br>
preferably contains from 0.001 to 50 mg, more preferably 0.01 to 5 mg, of a compound of<br>
the formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.<br>
A pharmaceutically acceptable compound or salt of the invention is preferably<br>
administered to a mammal (e.g. human) in a daily oral or parenteral dose of 0.001 mg to<br>
50 mg per kg body weight per day (mg/kg/day), for example 0.01 to 20 mg/kg/day or<br>
0.03 to 10 mg/kg/day or 0.1 to 2 mg/kg/day, of the compound of the formula (I) or a<br>
pharmaceutically acceptable salt thereof, calculated as the free base.<br>
A pharmaceutically acceptable compound or salt of the invention is preferably<br>
administered to a mammal (e.g. human) in a daily nasal or inhaled dose of: 0.0001 to 5<br>
mg/kg/day or 0.0001 to 1 mg/kg/day, e.g. 0.001 to 1 mg/kg/day or 0.001 to 0.3 mg/kg/day<br>
or 0.001 to 0.1 mg/kg/day or 0.005 to 0.3 mg/kg/day, of the compound of the formula (I)<br>
or a pharmaceutically acceptable salt thereof, calculated as the free base.<br>
The pharmaceutically acceptable compounds or salts of the invention is preferably<br>
administered in a daily dose (for an adult patient) of, for example, an oral or parenteral<br>
dose of 0.01 mg to 3000 mg per day or 0.5 to 1000 mg per day e.g. 2 to 500 mg per day,<br>
or a nasal or inhaled dose of 0.001 to 300 mg per day or 0.001 to 50 mg per day or 0.01 to<br>
30 mg per day or 0.01 to 5 mg per day or 0.02 to 2 mg per day, of the compound of the<br>
formula (I) or a pharmaceutically acceptable salt thereof, calculated as the free base.<br>
Combinations<br>
The compounds, salts and/or pharmaceutical compositions according to the invention<br>
may also be used in combination with another therapeutically active agent, for example, a<br>
P2 adrenoreceptor agonist, an anti-mstamine, an anti-allergic or an anti-inflammatory<br>
agent.<br>
The invention thus provides, in a further aspect, a combination comprising a compound<br>
of formula (I) or a pharmaceutically acceptable salt thereof together with another<br>
therapeutically active agent, for example, a P2-adrenoreceptor agonist, an anti-histamine,<br>
an anti-allergic, an anti-inflammatory agent or an antiinfective agent.<br>
Preferably, the P2-adrenoreceptor agonist is salmeterol (eg as racemate or a single<br>
enantiomer such as the R-enantiomer), salbutamol, formoterol, salmefamoi, fenoterol or<br>
terbutaline, or a salt thereof (e.g. pharmaceutically acceptable salt thereof), for example<br>
the xinafoate salt of salmeterol, the sulphate salt or free base of salbutamol or the<br>
fumarate salt of formoterol. Long-acting p2-adrenoreceptor agonists are preferred,<br>
especially those having a therapeutic effect over a 12-24 hour period such as salmeterol<br>
or formoterol. Preferably, the p2-adrenoreceptor agonist is for inhaled administration,<br>
e.g. once per day and/or for simultaneous inhaled administration; and more preferably the<br>
P2-adrenoreceptor agonist is in particle-size-reduced form e.g. as defined herein.<br>
Preferably, the P2-adrenoreceptor agonist combination is for treatment and/or<br><br>
prophylaxis of COPD or asthma. Salmeterol or a pharmaceutically acceptable salt<br>
thereof, e.g. salmeterol xinofoate, is preferably administered to humans at an inhaled dose<br>
of 25 to 50 micrograms twice per day (measured as the free base). The combination with<br>
a P2-adrenoreceptor agonist can be as described in WO 00/12078.<br>
Preferred long acting Î²2-adrenoreceptor agonists include tihose described in WO<br>
02/066422A, WO 03/024439, WO 02/070490 and WO 02/076933.<br>
Especially preferred long-acting Î²2-adrenoreceptor agonists include compounds of<br>
formula (X) (described in WO 02/066422) (note that the R groups therein are defined<br>
independently of the corresponding R groups of formula (1)):<br><br>
or a salt or solyate thereof, wherein in formula (X):<br>
m is an integer of from 2 to 8;<br>
n is an integer of from 3 to 11,<br>
with the proviso that m + n is 5 to 19,<br>
Ru is -XS02NR16R17 wherein X is -(CH2)P- or C2-6 alkenylene;<br>
R16 and R17 are independently selected from hydrogen, C1-2alkyl, C3-7cycloalkyl,<br>
C(O)NR18R19, phenyl, and phenyl (C1-4alkyl)-,<br>
or R16 and R17, together with the nitrogen to which they are bonded, form a 5-, 6-, or 7-<br>
membered nitrogen containing ring, and R16 and R17 are each optionally substituted by<br>
one or two groups selected from halo, C1-6alkyl, C1-6haloalkyl, C1-6alkoxy, hydroxy-<br>
substituted C1-6alkoxy, -CO2R18, -SO2NR18R19, -CONR18R19, -NR18C(O)R19, or a 5-, 6-<br>
or 7-membered heterocylic ring;<br>
R18 and R19 are independently selected from hydrogen, C1-6alkyl,<br>
C3-6cycloalkyl, phenyl, and phenyl (C1-4alkyl)-; and<br>
p is an integer of from 0 to 6, preferably from 0 to 4;<br>
R12 and R13 are independently selected from hydrogen, C1-2alkyl, C1-6alkoxy, halo,<br>
phenyl, and C1-2haloalkyl; and<br>
R14 and R15 are independently selected from hydrogen and C1-4alkyl with the proviso that<br>
the total number of carbon atoms in R14 and R15 is not more than 4.<br>
Preferred Î²2-adrenoreceptor agonists disclosed in WO 02/066422 include:<br><br><br>
A preferred P2-adrenoreceptor agonist disclosed in WO 03/024439 is:<br>
4-{(li?)-2-[(6-{2-[(2,6-dicWorobenzyl)oxy]ethoxy}hexyl)amin.o]-1-hydroxyethyl}-2-<br>
(hydroxymethyl)phenol.<br>
A combination of a compound of formula (I) or salt together with an anti-histamine is<br>
preferably for oral administration (e.g. as a combined composition such as a combined<br>
tablet), and can be for treatment and/or prophylaxis of allergic rhinitis. Examples of anti-<br>
histamines include methapyrilene, or H1 antagonists such as cetirizine, loratadine (e.g.<br>
Clarityn TM), desloratadine (e.g. Clarinex TM) or fexofenadine (e.g. Allegra TM).<br>
The invention also provides, in a further aspect, a combination comprising a compound of<br>
formula (T) or a pharmaceutically acceptable salt thereof together with an anticholinergic<br>
compound, e.g. a muscarinic (M) receptor antagonist in particular an M1, M2, M1/M2, or<br>
M3 receptor antagonist, more preferably a M3 receptor antagonist, still more preferably a<br>
M3 receptor antagonist which selectively antagonises (e.g. antagonises 10 times or more<br>
strongly) the M3 receptor over the M1 and/or M2 receptor. For combinations of<br>
anticholinergic compounds / muscarinic (M) receptor antagonists with PDE4 inhibitors,<br>
see for example WO 03/011274 A2 and WO 02/069945 A2 / US 2002/0193393 Al and<br>
US 2002/052312 Al, and some or all of these publications give examples of<br>
anticholinergic compounds / muscarinic receptor antagonists which may be used with the<br>
compounds of formula (I) or salts, and/or suitable pharmaceutical compositions. For<br>
example, the muscarinic receptor antagonist can comprise or be an ipratropium salt (e.g.<br>
ipratropium bromide), an oxitropium salt (e.g. oxitropium bromide), or more preferably a<br>
tiotropium salt (e.g. tiotropium bromide); see e.g. EP 418 716 Al for tiotropium.<br>
The anticholinergic compound or muscarinic (M) receptor antagonist, e.g. M3 receptor<br>
antagonist, is preferably for inhaled administration, more preferably in particle-size-<br>
reduced form e.g. as defined herein. More preferably, both the muscarinic (M) receptor<br>
antagonist and the compound of formula (I) or the pharmaceutically acceptable salt<br>
thereof are for inhaled administration. Preferably, the anticholinergic compound or<br>
muscarinic receptor antagonist and the compound of formula (I) or salt are for<br>
simultaneous administration. The muscarinic receptor antagonist combination is<br>
preferably for treatment and/or prophylaxis of COPD.<br>
Other suitable combinations include, for example, a combination comprising a compound<br>
of formula (I) or a pharmaceutically acceptable salt thereof together with another anti-<br>
inflammatory agent such as an anti-inflammatory corticosteroid; or a non-steroidal anti-<br>
inflammatory drug (NSAID) such as a leukotriene antagonist (e.g. montelukast), an<br>
iNOS inhibitor, a tryptase inhibitor, an elastase inhibitor, a beta-2 integrin antagonist, an<br>
adenosine 2a agonist, a CCR3 antagonist, or a 5-lipoxogenase inhibitor; or an<br>
antiinfective agent (eg. an antibiotic or an antiviral). An iNOS inhibitor is preferably for<br><br>
oral administration. Suitable iNOS inhibitors (inducible nitric oxide synthase inhibitors)<br>
include those disclosed in WO 93/13055, WO 98/30537, WO 02/50021, WO 95/34534<br>
and WO 99/62875. Suitable CCR3 inhibitors include those disclosed in WO 02/26722.<br>
In a combination comprising a compound of formula (I) or a pharmaceutically acceptable<br>
salt thereof together with an anti-inflammatory corticosteroid (which is preferably for<br>
treatment and/or prophylaxis of asthma, COPD or allergic rhinitis), then preferably the<br>
anti-inflammatory corticosteroid is fluticasone, fluticasone propionate (e.g. see US patent<br>
4,335,121), beclomethasone, beclomethasone 17-propionate ester, beclomethasone<br>
17,21-dipropionate ester, dexamethasone or an ester thereof, mometasone or an ester<br>
thereof, ciclesonide, budesonide, flunisolide, or a compound as described in WO<br>
02/12266 Al (e.g. as claimed in any of claims 1 to 22 therein), or a pharmaceutically<br>
acceptable salt of any of the above. If the anti-inflammatory corticosteroid is a<br>
compound as described in WO 02/12266 Al, then preferably it is Example 1 therein<br>
{which is 6Î±,9Î±-difluoro-17Î±-[(2-furanylcarbonyl)oxy]-11Î²-hydroxy-16Î±-methyl-3-<br>
oxo-androsta-l,4-diene-17Î²-carbothioic acid is-fluoromethyl ester} or Example 41 therein<br>
{which is 6Î±,9Î±-difluoro-11Î²-hydroxy-16Î±-methyl-17Î±-[(4-methyl-l,3-thiazole-5-<br>
carbonyl)oxy]-3-oxo-androsta-l,4-diene-17Î²-carbothioic acid S-fluoromethyl ester}, or a<br>
pharmaceutically acceptable salt thereof. The anti-inflammatory corticosteroid is<br>
preferably for intranasal or inhaled administration. Fluticasone propionate is preferred<br>
and is preferably for inhaled administration to a human either (a) at a dose of 250<br>
micrograms once per day or (b) at a dose of 50 to 250 micrograms twice per day.<br>
Also provided is a combination comprising a compound of formula (I) or a<br>
pharmaceutically acceptable salt thereof together with P2-adrenoreceptor agonist and an<br>
anti-inflammatory corticosteroid, for example as described in WO 03/030939 A1.<br>
Preferably this combination is for treatment and/or prophylaxis of asthma, COPD or<br>
allergic rhinitis. The Î²2-adrenoreceptor agonist and/or the anti-inflammatory<br>
corticosteroid can be as described above and/or as described in WO 03/030939 A1. Most<br>
preferably, in this "triple" combination, the Î²2-adrenoreceptor agonist is sahneterol or a<br>
pharmaceutically acceptable salt thereof (e.g. salmeterol xinafoate) and the anti-<br>
inflammatory corticosteroid is fluticasone propionate.<br>
The combinations referred to above may conveniently be presented for use in the form of<br>
a pharmaceutical composition and thus a pharmaceutical composition comprising a<br>
combination as defined above together with one or more pharmaceutically acceptable<br>
carriers and/or excipients represent a further aspect of the invention.<br>
The individual compounds of such combinations may be administered either sequentially<br>
or simultaneously in separate or combined pharmaceutical composition(s).<br>
In one embodiment, the combination as defined herein can be for simultaneous inhaled<br>
administration and is disposed in a combination inhalation device. Such a combination<br><br>
inhalation device is another aspect of the invention. Such a combination inhalation<br>
device can comprise a combined pharmaceutical composition for simultaneous inhaled<br>
administration (e.g. dry powder composition), the composition comprising all the<br>
individual compounds of the combination, and the composition being incorporated into a<br>
plurality of sealed dose containers mounted longitudinally in a strip or ribbon inside the<br>
inhalation device, the containers being rupturable or pee1-openable on demand; for<br>
example such inhalation device can be substantially as described in GB 2,242,134 A<br>
(DisKUS â¢) and/or as described above. Alternatively, the combination inhalation<br>
device can be such that the individual compounds of the combination are adrninistrable<br>
simultaneously but are stored separately (or wholly or partly stored separately for triple<br>
combinations), e.g. in separate pharmaceutical compositions, for example as described in<br>
PCT/EP03/00598 filed on 22 January 2003 (e.g. as described in the claims thereof e.g.<br>
claim 1).<br>
The invention also provides a method of preparing a combination as defined herein,<br>
the method comprising either<br>
(a)	preparing a separate pharmaceutical composition for adrninistration of the<br>
individual compounds of the combination either sequentially or simultaneously, or<br>
(b)	preparing a combined pharmaceutical composition for administration of the<br>
individual compounds of the combination simultaneously,<br>
wherein the pharmaceutical composition comprises the combination together with<br>
one or more pharmaceutically acceptable carriers and/or excipients.<br>
The invention also provides a combination as defined herein, prepared by a method as<br>
defined herein.<br><br>
Biological Test Methods<br>
PDE 3, PDE 4B, PDE 4D, PDE 5, PDE 6 Primary assay methods<br>
The activity of the compounds can be measured in the assay methods shown below.<br>
Preferred compounds of the invention are selective PDE4 inhibitors, i.e. they inhibit<br>
PDE4 (e.g. PDE4B and/or PDE4D, preferably PDE4B) more strongly than they inhibit<br>
PDE3 and/or more strongly than they inhibit PDE5 and/or more strongly than they inhibit<br>
PDE6.<br>
PDE enzyme sources and literature references<br>
Human recombinant PDE4B, in particular the 2B splice variant thereof (HSPDE4B2B), is<br>
disclosed in WO 94/20079 and also M.M. McLaughlin et al., "A low .Km, rolipram-<br>
sensitive, cAMP-specific phosphodiesterase from human brain: cloning and expression of<br>
cDNA, biochemical characterisation of recombinant protein, and tissue distribution of<br>
mRNA", J. Biol. Chem., 1993,268, 6470-6476. Human recombinant PDE4B was<br>
expressed in the PDE-deficient yeast Saccharomyces cerevisiae strain GL62. 100,000 x g<br>
supernatant fractions of yeast cell lysates were used for PDE4B assays and inhibitor<br>
studies.<br>
Human recombinant PDE4D (HSPDE4D3A) is disclosed in P. A. Baecker et al.,<br>
"isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phoshodiesterase<br>
(PDE IVD)", Gene, 1994,138,253-256.<br>
Human recombinant PDE5 is disclosed in K. Loughney et al., "isolation and<br>
characterisation of cDNAs encoding PDE5 A, a human cGMP-binding, cGMP-specific<br>
3',5'-cyclic nucleotide phosphodiesterase", Gene, 1998, 216,139-147.<br>
PDE3 was purified from bovine aorta as described by H. Coste and P. Grondin,<br>
"Characterisation of a novel potent and specific inhibitor of type V phosphodiesterase",<br>
Biochem. Pharmacol, 1995,50,1577-1585.<br>
PDE6 was purified from bovine retina as described by: P. Catty and P. Deterre,<br>
"Activation and solubilization of the retinal cGMP-specific phosphodiesterase by limited<br>
proteolysis", Eur. J. Biochem., 1991,199,263-269; A. Tar et al. "Purification of bovine<br>
retinal cGMP phosphodiesterase", Methods in Enzymology, 1994, 238, 3-12; and/or D.<br>
Srivastava et al. "Effects of magnesium on cyclic GMP hydrolysis by the bovine retinal<br>
rod cyclic GMP phosphodiesterase", Biochem. J., 1995,308,653-658.<br>
Inhibition of PDE 3, PDE 4B, PDE 4D, PDE 5 or PDE 6 activity: radioactive<br>
Scintillation Proximity Assay (SPA)<br><br>
The ability of compounds to inhibit catalytic activity at PDE4B or 4D (human<br>
recombinant), PDE3 (from bovine aorta) or PDE5 (human recombinant) or PDE6 (from<br>
bovine retina) was determined by Scintillation Proximity Assay (SPA) in 96-well format.<br>
Test compounds (preferably as a solution in DMSO, e.g. about 2 microlitre (ul) volume<br>
of DMSO solution) were preincubated at ambient temperature (room temperature, e.g.<br>
19-23Â°C) in Wallac isoplates (code 1450-514) with PDE enzyme in 50mM Tris-HCl<br>
buffer pH 7.5 , 8.3mM MgCl2,1.7mM EGTA, 0.05% (w/v) bovine serum albumin for 10-<br>
30 minutes (usually 30 minutes). The enzyme concentration was adjusted so that no<br>
more than 20% hydrolysis of the substrate defined below occurred in control wells<br>
without compound, during the incubation. For PDE3, PDE4B and PDE4D assays, [5',8-<br>
3H]Adenosine 3\5'-cyclic phosphate ( Amersham Pharmacia Biotech, code TRK.559; or<br>
Amersham Biosciences UK Ltd, Pollards Wood, Chalfont St Giles, Buckinghamshire<br>
HP8 4SP, UK) was added to give 0.05uCi per well and ~ lOnM final concentration. For<br>
thePDE5 and PDE6 assay [8-3H]Guanosine 3',5'-cyclicphosphate ( Amersham<br>
Phannacia Biotech , code TRK.392) was added to give 0.05uCi per well and ~ 36nM<br>
final concentration. Plates, preferably containing approx. 100 ul volume of assay<br>
mixture, were mixed on an orbital shaker for 5 minutes and incubated at ambient<br>
temperature for 1 hour. Phosphodiesterase SPA beads (Amersham Pharmacia Biotech,<br>
code PvPNQ 0150) were added (~lmg per well) to terminate the assay. Plates were sealed<br>
and shaken and allowed to stand at ambient temperature for 35 minutes to 1 hour<br>
(preferably 35 minutes) to allow the beads to settle. Bound radioactive product was<br>
measured using a WALLAC TRILUX 1450 Microbeta scintillation counter. For<br>
inhibition curves, 10 concentrations (1.5-M - 30uM) of each compound were assayed.<br>
Curves were analysed using ActivityBase and XLfit (ID Businesss Solutions Limited, 2<br>
Ocean Court, Surrey Research Park, Guildford, Surrey GU2 7QB, United Kindgom)<br>
Results were expressed as pICso values.<br>
In an alternative to the above radioactive SPA assay, PDE4B or PDE4D inhibition can be<br>
measured in the following Fluorescence Polarisation (FP) assay:<br>
Inhibition ofPDE4B or PDE4D activity: Fluorescence Polarisation (FP) assay<br>
The ability of compounds to inhibit catalytic activity at PDE4B (human<br>
recombinant) or PDE4D (human recombinant) was determined by IMAP Fluorescence<br>
Polarisation (FP) assay (MAP Explorer kit, available from Molecular Devices<br>
Corporation, Sunnydale, CA, USA; Molecular Devices code: R8062) in 384-well format.<br>
The MAP FP assay is able to measure PDE activity in an homogenous, non-radioactive<br>
assay format. The FP assay uses the ability of immobilised trivalent metal cations, coated<br>
onto nanoparticles (tiny beads), to bind the phosphate group of F1-AMP that is produced<br>
on the hydrolysis of fluorescein-labelled (Fl) cyclic adenosine mono-phosphate<br>
(F1-cAMP) to the non-cyclic F1-AMP form. F1-cAMP does not bind. Binding of F1-AMP<br>
product to the beads (coated with the immobilised trivalent cations) slows the rotation of<br>
the bound F1-AMP and leads to an increase in the fluorescence polarisation ratio of<br>
parallel to perpendicular light. Inhibition of the PDE reduces/inhibits this signal increase.<br><br>
Test compounds (small volume, e.g. ca. 0.5 to 1 ul, preferably ca. 0.5 ul, of<br>
solution in DMSO) were preincubated at ambient temperature (room temperature, e.g. 19-<br>
23Â°C) in black 384-well microtitre plates (supplier: NUNC, code 262260) with PDE<br>
enzyme in lOmM Tris-HCl buffer pH 7.2, 10mM MgCl2, 0.1% (w/v) bovine serum<br>
albumin, and 0.05% NaN3 for 10-30 minutes. The enzyme level was set by<br>
experimentation so that reaction was linear throughout the incubation. Fluorescein<br>
adenosine 3',5'-cyclic phosphate (from Molecular Devices Corporation, Molecular<br>
Devices code: R7091) was added to give about 40nM final concentration (final assay<br>
volume usually ca. 20-40 ul, preferably ca. 20 ul). Plates were mixed on an orbital shaker<br>
for 10 seconds and incubated at ambient temperature for 40 minutes. IMAP binding<br>
reagent (as described above, from Molecular Devices Corporation, Molecular Devices<br>
code: R7207) was added (60ul of a 1 in 400 dilution in binding buffer of the kit stock<br>
solution) to terminate the assay. Plates were allowed to stand at ambient temperature for<br>
1 hour. The Fluorescence Polarisation (FP) ratio of parallel to perpendicular light was<br>
measured using an Analyst^M plate reader (from Molecular Devices Corporation). For<br>
inhibition curves, 10 concentrations (1.5nM - 30uM) of each compound were assayed.<br>
Curves were analysed using ActivityBase and XLfit (ID Businesss Solutions Limited, 2<br>
Ocean Court, Surrey Research Park, Guildford, Surrey GU2 7QB, United Kindgom).<br>
Results were expressed as pICso values.<br>
In the FP assay, all reagents were dispensed using MultidropTM (available from<br>
Thermo Labsystems Oy, Ratastie 2, PO Box 100, Vantaa 01620, Finland).<br>
For a given PDE4 inhibitor, the PDE4B (or PDE4D) inhibition values measured using the<br>
SPA and FP assays can differ slightly. However, in a regression analysis of 100 test<br>
compounds, the PIC50 inhibition values measured using SPA and FP assays have been<br>
found generally to agree within 0.5 log units, for PDE4B and PDE4D (linear regression<br>
coefficient 0.966 for PDE4B and 0.971 for PDE4D; David R.Mobbs et al., "Comparison<br>
of the IMAP Fluorescence Polarisation Assay with the Scintillation Proximity Assay for<br>
Phosphodiesterase Activity", poster to be presented at 2003 Molecular Devices UK &amp;<br>
Europe User Meeting, 2nd October 2003, Down Hall, Harlow, Essex, United Kingdom).<br>
Biological Data obtained for some of the Examples (PDE4B inhibitory activity, either as<br>
one reading or as an average of ca. 2-6 readings) are as follows, based on current<br>
measurements only. In each of the SPA and FP assays, absolute accuracy of<br>
measurement is not possible, and the readings given are accurate only up to about Â± 0.5 of<br>
a log unit, depending on the number of readings made and averaged:<br><br><br><br>
Many, but not all, of the Examples have been tested for PDE4B inhibition. Of the<br>
Examples tested for PDE4B inhibition, some were tested by the radioactive SPA assay,<br>
some were tested by the FP assay.<br>
Most or substantially all of Examples 1-45, 47-55, 57-81, 83 and 84 have PDE4B<br>
inhibitory activities in the range of pICso = about 6 (Â± about 0.5) to about 9.1 (Â± 0.5).<br>
The Examples wherein B? = cyclohexyl (NHR.3 or NR3R3a = sub-formula (c)),<br>
tetrahydro-2H-pyran-4-yl (NHR3 or NR3R3a = group (h)), or certain other types of<br>
substituted cyclohexyl or certain heterocycles, or Examples wherein NHR3 or NR3R3a =<br>
sub-formula (s), usually or often (based on data for R1 = ethyl) have a higher level of<br>
selectivity for PDE4B over PDE5, as measured in the above enzyme inhibition assays,<br>
compared to the selectivities of comparable Examples wherein R^ = cyclopropyl (NHR3<br>
or NR3R3a = sub-formula (b)).<br>
Emesis:	Some known PDE4 inhibitors can cause emesis and/or nausea to greater or<br>
lesser extents (e.g. see Z. Huang et al., Current Opinion in Chemical Biology, 2001, 5:<br>
432-438, see especially pages 433-434 and refs cited therein). Therefore, it would be<br>
preferable, but not essential, if a particular PDE4 inhibitory compound or salt of the<br>
invention were to cause only limited or manageable emetic side-effects. Emetic side-<br>
effects can for example be measured by the emetogenic potential of the compound or salt<br>
when administered to ferrets; for example one can measure the time to onset, extent,<br>
frequency and/or duration of vomiting, retching and/or writhing in ferrets after oral or<br>
parenteral administration of the compound or salt. See for example In vivo Assay 4<br>
hereinafter for a measurement method for anti-inflammatory effect, emetic side-effects<br>
and therapeutic index (TI) in the ferret. See also for example A. Robichaud et al.,<br>
"Emesis induced by inhibitors of [PDEIV] in the ferret", Neuropharmacology, 1999,38,<br>
289-297, erratum Neuropharmacology, 2001, 40,465-465. However, optionally, emetic<br>
side-effects and therapeutic index (TI) in rats can be conveniently measured by<br>
monitoring the pica feeding behaviour of rats after administration of the compound or salt<br>
of the invention (see In Vivo Assay 2 below).<br><br>
Other side effects: Some known PDE4 inhibitors can cause other side effects such as<br>
headache and other central nervous sytem (CNS-) mediated side effects; and/or<br>
gastrointestinal (GI) tract disturbances. Therefore, it would be preferable but not<br>
essential if a particular PDE4 inhibitory compound or salt of the invention were to cause<br>
only limited or manageable side-effects in one or more of these side-effect categories.<br>
In Vivo Biological Assays<br>
The in vitro enzymatic PDE4B inhibition assay described above should be regarded as<br>
being the primary test of biological activity. However, additional in vivo biological tests,<br>
which are optional and which are not an essential measure of efficacy or side-effects, are<br>
described below.<br>
In Vivo Assay 1. LPS-induced pulmonary neutrophilia in rats: effect of orally<br>
administeredPDE4 inhibitors<br>
Pulmonary neutrophil influx has been shown to be a significant component to the<br>
family of pulmonary diseases like chronic obstructive pulmonary disease (COPD) which<br>
can involve chronic bronchitis and/or emphysema (G.F. Filley, Chest. 2000; 117(5);<br>
251s-260s). The purpose of this neutrophilia model is to study the potentially anti-<br>
inflammatory effects in vivo of orally administered PDE4 inhibitors on neutrophilia<br>
induced by inhalation of aerosolized lipopolysaccharide (LPS), modelling the neutrophil<br>
inflammatory components) of COPD. See the literature section below for scientific<br>
background.<br>
Male Lewis rats (Charles River, Raleigh, NC, USA) weighing approximately 300-<br>
400 grams are pretreated with either (a) test compound suspended in 0.5%<br>
methylcellulose (obtainable from Sigma-Aldrich, St Louis, MO, USA) in water or (b)<br>
vehicle only, delivered orally in a dose volume of 10 ml/kg. Generally, dose response<br>
curves are generated using the following doses of PDE4 inhibitors: 10.0, 2.0, 0.4, 0.08<br>
and 0.016 mg/kg. Thirty minutes following pretreatment, the rats are exposed to<br>
aerosolized LPS (Serotype E. Coli 026:B6 prepared by trichloroacetic acid extraction,<br>
obtainable from Sigma-Aldrich, St Louis, MO, USA), generated from a nebulizer<br>
containing a 100 jj.g/ml LPS solution. Rats are exposed to the LPS aerosol at a rate of 4<br>
L/min for 20 minutes. LPS exposure is carried out in a closed chamber with internal<br>
dimensions of 45 cm length x 24 cm width x 20 cm height. The nebulizer and exposure<br>
chamber are contained in a certified fume hood. At 4 hours-post LPS exposure the rats<br>
are euthanized by overdose with pentobarbital at 90 mg/kg, administered<br>
intraperitoneally. Bronchoalveolar lavage (BAL) is performed through a 14 gauge blunt<br>
needle into the exposed trachea. Five, 5 ml washes are performed to collect a total of 25<br>
ml of BAL fluid. Total cell counts and leukocyte differentials are performed on BAL<br>
fluid in order to calculate neutrophil influx into the lung. Percent neutrophil inhibition at<br>
each dose (cf. vehicle) is calculated and a variable slope, sigmoidal dose-response curve<br>
is generated, usually using Prism Graph-Pad. The dose-response curve is used to<br>
calculate an ED50 value (in mg per kg of body weight) for inhibition by the PDE4<br>
inhibitor of the LPS-induced neutrophilia.<br><br>
Results: Based on current measurements, the compounds of Examples 14,17,23,<br>
35 and 38, administered orally in the above procedure, exhibited neutrophilia-inhibition<br>
ED50 values in the range of about 0.03 mg/kg to about 1 mg/kg, subject to testing<br>
inaccuracies.<br>
Alternative method and results: In an alternative embodiment of the procedure, a<br>
single oral dose of 10 mg/kg or 1 mg/kg of the PDE4 inhibitor (or vehicle) is<br>
administered to the rats, and percent neutrophil inhibition is calculated and reported for<br>
that specific dose. In this embodiment, based on current measurements, the compounds<br>
of Examples 2,14, 23 and 38, administered orally in this alternative procedure at a single<br>
dose of 10 mg/kg, exhibited percent neutrophilia-inhibition in the range of about 74% to<br>
about 86%, subject to testing inaccuracies.<br>
Literature:<br>
Filley G.F. Comparison of the structural and inflammatory features of COPD and<br>
asthma. Chest. 2000; 117(5) 251 s-260s.<br>
Howell RE, Jenkins LP, Fielding LE, and Grimes D. Inhibition of antigen-<br>
induced pulmonary eosinophilia and neutrophilia by selective inhibitors of<br>
phosphodiesterase types 3 and 4 in brown Norway rats. Pulmonary Pharmacology.<br>
1995; 8: 83-89.<br>
Spond J, Chapman R, Fine J, Jones H, Kreutner W, Kung TT, Minnicozzi M.<br>
Comparison of PDE 4 inhibitors, Rolipram and SB 207499 (Arifloâ¢), in a rat model of<br>
pulmonary neutrophilia. Pulmonary Pharmacology and Therapeutics. 2001; 14: 157-<br>
164.<br>
Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC,<br>
Romanic AM, Adams JL, Hay DWP, and Griswold DE. SB 239063, a p38 MAPK<br>
inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.<br>
Am J Physiol Lung Cell Mol Physiol. 2000; 279: L895-L902.<br>
In Vivo Assay 2. Rat Pica Model ofemesis<br>
Background: Selective PDE4 inhibitors have been shown to inhibit inflammation<br>
in various in vitro and in vivo models by increasing intracellular levels of cAMP of many<br>
immune cells (e.g. lymphocytes, monocytes). However, a side effect of some PDE4<br>
inhibitors in many species is emesis. Because many rat models of inflammation are well<br>
characterized, they have been used in procedures (see e.g. In Vivo Assay 1 above) to<br>
show beneficial anti-inflammatory effects of PDE 4 inhibitors. However rats have no<br>
emetic response (they have no vomit reflex), so that the relationship between beneficial<br>
anti-inflammatory effects of PDE 4 inhibitors and emesis is difficult to study directly in<br>
rats.<br>
However, in 1991, Takeda et al. (see Literature section below) demonstrated that<br>
the pica feeding response is analogous to emesis in rats. Pica feeding is a behavioural<br>
response to illness in rats wherein rats eat non-nutritive substances such as earth or in<br>
particular clay (e.g. kaolin) which may help to absorb toxins. Pica feeding can be<br>
induced by motion and chemicals (especially chemicals which are emetic in humans), and<br>
can be inhibited pharmacologically with drugs that inhibit emesis in humans. The Rat<br>
Pica Model, In Vivo Assay 2, can determine the level of pica response of rats to PDE 4<br>
inhibition at pharmacologically relevant doses in parallel to in vivo anti-inflammatory<br>
Assays in (a separate set of) rats (e.g. In Vivo Assay 1 above). Anti-inflammatory and<br>
pica assays in the same species together can provide data on the "therapeutic index" (TI)<br>
in the rat of the compounds/salts of the invention. The Rat TI can for example be<br><br>
calculated as the ratio of a) the potentially-emetic Pica Response ED50 dose from Assay<br>
2 to b) the rat anti-infiammatory ED50 dose (e.g. measured by rat neutrophilia-inhibition<br>
in eg In Vivo Assay 1), with larger TI ratios possibly indicating lower emesis at many<br>
anti-inflammatory doses. This might allow a choice of a non-emetic or minima1-emetic<br>
pharmaceutical dose of the compounds or salts of the invention which has an<br>
anti-inflammatory effect. It is recognised however that achieving a low-emetic PDE4<br>
inhibitory compound is not essential to the invention.<br>
Procedure: On the first day of the experiment, the rats are housed individually<br>
in cages without bedding or "enrichment". The rats are kept off of the cage floor by a<br>
wire screen. Pre-weighed food cups containing standard rat chow and clay pellets are<br>
placed in the cage. The clay pellets, obtainable from Languna Clay Co, City of Industry,<br>
CA, USA, are the same size and shape as the food pellets. The rats are acclimated to the<br>
clay for 72 hours, during which time the cups and food and clay debris from the cage are<br>
weighed daily on an electronic balance capable of measuring to the nearest 0.1 grams. By<br>
the end of the 72 hour acclimation period the rats generally show no interest in the clay<br>
pellets.<br>
At the end of 72 hours the rats are placed in clean cages and the food cups<br>
weighed. Rats that are still consuming clay regularly are removed from the study.<br>
Immediately prior to the dark cycle (the time when the animals are active and should be<br>
eating) the animals are split into treatment groups and dosed orally with a dose of the<br>
compound/salt of the invention (different doses for different treatment groups) or with<br>
vehicle alone, at a dose volume of 2 ml/kg. In this oral dosing, the compound/salt is in<br>
the form of a suspension in 0.5% methylcellulose (obtainable Sigma-Aldrich, St. Louis,<br>
MO, USA) in water. The food and clay cups and cage debris are weighed the following<br>
day and the total clay and food consumed that night by each individual animal is<br>
calculated.<br>
A dose response is calculated by first converting the data into quantal response,<br>
where animals are either positive or negative for the pica response. A rat is "pica<br>
positive" if it consumes greater than or equal to 0.3 grams of clay over the mean of is<br>
usually calculated using logistic regression performed by the Statistica software statistical<br>
package. A Pica Response ED50 value in mg per kg of body weight can then be<br>
calculated.<br>
The Pica Response ED50 value can be compared to the neutrophilia-inhibition<br>
ED50 values for the same compound administered orally to the rat (measurable by In<br>
Vivo Assay 1 above), so that a Therapeutic Index (TI) in rats can be calculated thus:<br><br>
In general, the Therapeutic Index (TI) calculated this way is often substantially<br>
different to, for example can often be substantially higher than, the TI (D20/D50)<br>
calculated in the ferret (see In vivo Assay 4 below).<br>
Results: Using the above procedure, and according to current measurements, the<br>
compounds of Examples 14,17, 23, 35 and 38 exhibited a Pica Response ED50 in the<br>
range of about 2 mg/kg to greater than about 50 mg/kg, subject to testing inaccuracies.<br>
Taking the specific Pica Response ED50 values for these compounds together with the<br>
specific rat neutrophilia-inhibition ED50 values measured in In Vivo Assay 1 for<br>
Examples 14,17,23,35 and 38, the Rat Therapeutic Index (TI) for orally-administered<br><br>
Examples 14,17,23,35 and 38 was calculated using the above equation as being in the<br>
range of from about 12 to about 470, according to current measurements, subject to<br>
testing inaccuracies.<br>
Literature:<br>
Beavo JA, Contini, M., Heaslip, R.J. Multiple cyclic nucleotide<br>
phosphodiesterases. Mol Pharmacol. 1994;46:399-405.<br>
Spond J, Chapman R, Fine J, Jones H, Kreutner W, Kung TT, Minnicozzi M.<br>
Comparison of PDE 4 inhibitors, Rolipram and SB 207499 (Arifloâ¢), in a rat model of<br>
pulmonary neutrophilia. Pulmonary Pharmacology and Therapeudtics. 2001; 14:157-<br>
164.<br>
Takeda N, Hasegawa S, Morita M, and Matsunaga T. Pica in rats is analogous to<br>
emesis: an animal model in emesis research. Pharmacology, Biochemistry and Behavior.<br>
1991; 45:817-821.<br>
Takeda N, Hasegawa S, Morita M, Horii A, Uno A, Yamatodani A and<br>
Matsunaga T. Neuropharmacological mechanisms of emesis. I. Effects of antiemetic<br>
drugs on motion- and apomorphine-induced pica in rats. Meth Find Exp Clin Pharmacol.<br>
1995; 17(9) 589-596.<br>
Takeda N, Hasegawa S, Morita M, Horii A, Uno A, Yamatodani A and<br>
Matsunaga T. Neuropharmacological mechanisms of emesis. II. Effects of antiemetic<br>
drugs on cisplatin-induced pica in rats. Meth Find Exp Clin Pharmacol. 1995; 17(9)<br>
647-652.<br>
In Vivo Assay 3. LPS induced pulmonary neutrophilia in rats: effect of<br>
intratracheally administered PDE4 inhibitors<br>
This assay is an animal model of inflammation in the lung - specifically<br>
neutrophilia induced by lipopolysaccharide (LPS) - and allows the study of putative<br>
inhibition of such neutrophilia (anti-inflammatory effect) by intratracheally (i.t.)<br>
administered PDE4 inhibitors. The PDE4 inhibitors are preferably in dry powder or wet<br>
suspension form. It. administration is one model of inhaled administration, allowing<br>
topical delivery to the lung.<br>
Animals: Male CD (Sprague Dawley Derived) rats supplied by Charles River,<br>
Raleigh, NC, USA are housed in groups of 5 rats per cage, acclimatised after delivery for<br>
at least 7 days with bedding/nesting material regularly changed, fed on SDS diet Rl<br>
pelleted food given ad lib, and supplied with daily-changed pasteurised animal grade<br>
drinking water.<br>
Device for dry powder administration: Disposable 3-way tap between dosing<br>
needle and syringe. A 3-way sterile tap (Vycon Ref 876.00) is weighed, the drug blend<br>
or inhalation grade lactose (vehicle control) is then added to the tap, the tap closed to<br>
prevent loss of drug, and the tap is re-weighed to determine the weight of drug in the tap.<br>
After dosing, the tap is weighed again to determine the weight of drug that had left the<br>
tap. The needle, a Sigma Z21934-7 syringe needle 19-gauge 152 mm (6 inches) long<br>
with luer hub, is cut by engineering to approximately 132 mm (5.2 inches), a blunt end is<br><br>
made to prevent them damaging the rat's trachea, and the needle is weighed prior to and<br>
after drug delivery to confirm that no drug is retained in the needles after dosing.<br>
Device for wet suspension administration: This is the similar to'the above but a<br>
blunt dosing needle, whose forward end is slightly angled to the needle axis, is used,<br>
with a flexible plastic portex canula inserted into the needle.<br>
Drugs and Materials: lipopolysaccharide (LPS) (Serotype:0127:B8) (L3129 Lot<br>
61K4075) was dissolved in phosphate-buffered saline (PBS). PDE4 inhibitors are used in<br>
size-reduced (e.g. micronised) form, for example according to the Micronisation Example<br>
given above. For dry powder administration of the drug, the Dry Powder Formulation<br>
Example given above, comprising drug and inhalation-grade lactose, can be used. The<br>
inhalation-grade lactose usually used (Lot E98L4675 Batch 845120) has 10% fines (10%<br>
of material under 15um particle size measured by Malvern particle size).<br>
Wet suspensions of the drug can be prepared by added the required volume of<br>
vehicle to the drug, the vehicle being used being a mixture of saline/tween (0.2% tween<br>
80). The wet suspension was sonicated for 10 minutes prior to use.<br>
Preparation, and dosing with PDE 4 inhibitor: Rats are anaesthetised by placing<br>
the animals in a sealed Perspex chamber and exposing them to a gaseous mixture of<br>
isoflourane (4.5 %), nitrous oxide (3 htres.minute"1) and oxygen (1 litre.minute"1). Once<br>
anaesthetised, the animals are placed onto a stainless steel i.t. dosing support table. They<br>
are positioned on their back at approximately a 35Â° angle. A light is angled against the<br>
outside of the throat to highlight the trachea. The mouth is opened and the opening of the<br>
upper airway visualised. The procedure varies for wet suspension and dry powder<br>
administration of PDE4 inhibitors as follows:<br>
Dosing with a Wet suspension: A portex cannula is introduced via a blunt metal<br>
dosing needle that had been carefully inserted into the rat trachea. The animals are<br>
intratracheally dosed with vehicle or PDE4 inhibitor via the dosing needle with a new<br>
internal canula used for each different drug group. The formulation is slowly (10<br>
seconds) dosed into the trachea using a syringe attached to the dosing needle.<br>
Dosing with a Dry Powder: The three-way tap device and needle are inserted into<br>
the rat trachea up to a pre-determined point established to be located approximately 1 cm<br>
above the primary bifurcation. Another operator holds the needle at the specified position<br>
whilst 2 x 4ml of air is delivered through the three-way tap by depressing the syringes<br>
(ideally coinciding with the animal inspiring), aiming to expel the entire drug quantity<br>
from the tap. After dosing, the needle and tap are removed from the airway and the tap is<br>
closed off to prevent any retained drug leaving the tap.<br>
After dosing with either wet suspension or dry powder, the animals are then removed<br>
from the table and observed constantly until they have recovered from the effects of<br>
anaesthesia. The animals are returned to the holding cages and given free access to food<br>
and water; they are observed and any unusual behavioural changes noted.<br>
Exposure to LPS: About 2 hours after i.t. dosing with vehicle control or the PDE4<br>
inhibitor, the rats are placed into sealed Perspex containers and exposed to an aerosol of<br>
LPS (nebuliser concentration 150 ug.mr1) for 15 minutes. Aerosols of LPS are generated<br>
by a nebuliser (DeVilbiss, USA) and this is directed into the Perspex exposure chamber.<br><br>
Following the 15-minute LPS-exposure period, the animals are returned to the holding<br>
cages and allowed free access to both food and water.<br>
[In an alternative embodiment, the rats can exposed to LPS less than 2 hours after<br>
i.t. dosing. In another alternative embodiment, the rats can exposed to LPS more than 2<br>
hours (e.g. ca. 4 or ca. 6 hours) after i.t. dosing by vehicle or PDE4 inhibitor, to test<br>
whether or not the PDE4 inhibitor has a long duration of action (which is not essential).]<br>
Bronchoalveolar lavage: 4 hours after LPS exposure the animals are killed by<br>
overdose of sodium pentobarbitone (i.p.). The trachea is cannulated with polypropylene<br>
tubing and the lungs lavaged (washed out) with 3 x 5 mis of heparinised (25 units-ml-1)<br>
phosphate buffered saline (PBS).<br>
Neutrophil cell counts: The Bronchoalveolar lavage (BAL) samples are<br>
centrifuged at 1300 rpm for 7 minutes. The supernatant is removed and the resulting cell<br>
pellet resuspended in 1 ml PBS. A cell slide of the resuspension fluid is prepared by<br>
placing 100Âµl of resuspended BAL fluid into cytospin holders and then spun at 5000 rpm<br>
for 5 minutes. The slides are allowed to air dry and then stained with Leishmans stain (20<br>
minutes) to allow differential cell counting. The total cells are also counted from the<br>
resuspension. From these two counts, the total numbers of neutrophils in the BAL are<br>
determined. For a measure of PDE4-inhibitor-induced inhibition of neutrophilia, a<br>
comparison of the neutrophil count in rats treated with vehicle and rats treated with PDE4<br>
inhibitors is conducted.<br>
By varying the dose of the PDE4 inhibitor used in the dosing step (e.g. 0.2 or 0.1<br>
mg of PDE4 inhibitor per kg of body weight, down to e.g. 0.01 mg/kg), a dose-response<br>
curve can be generated.<br>
In vivo Assay 4.	Evaluation of Therapeutic Index of Orally-administered PDE 4<br>
inhibitors in the conscious ferret<br>
1.1	Materials<br>
The following materials are used for these studies:<br>
PDE4 inhibitors are prepared for oral (p.o.) administration by dissolving in a fixed<br>
volume (1 ml) of acetone and then adding cremophor to 20% of the final volume.<br>
Acetone is evaporated by directing a flow of nitrogen gas onto the solution. Once the<br>
acetone is removed, the solution is made up to final volume with distilled water.<br>
LPS is dissolved in phosphate buffered saline.<br>
1.2	Animals<br>
Male ferrets (Mustela Pulorius Furo, weighing 1 - 2 kg) are transported and allowed to<br>
acclimatise for not less than 7 days. The diet comprises SDS diet C pelleted food given<br>
ad lib with Whiskersâ¢ cat food given 3 times per week. The animals are supplied with<br>
pasteurised animal grade drinking water changed daily.<br>
1.3	Experimental Protocol(s)<br>
1.3.1 Dosing with PDE4 inhibitors<br>
PDE4 inhibitors are administered orally (p.o.), using a dose volume of lml/kg.<br><br>
Ferrets are fasted overnight but allowed free access to water. The animals are orally<br>
dosed with vehicle or PDE 4 inhibitor using a 15cm dosing needle that is passed down the<br>
back of the throat into the oesophagus. After dosing, the animals are returned to holding<br>
cages fitted with perspex doors to allow observation, and given free access to water. The<br>
animals are constantly observed and any emetic episodes (retching and vomiting) or<br>
behavioural changes axe recorded. The animals are allowed access to food 60 - 90<br>
minutes after p.o. dosing.<br>
1.3.2	Exposure to LPS<br>
Thirty minutes after oral dosing with compound or vehicle control, the ferrets are placed<br>
into sealed perspex containers and exposed to an aerosol of LPS (30 Âµg/ml) for 10<br>
minutes. Aerosols of LPS are generated by a nebuliser (DeVilbiss, USA) and this is<br>
directed into the perspex exposure chamber. Following a 10-minute exposure period, the<br>
animals are returned to the holding cages and allowed free access to water, and at a later<br>
stage, food. General observation of the animals continues for a period of at least 2.5<br>
hours post oral dosing. All emetic episodes and behavioural changes are recorded.<br>
1.3.3	Bronchoalveolar lavage and cell counts<br>
Six hours after LPS exposure the animals are killed by overdose of sodium<br>
pentobarbitone administered intraperitoneally. The trachea is then cannulated with<br>
polypropylene tubing and the lungs lavaged twice with 20 ml heparinised (10 units/ml)<br>
phosphate buffered saline (PBS). The bronchoalveolar lavage (BAL) samples are<br>
centrifuged at 1300 rpm for 7 minutes. The supernatant is removed and the resulting cell<br>
pellet re-suspended in 1 ml PBS. A cell smear of re-suspended fluid is prepared and<br>
stained with Leishmans stain to allow differential cell counting. A total cell count is<br>
made using the remaining re-suspended sample. From this, the total number of<br>
neutrophils in the BAL sample is determined.<br>
1.3.4	Pharmacodynamic readouts<br>
The following parameters are recorded:<br>
a)	% inhibition of UPS-induced pulmonary neutrophilia to determine the dose of PDE4<br>
inhibitor which gives 50% inhibition (D50).<br>
b)	Emetic episodes - the number of vomits and retches are counted to determine the dose<br>
of PDE4 inhibitor that gives a 20% incidence of emesis (D20).<br>
c)	A therapeutic index (TI), using this assay, is then calculated for each PDE4 inhibitor<br>
using the following equation:<br><br>
It is noted that the Ferret Therapeutic index (TI) (D20/D50) calculated using this in vivo<br>
Assay 4 is often substantially different to, and for example is often substantially lower<br>
than, the Rat TI (50/50) calculated using the rat oral inflammation and pica feeding<br>
Assays 1+2.<br>
The calculation of TI using the known PDE4 inhibitor roflumilast in this Assay 4 is:<br><br>
D20 for emesis = 0.46 mg/kg p.o., D50 for ferret neutroplilia = 0.42 mg/kg p.o., Ferret<br>
TI=1.1.<br>
All publications, including but not limited to patents and patent applications, cited in this<br>
specification are herein incorporated by reference as if each individual publication were<br>
specifically and individually indicated to be incorporated by reference herein as though<br>
fully set forth.<br><br>
EXAMPLES<br>
The various aspects of the invention will now be described by reference to the following<br>
examples. These examples are merely illustrative and are not to be construed as a<br>
limitation of the scope of the present invention. In this section, "Intermediates" represent<br>
syntheses of intermediate compounds intended for use in the synthesis of the "Examples".<br><br><br>
Machine Methods used herein:<br>
LCMS (liquid chromatography / mass spectroscopy)<br>
Waters ZQ mass spectrometer operating in positive ion electrospray mode, mass range<br>
100-1000 amu.<br>
UV wavelength: 215-330nM<br>
Column : 3.3cm x 4.6mm ID, 3um ABZ+PLUS<br>
Flow Rate: 3ml/min<br>
Injection Volume: 5Âµl<br>
Solvent A : 95% acetonitrile + 0.05% formic acid<br>
Solvent B : 0.1% formic acid + 10mMolar ammonium acetate<br>
Gradient: 0% A/0.7min, 0-100% A/3.5min, 100% A/1.1min, 100-0% A/0.2min<br>
Mass directed autoprep HPLC<br>
The prep column used was a Supelcosil ABZplus (10cm x 2.12cm) (usually 10cm x<br>
2.12cm x 5 (xm).<br>
UV wavelength: 200-320nM<br>
Flow: 20ml/min<br>
Injection Volume: 1ml; or more preferably 0.5 ml<br>
Solvent A : 0.1 % formic acid (or 0.1 % trifluoroacetic acid)<br>
Solvent B : 95% acetonitrile + 5% of (formic acid or trifluoroacetic acid); or more usually<br>
99.95% acetonitrile + 0.05% of (formic acid or trifluoroacetic acid)<br>
Gradient: 100% A/lmin, 100-80% A/9min, 80-1% A/3.5min, 1% A/1.4min, 1-<br>
100%A/0.1min<br>
Microwave<br>
The CEM Discover Focused Microwave Synthesis system was used.<br>
Intermediates and Examples<br>
AU reagents not detailed in the text below are commercially available from established<br>
suppliers such as Sigma-Aldrich. The addresses of the suppliers for some of the starting<br>
materials mentioned in the Intermediates and Examples below or the Assays above are as<br>
follows:<br>
-	ABCRGmbH &amp; CO. KG, P.O. Box 21 01 35, 76151 Karlsruhe, Germany<br>
-	Aceto Color Intermediates (catalogue name), Aceto Corporation, One Hollow Lane, Lake<br>
Success, NY, 11042-1215, USA<br>
-	Acros Organics, A Division of Fisher Scientific Company, 500 American Road, Morris Plains,<br>
NJ 07950, USA<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Intermediate 1: Ethyl 4-chloro-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate<br>
Prepared from commercially available 5-amino-1-ethyl pyrazole as described by G. Yu<br>
et. al. in J. Med Chem., 2001,44,1025-1027:<br><br>
Intermediate 2: Ethyl 4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-<br>
carboxylate<br><br><br>
Intermediate 1 (0.051g) and cyclopentyl amine (0.019g) were suspended in ethanol (2ml)<br>
and triethylamine (0.14ml) was added. The mixture was stirred under nitrogen and heated<br>
at 80Â°C for 16h. After cooling to room temperature, ethanol was removed by evaporation<br>
under a stream of nitrogen and the residue partitioned between DCM and water. The<br>
organic layer was loaded directly onto an SPE cartridge (silica, 5g) and eluted<br>
sequentially with; (i) DCM, (ii) DCM : Et2O (2:1), (iii) DCM : Et2O (1:1), (iv) Et2O, (v)<br>
EtOAc and (vi) MeOH. Fractions containing desired material were combined and<br>
concentrated in vacuo to afford Intermediate 2 (0.074g). LCMS showed MH+ = 303; TRET<br>
= 3.45min<br>
Intermediate 3; 4-(Cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-S-<br>
carboxylic acid<br><br>
A solution of Intermediate 2 (2.2g) in ethanol: water (95:5, 16.85ml) was treated with<br>
sodium hydroxide (1.2g) and heated at 50Â°C for 16h. The mixture was concentrated in<br>
vacuo and the residue re-dissolved in water (0.85ml). The solution was acidified to pH4<br>
using acetic acid and the resultant white precipitate was collected by filtration and dried<br>
under vacuum to afford Intermediate 3 (1.9g). LCMS showed MH+ = 275; TRET =<br>
2.65min<br>
Intermediate	4;	N'-Acetyl-4-(Cyclopentylamino)-1-ethyl-l H-pyrazolo [3,4-<br>
b]pyridine-5-carbohydrazide<br><br><br>
Intermediate 3 (0.066g), EDC (0.06g) and HOBT (0.035g) were suspended in DMF (2ml)<br>
and the mixture was stirred for 15 minutes. Acetic hydrazide (0.02g) was then added and<br>
the mixture stirred under nitrogen for 18h. Solvents were removed by concentration in<br>
vacuo and the residue partitioned between DCM and water. The layers were separated<br>
and the organic phase was washed with saturated aqueous sodium bicarbonate solution,<br>
then concentrated and applied to an SPE cartridge (aminopropyl, lg) which was eluted<br>
with methanol. Concentration in vacuo afforded Intermediate 4 (0.043 g). LCMS showed<br>
MH+ = 331; TRET = 2.38min.<br>
Intermediate 5: 4-(Cyclopentylamino)-1-ethyl-N'-[(methylsulfonyl)acetyl]-1H-<br>
pyrazolo[3,4-b]pyridine-5-carbohydrazide<br><br>
Intermediate 3 (0.12g), EDC (0.12g) and HOBT (0.072g) were suspended in DMF (2ml)<br>
and stirred for 15 minutes. Intermediate 8 (0.082g) was then added and the mixture stirred<br>
under nitrogen for 18h. Reaction was incomplete so a further portion of Intermediate 8<br>
was added (0.040g) and stirring continued for a further 66h. Solvents were removed in<br>
vacuo and the residue partitioned between DCM and water. The aqueous phase was<br>
further extracted with DCM and the combined organic layers applied to an SPE cartridge<br>
(silica, 5g) which was eluted sequentially with a gradient of Et2O: MeQH (1:0, 9:1, 8:2,<br>
7:3 and 6:4). Fractions containing desired material were combined and concentrated in<br>
vacuo to afford Intermediate 5 (0.154g). LCMS showed MH4 = 409; TRET = 2.42min.<br>
Intermediate 6: Ethyl 4-(4-fluorophenylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-<br>
5-carboxylate<br><br><br>
Intermediate 1 (0.05 lg) and 4-fluoroaniline (0.024g) were suspended in ethanol (2ml)<br>
and triethylamine (0.14ml) was added. The mixture was stirred under nitrogen and heated<br>
at 80Â°C for 16h. After cooling to room temperature, ethanol was removed by evaporation<br>
under a stream of nitrogen and the residue partitioned between DCM and water. The<br>
organic layer was loaded directly onto an SPE cartridge (silica, 5g) and eluted<br>
sequentially with; (i) DCM, (ii) DCM : Et2O (2:1), (iii) DCM : Et20 (1:1), (iv) Et2O, (v)<br>
EtOAc, (vi) MeOH. Fractions containing desired material were combined and<br>
concentrated in vacuo to afford Intermediate 6 (0.077g). LCMS showed MH+ = 328; TRBT<br>
= 3.36min.<br><br>
Intermediate 3 (0.10g) was dissolved in DMF (2ml) and treated with HBTU (0.136g) and<br>
DIPEA (0.116g). A separate portion of Intermediate 3 (0.10g) was dissolved in DMF<br>
(2ml) and treated with EDC (0.096g) and HOBT (0.058g). The resultant suspensions<br>
were both stirred under nitrogen for 15min, then methyl hydrazine (0.017g) added to each<br>
and stirring continued under nitrogen for 18h. The mixtures were independently<br>
concentrated in vacuo and the residues partitioned between DCM and water. The organic<br>
layers were concentrated and each applied to an SPE cartridge (aminopropyl, 2g) which<br>
was eluted with methanol, followed by 10% ammonia in methanol. The two portions of<br>
Intermediate 7 thus afforded were combined (0.16g). LCMS showed MH+ = 303; TRET =<br>
2.22min.<br><br><br>
Intermediate 3 (0.060g), EDC (0.06g) and HOBT (0.035g) were suspended in DMF (2ml)<br>
and stirred under nitrogen for 15 minutes. isobutyric acid hydrazide (0.027g) was then<br>
added and the mixture stirred under nitrogen for 18h. Solvents were removed in vacuo<br>
and the residue partitioned between DCM and water. The organic phase was washed with<br>
saturated aqueous sodium bicarbonate solution, then concentrated in vacuo and applied to<br>
an SPE cartridge (aminopropyl, lg) which was eluted with methanol. Concentration in<br>
vacuo afforded Intermediate 10. LCMS showed MH+ = 359; 1W = 2.70min.<br><br>
A solution of Intermediate 1 (3.5g) in dioxane (28ml) was treated with potassium<br>
hydroxide (6.3g) as a solution in water (20ml). The mixture was stirred for 2h, then<br>
concentrated in vacuo, acidified to pH 3 with 2M aqueous hydrochloric acid and<br>
extracted with ethyl acetate. The layers were separated, the organic layer dried over<br>
sodium sulphate, then concentrated in vacuo to afford Intermediate 11 as a white solid<br>
(2.4g). LCMS showed MH+ = 226; TRET = 2.62min.<br><br><br>
Intennediate 11 (0.4g) was dissolved in thionyl chloride (3ml) and the mixture was<br>
heated at reflux (95Â°C) with stirring for lh. After cooling to room temperature, excess<br>
thionyl chloride was removed by evaporation under reduced pressure and the resultant<br>
solid dissolved in anhydrous acetonitrile (2ml). This solution was added to a solution of<br>
acetic hydrazide (0.145g) and diisopropylethylamine (0.465ml) in anhydrous acetonitrile<br>
(2ml), and the mixture stirred for a further 2h. The mixture was concentrated in vacuo<br>
and the residue treated directly with phosphorus oxychloride (4ml). The resultant solution<br>
was stirred and heated at reflux (120Â°C) for 0.5h, then allowed to cool and purified by<br>
Biotage (silica, 40g), eluting with cyclohexane : EtOAc (1:1) to afford Intermediate 12<br>
(0.32g). LCMS showed MH+ = 264; TRET = 2.55 min.<br><br>
Intermediate 11 (0.05g) was dissolved in thionyl chloride (1ml) and the mixture was<br>
heated at reflux (95Â°C) with stirring for 1h. After cooling to room temperature, excess<br>
thionyl chloride was removed by evaporation under reduced pressure and the resultant<br>
solid dissolved in anhydrous acetonitrile (0.5ml). This solution was added to a solution of<br>
isobutyric acid hydrazide (0.025g) and diisopropylethylamine (0.058ml) in anhydrous<br>
acetonitrile (1ml), and the mixture stirred for a further 1.5h. The mixture was<br>
concentrated in vacuo and the residue treated directly with phosphorus oxychloride (2ml).<br>
The resultant solution was stirred and heated at reflux (120Â°C) for 2h, then allowed to<br>
cool and concentrated in vacuo. The residue was applied to an SPE cartridge (silica, 5g)<br>
which was eluted sequentially with a gradient of EtOAc : cyclohexanl (i) 1:16, (ii) 1:8,<br>
(iii) 1:4, (iv) 1:2, (v) 1:1 and (vi) 1:0. Fractions containing desired material were<br>
combined and concentrated in vacuo to afford Intermediate 13 (0.049g). LCMS showed<br>
MH+ = 292; TRET = 2.96min.<br><br><br>
Intermediate 11 (0.40g) was dissolved in thionyl chloride (3ml) and the mixture was<br>
heated at reflux (95Â°C) with stirring for lh. After cooling to room temperature, excess<br>
thionyl chloride was removed by evaporation under reduced pressure and the resultant<br>
solid dissolved in anhydrous acetonitrile (2ml). This solution was added to a solution of<br>
pivalic acid hydrazide (0.228g) and diiscrpropylemylarnine (0.465ml) in anhydrous<br>
acetonitrile (2ml), and the mixture stirred for a further 1.5h. The mixture was<br>
concentrated in vacuo and the residue treated directly with phosphorus oxychloride (5ml).<br>
The resultant solution was stirred and heated at reflux (120Â°C) for 1.5h, then allowed to<br>
cool, concentrated in vacuo and purified by Biotage (silica, 40g), eluting with petroleum<br>
ether (40/60) : EtOAc (1:1) to afford Intermediate 14 (0.388g). LCMS showed MH+ =<br>
306; TRET = 3.14 min.<br><br>
Intermediate 11 (0.68g) was dissolved in thionyl chloride (4ml) and the mixture was<br>
heated at reflux (95Â°C) with stirring for lh. After cooling to room temperature, excess<br>
thionyl chloride was removed by evaporation under reduced pressure and the resultant<br>
solid dissolved in anhydrous acetonitrile (3ml). This solution was added dropwise over 5<br>
minutes to a solution of Intermediate 8 (0.504g) and diisopropylethylamine (0.787ml) in<br>
anhydrous acetonitrile (12ml), and the mixture then stirred for a further lh. The mixture<br>
was concentrated in vacuo and the residue treated directly with phosphorus oxychloride<br>
(8ml). The resultant solution was stirred and heated at reflux (120Â°C) for 2.5h, then<br>
allowed to cool, concentrated in vacuo and purified by Biotage (silica, 40g), eluting first<br>
with petroleum ether (40/60) : EtOAc (2:1), then with petroleum ether (40/60) : EtOAc<br>
(1:1). Fractions containing desired material were combined, concentrated in vacuo and<br>
the residue further purified by trituration with diethyl ether to afford Intermediate 15<br>
(0.41g). LCMS showed MH+ = 342; TRET = 2.46 min.<br><br><br>
Intermediate 1 (0.20g) and triethylamine (0.55ml) were suspended in ethanol (8ml) and<br>
4-aminotetrahydropyran (Intermediate 21, 0.088g) was added. The mixture was stirred<br>
under nitrogen, heated at 80Â°C for 16h, then concentrated in vacuo. The residue was<br>
partitioned between DCM and water. The layers were separated and the organic layer was<br>
loaded directly onto an SPE cartridge (silica, 5g) which was eluted sequentially witl; (i)<br>
DCM, (ii) DCM : Et2O (2:1), (iii) DCM : Et2O (1:1), (iv) Et2O and (v) EtOAc Fractions<br>
containing desired material were combined and concentrated in vacuo to afford<br>
Intermediate 16 (0.21g). LCMS showed MH+ = 319; TRET - 2.93min.<br><br>
A solution of Intermediate 16 (0.21g) in ethanol : water (95:5, 10ml) was treated with<br>
sodium hydroxide (0.12g). The mixture was heated at 50Â°C for 8h, then concentrated in<br>
vacuo, dissolved in water and acidified to pH 4 with acetic acid. The resultant white solid<br>
was removed by filtration and dried under vacuum to afford Intermediate 17 as an off-<br>
white solid (0.16g). LCMS showed MH+ = 291; TRET = 2.1 lmin.<br>
An alternative preparation of Intermediate 17 is as follows:<br>
A solution of Intermediate 16 (37.8g) in ethanol : water (4:1, 375ml) was treated with<br>
sodium hydroxide (18.9g). The mixture was heated at 50 Â°C for 5 hours, then<br>
concentrated in vacuo, dissolved in water and acidified to pH 2 with aqueous<br>
hydrochloric acid (2M). The resultant white solid was removed by filtration and dried<br>
under vacuum to afford Intermediate 17 as an off-white solid (29.65g). LCMS showed<br>
MH* = 291; TRET = 2.17 min.<br><br><br>
A suspension of Intermediate 17 (1.48g), EDC (1.34g) and HOBT (0.83g) in DMF<br>
(20ml) was stirred at room temperature for 30min. t-Butyl carbazate (0.68g) was then<br>
added and stirring continued under nitrogen for a further 66h. The mixture was<br>
concentrated in vacuo and the residue divided into two portions for purification. Each<br>
portion was applied to an SPE cartridge (aminopropyl, 10g) which was eluted with<br>
methanol and the combined eluents were concentrated in vacuo. Further purification was<br>
carried out by Biotage (silica, 40g), eluting with cyclohexane : ethyl acetate (1:4).<br>
Fractions containing desired material were combined and concentrated in vacuo to afford<br>
Intermediate 18 (1.39g). LCMS showed MH+ = 405; TRET = 2.64min.<br><br>
Intermediate 18 (1.39g) was treated with a 4M solution of hydrochloric acid in dioxane<br>
(8ml) and the mixture stirred under nitrogen for lh. Concentration in vacuo afforded<br>
Intermediate 19 as a white solid (1.17g). LCMS showed MH+ = 305; TRET = 2.04min.<br><br><br>
dichloromethane and water. The layers were separated and the organic layer concentrated<br>
in vacuo, then applied to an SPE cartridge (aminopropyl, lg). The column was eluted<br>
with methanol to afford Intermediate 20 as a white solid (0.02g). LCMS showed MH4 =<br>
373; TRET = 2.15rnin.<br><br>
Commercially available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San<br>
Diego, CA 92126. CAS (Chemical Abstracts) Registry Number 38041-19-9.<br><br>
Stepl: N,N-dibenzyltetrahydro2H-pyran-4-amine<br>
Diben2ylamine (34.5g) and acetic acid (6.7ml) were added to a stirred solution of<br>
tetrahydro-4H-pyran-4-one (16.4g, commercially available from e.g. Aldrich) in<br>
dichloromethane (260ml) at 0 Â°C to 5 Â°C. After 2.5h at 0 Â°C to 5 Â°C, sodium<br>
triacetoxyborohydride (38.9g) was added portionwise, and the mixture was allowed to<br>
warm to room temperature. After stirring at room temperature overnight, the reaction<br>
mixture was washed successively with 2M-sodium hydroxide (200ml and 50ml), water (2<br>
x 50ml) and brine (50ml), then dried and evaporated to give a yellow oil (45g). This oil<br>
was stirred with methanol (50ml) at 4 Â°C for 30min to give the product as a white solid<br>
(21.5g). LCMS showed MH+= 282; TRET = 1-98 min.<br>
Step 2: Tetrahydro-2H-pyran-4-amine hydrochloride<br>
N,N-dibenzyltetrahydro-2H-pyran-4-amine (20.5g) was dissolved in ethanol (210ml) and<br>
hydrogenated over 10% palladium on carbon catalyst (4g) at 100 psi for 72h at room<br>
temperature. The reaction mixture was filtered and the filtrate was adjusted to pH 1 with<br>
2M-hvdrogen chloride in diethyl ether. Evaporation of solvents gave a solid which was<br><br><br>
A solution of methoxyacetonitrile (12.26g) in ethanol (220ml) was treated with<br>
hydroxylamine hydrochloride (11.95g) followed by potassium carbonate (22.9g) and<br>
heated under reflux for 2 days. The mixture was concentrated in vacuo, then partitioned<br>
between ethylacetate and water. The organic layer was concentrated in vacuo to afford<br>
Intermediate 22 as a colourless liquid (7.6g). 1H NMR (CDC13) 7.16 (3H, s), 7.67 (s, 2H),<br>
9.32 (brs, 2H), 13.08 (1H, s).<br><br>
Can be prepared in an analogous manner to Intermediate 9, starting from morpholino<br>
acetonitrile (itself commercially available from TCI America, 9211 North Harborgate<br>
Street, Portland, OR 97203, USA).<br>
Intermediate 25: 1-Acetyl-4-aminopiperidine hydrochloride<br>
Prepared from commercially available N1-berizyl-4-aminopiperidine as described by<br>
Yamada et. al. In WO 00/42011:<br><br>
Can be prepared by oxidation of 3-Methyl-3-oxetanemethanol (commercially available<br>
from e.g. Fluka, CAS (Chemical Abstracts) Registry Number 3143-02-0) according to the<br>
procedure described by H. Fiege et. al. in DE3618142.<br>
Intermediate 27: (4-Methylpiperazin-1-yl)acetic acid<br><br><br>
Commercially available from ChemPacific USA Sales Marketing and Research Center,<br>
6200 Freeport Centre, Baltimore, MD 21224, USA (CAS Registry Number 54699-92-2).<br><br>
Commercially available from Austin Chemical Company, Inc., 1565 Barclay Blvd.,<br>
Buffalo Grove, EL 60089, USA. CAS (Chemical Abstracts) Registry Number 3338-22-5.<br><br>
Commercially available from MicroChemistry-RadaPharma, Shosse Entusiastov 56,<br>
Moscow 111 123, Russia. CAS (Chemical Abstracts) Registry Number 42346-68-9.<br><br>
Commercially available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San<br>
Diego, CA 92126, USA. CAS (Chemical Abstracts) Registry Number 5337-03-1.<br><br>
Can be prepared from ethyl bromoacetate as described by Z. Dega-Szafran et. al. in J.<br>
Molecular Structure, 2001, 560,261-273.<br><br>
A suspension of sodium t-butoxide (24.1 g) in t-butanol (150ml) was cooled in a water<br>
bath and treated drop-wise with a solution of chloroacetic acid (11.4g) in t-butanol<br><br>
(30ml). The mixture was heated under reflux for 5h then concentrated in vacuo. The<br>
resultant white solid was dried in vacuo for 16h then water (100ml) was added and the<br>
mixture was filtered. The filtrate was treated with diethyl ether (150ml), then cooled in an<br>
ice bath, stirred and acidified to pH1 with 2N sulphuric acid. The layers were separated<br>
and the aqueous layer was further extracted with diethyl ether. The combined organic<br>
extracts were dried (MgSO4) and concentrated in vacuo to afford Intermediate 32 (11.lg).<br>
1H NMR (400MHz, CDC13, Î´ppm) 1.27 (9H, s), 4.04 (2H, s).<br><br>
Intermediate 17 (O.lg, 0.34mmol), EDC (0.066g, 0.34mmol) and HOBT (0.05g,<br>
0.37mmol) were suspended in DMF (2ml) and stirred at room temperature under nitrogen<br>
for 15 mins. L-Serine methyl ester hydrochloride (0.054g, 0.34mmol) and triethylamine<br>
(0.036g, 0.36mmol) were added and the mixture stirred at room temperature under<br>
nitrogen for 18 hours. Solvents were removed in vacuo and the residue was partitioned<br>
between DCM and water. The organic layer was concentrated in vacuo and applied to an<br>
SPE cartridge (aminopropyl, 5g), which was eluted with methanol. Concentration in<br>
vacuo afforded an impure residue which was further purified by SPE cartridge (silica,<br>
5g), eluting with ethyl acetate followed by 5% methanol/ethyl acetate. The desired<br>
fractions were concentrated in vacuo to afford Intermediate 33 (0.055g). LCMS showed<br>
MH+ = 393; TRET = 2.22min.<br><br><br>
Intermediate 17 (0.1g, 0.34mmol), EDC (0.066g, 0.34mmol) and HOBT (0.05g,<br>
0.37mmol) were suspended in DMF (2ml) and stirred at room temperature under<br>
nitrogen for 15 min. 2-aminopropan-1-ol (0.026g, 0.34mmol) and triemylarnine (0.036g,<br>
0.36mmol) were added and the mixture was stirred at room temperature under nitrogen<br>
for 6 hours. Solvents were removed in vacuo and the residue partitioned between DCM<br>
and water. The organic layer was concentrated and applied to an SPE cartridge<br>
(amine-propyl, 5g), which was eluted with methanol. Concentration in vacuo afforded<br>
Intermediate 34 (0.095 g). LCMS showed MH+ = 348, TRET= 2.15min.<br><br>
Sodium (0.55g, 23.7mmol) was added portionwise to anhydrous ethanol (25ml) at 20 Â°C<br>
under an atmosphere of nitrogen. After stirring for 1 hour the solution was added to<br>
Intermediate 1 (4.622g, 18.22mmol) and the reaction mixture heated at reflux for 2 hours.<br>
The mixture was evaporated in vacuo and the residue partitioned between<br>
dichloromethane and water. The organic phase was washed with brine, dried (Na2SO4)<br>
and evaporated in vacuo. The residue was purified on SPE cartridges (silica, 4 x 20g)<br>
eluting with dichloromethane, ethyl acetate:petroleum ether (1:4,1:2 then 1:1) followed<br>
by ethyl acetate). Appropriate fractions were combined and evaporated in vacuo to afford<br>
Intermediate 35 as white solid (4.33g). LCMS showed MH+ = 264, TRET= 2.77min.<br><br><br>
A mixture of Intermediate 35 (1.0g, 3.8mmol) and N-bromosuccinimide (1.49g,<br>
8.4mmol) in carbon tetrachloride (35ml) was heated at reflux for 3 hours. The reaction<br>
mixture was cooled in an ice-bath and the precipitate filtered. The filtrate was<br>
concentrated in vacuo and the residue dissolved in tetrahydrofuran (12.5ml). Water<br>
(3.5ml) and saturated sodium carbonate solution (3ml) were added and the mixture stirred<br>
at 20 Â°C for 18 hours. The reaction was diluted with water and extracted with ethyl<br>
acetate. The combined organic phases were dried (Na2SO4) and evaporated in vacuo.<br>
The residue was purified on an SPE cartridge (silica, 20g) eluting with dichloromethane,<br>
chloroform, then chloroform:methanol (99:1,49:1,19:1 then 9:1). Appropriate fractions<br>
were combined and evaporated in vacuo to afford Intermediate 36 as an off-white solid<br>
(0.45g). LCMS showed MH+ = 236, TRET= 2.46min.<br><br><br>
Method 1: Intermediate 36 (0.035g) was placed in a Reactivialâ¢ and treated with<br>
4-aminotetrahydropyran (0.05ml). The mixture was heated at 90 ÂºC for 1.5 hours, then<br>
allowed to cool to room temperature and partitioned between chloroform (2ml) and water<br>
(lml). The layers were separated and the organic phase was concentrated. The crude<br>
product was purified by mass directed autoprep HPLC to afford Intermediate 37 as an<br>
off-white solid (0.01 lg). LCMS showed MH+= 291; TRET = 2.08 min.<br>
Alternative Method 2: Intermediate 36 (2g) was suspended in 4-aminotetrahydropyran<br>
(2g), and the mixture was heated at 90 Â°C for 6 hours. The residual mixture was allowed<br>
to cool to room temperature and partitioned between chloroform (50ml) and water<br>
(50ml). The phases were separated and the organic phase was evaporated to dryness. The<br>
residue was triturated with Et20 (30ml) and the insoluble solid was collected and dried to<br>
afford Intermediate 37 as a cream solid (2.24g). LCMS showed MH+= 291; TRET = 2.19<br>
min.<br><br>
Sodium hydride (0.067 g, 60% dispersion in oil) was added to a stirred solution of<br>
Intermediate 37 (0.47 g) in DMF (19 ml), followed by n-propyl iodide (0.17 ml). The<br>
mixture was stirred at 23 Â°C for 16 hours, then concentrated, diluted with chloroform (30<br>
ml) and washed with 1:1 water.brine solution (30 ml), separated and the organic layer<br>
concentrated. The residue was purified on a SPE cartridge (silica, 10 g) eluting with 10<br>
ml volumes of dichloromethane, 1:1 diethyl ethencyclohexane, and diethyl ether. The<br>
combined 1:1 diethyl ether: cyclohexane, and diethyl ether, fractions were concentrated<br><br><br>
2M-Sodium hydroxide solution (0.7 ml) was added to a stirred suspension of<br>
Intermediate 38 (0.23 g) in ethanol (5 ml) and water (1.5 ml). After stirring overnight at<br>
room temperature, a further quantity of 2M-sodium hydroxide solution (0.7 ml) was<br>
added, and the reaction mixture was heated at 43 Â°C for 2.5 hours. The reaction solution<br>
was concentrated, diluted with water (5 ml) and acidified with 2M-hydrochloric acid. The<br>
resulting precipitate was collected by filtration, washed with water and dried to give<br>
Intermediate 39 asa white solid (0.14 g). LCMS showed MH+ = 305; TRET = 2.42min.<br><br>
Intermediate 40 can be made from Intermediate 39 in a similar way to the process<br>
described for Intermediate 4, for example using a similar or the same number of moles of<br>
reagents and/or volumes of solvents.<br><br><br>
Intermediate 1 (0.079g, 0.56mmol), Intermediate 25 (0.129g, 0.51mmol) and<br>
diisopropylethylamine (0.45ml, 2.55mmol) in acetonitrile (2ml) were heated at 85 Â°C for<br>
36 hours. The reaction mixture was concentrated in vacuo and the residue partitioned<br>
between DCM and water. The phases were separated using a hydrophobic frit<br>
(Whatman). The organic phase was evaporated in vacuo and the residue applied to an<br>
SPE cartridge (silica, 5g). The cartridge was eluted with EtOAc and then DCM / MeOH<br>
(1:1). Fractions containing the desired material were combined and concentrated in<br>
vacuo to afford Intermediate 41 (0.1g). LCMS showed MH+ = 360; TRET = 2.63min.<br><br>
Intermediate 17 (0.25g, 0.86mmol), EDC (0.23g, 1.2mmol) and HOBT (0.139g,<br>
1.03mmol) were suspended in DMF (5ml) and the suspension was stirred at room<br>
temperature. After 25min, (2R)-2-Amino-2-phenylethanol (0.13g, 0.95mmol,<br>
commercially available from Aldrich) was added, and the mixture was stirred at room<br>
temperature for 20 hours. Solvents were removed in vacuo and the residue was dissolved<br>
in DCM (50ml) and washed successively with water (25ml) and 5% sodium hydrogen<br>
carbonate solution (25ml). The organic layer was dried over anhydrous sodium sulphate<br>
and concentrated in vacuo. The residue was dissolved in dichloromethane (5ml) and<br>
applied to a SPE cartridge (silica, lOg), which was eluted with a gradient of ethyl acetate<br>
-petroleum ether (1:2,1:1 and 1:0). Fractions containing the desired material were<br>
combined and concentrated in vacuo to afford Intermediate 42 as a white foam (0.318g).<br>
LCMS showed MH+ = 410; TRET = 2.55min.<br><br><br>
Intermediate 43 was prepared from Intermediate 17 and (25)-2-amino-2-phenylethanol<br>
(commecially available from Lancaster Synthesis) using an analogous method to that for<br>
Intermediate 42. LCMS showed MH+ = 410; TRET = 2.55min.<br><br>
Intermediate 44 was prepared from Intermediate 17 and (25)-2-amino-3-phenyl-1-<br>
propanol (commercially available from Aldrich) using an analogous method to that for<br>
Intermediate 42. LCMS showed MH+ = 424; TRET = 2.60min.<br><br>
Intermediate 45 was prepared from Intermediate 17 and (2i?)-2-amino-3-phenyl-1-<br>
propanol (commecially available from Aldrich) using an analagous method to that for<br>
Intermediate 42. LCMS showed MH+ = 424; TRET = 2.59min.<br><br><br>
Intermediate 46 was prepared from Intermediate 17 and (1S,2R)-1-amino-1-phenyl-2-<br>
propanol hydrochloride (commercially available from Arch Corporation, 100 Jersey<br>
Avenue, Building D, New Brunswick, NJ 08901, USA) using an analogous method to<br>
that for Intermediate 42. LCMS showed MH+ = 424; TRET = 2.58rnin.<br><br>
Intermediate 47 was prepared from Intermediate 17 and (li?)-2-amino-1-phenylethanol<br>
(commercially available from Aldrich) using an analogous method to that for<br>
Intermediate 42. LCMS showed MH+ = 410; TRET = 2.62min.<br><br>
Intermediate 48 was prepared from Intermediate 17 and (lS)-2-amino-1-phenylethanol<br>
(commercially available from Fluka) using an analogous method to that for Intermediate<br>
42. LCMS showed MH+ = 410; TRET = 2.62min.<br><br><br>
Intermediate 49 was prepared from Intermediate 17 and 2-amino-2-methyl-1-propanol<br>
(commercially available from Aldrich) using an analogous method to that for<br>
Intermediate 42. LCMS showed MH+ = 362; TRET = 2.28min.<br><br>
Can be prepared from tetrahydro-4H-pyran-4-one (commercially available from e.g.<br>
Sigma Aldich; CAS (Chemical Abstracts) Registry Number 29943-42-8) according to the<br>
procedure described by H.Hashimoto et al. in Organic Process Research and<br>
Development 2002, 6,70.<br><br>
Intermediate 1 (1.2g, 4.76mmol), Intermediate 50 (0.79g, 5.2mmol) and<br>
diisopropylethylamine (4ml, 24mmol) in MeCN (8ml) was heated at 70 Â°C for 24 hours.<br>
The solvent was removed in vacuo and the residue partitioned between DCM and water.<br>
The organic phase was concentrated in vacuo and the residue chromatographed on silica<br>
(50g) eluting with cyclohexane:ethyl acetate (2:1 followed by 1:1 then 1:2). Appropriate<br>
fractions were combined and evaporated to give Intermediate 51 as a brown oil (1.21g).<br>
LCMS showed MH+ = 334; TRET = 2.61min.<br><br><br>
Sodium hydroxide (0.43g, 10.8mmol) was added to a solution of Intermediate 51 in<br>
ethanol (10ml, 95%). The reaction mixture was heated at 50 Â°C for 18 hours. The solvent<br>
was evaporated in vacuo and the residue dissolved in water and acidified to pH 3 by the<br>
addition of aqueous hydrochloric acid. The solution was extracted with DCM. The<br>
organic phase was separated using a hydrophobic frit (Whatman PTFE Folter Media with<br>
Polypropylene Housing 5ÂµM pore size) and the solvent evaporated in vacuo to give<br>
Intermediate 52 as a white solid (0.65g). LCMS showed MH+ = 305; TRET=1.97min.<br><br>
Intermediate 53 was prepared from Intermediate 52 using an analogous method to that for<br>
Intermediate 4. LCMS showed MH+ = 361; TRET = 1.91min.<br><br><br><br><br>
Can be prepared from tetrahydro-4H-pyran-4-onc (commercially available from e.g.<br>
Sigma Aldich CAS 29943-42-8) as described by C. Zagar in WO 99/07702.<br>
A solution of hydrogen chloride in dioxan (0.5ml, 2.0mmol, 4M) was added to a stirred<br>
solution of tert-butyl 4-oxocyclohexylcarbamate (0.043g, 0.20mmol, commercially<br>
available from Astatech Inc., Philadelphia, USA) in dioxan (0.5ml) and the mixture was<br>
stirred at room temperature. After lh, the reaction mixture was evaporated to give<br>
Intermediate 56 as a cream solid (34mg). 1H NMR (400MHz in d6-DMSO, 27Â°C, Î´ppm)<br>
8.09 (br. s, 3H), 3.51 (tt, 11, 3.5Hz, 1H), 2.45 (m, 2H, partially obscured), 2.29 (m, 2H),<br>
2.16 (m,2H), 1.76 (m,2H).<br><br>
A mixture of 5-amino-1-ethyIpyrazole (1.614g, 14.5mmol) and diethyl 2-(1-<br>
ethoxyethylidene)malonate (3.68g, 16.0mmol, as described by P.P.T. Sah, J. Amer.<br>
Chem. Soc, 1931, 53,1836) was heated at 150 Â°C under Dean Stark conditions for 5<br>
hours. Phosphorous oxychloride (25ml) was carefully added to the mixture and the<br>
resulting solution was heated at 130 Â°C under reflux for 18 hours. The mixture was<br>
concentrated in vacuo, then the residual oil was carefully added, with cooling, to water<br>
(100ml). The resulting mixture was extracted with DCM (3x100ml) and the combined<br>
organic extracts were dried over anhydrous sodium sulphate and concentrated in vacuo.<br>
The residual oil was purified by Biotage chromatography (silica, 90g) eluting with ethyl<br>
acetate-petrol (1:19). Fractions containing the desired product were combined and<br>
concentrated in vacuo to afford Intermediate 58 (1.15g). LCMS showed MH+ = 268; TRET<br>
= 3.18min.<br><br><br>
4-Aminotetrahydropyran hydrochloride (Intermediate 21, 0.413g, 3.0mmol) was added to<br>
a mixture of Intermediate 58 (0.268g, l.Ommol) and N.N-diisopropylethylamine (0.87ml,<br>
5.0mmol) in acetonitrile (3ml). The resulting mixture was heated at 85 Â°C for 24 hours.<br>
Volatiles were removed in vacuo and the residue was dissolved in chloroform (1.5ml) and<br>
applied to a SPE cartridge (silica, 5g). The cartridge was eluted successively with Et20,<br>
EtOAc and EtOAc-MeOH (9/1). Fractions containing the desired product were combined<br>
and concentrated in vacuo to give the desired product contaminated with starting material<br>
(Intermediate 51). Further purification using a SPE cartridge (silica, 5g) eluting with ethyl<br>
acetate-cyclohexane (1:3) afforded Intermediate 59 (0.248g). LCMS showed MH+ = 333;<br>
TRET = 2.75min.<br><br>
2M-Sodium hydroxide solution (0.75ml, 1.5mmol) was added to Intermediate 59 (0.248g,<br>
0.75mmol) in ethanol (2ml), and the mixture was heated at reflux for 16 hours. The<br>
reaction mixture was concentrated, diluted with water (1ml) and acidified with 2M-<br>
hydrochloric acid (0.75ml) to precipitate a solid which was collected by filtration to<br>
afford Intermediate 60 (0.168g). LCMS showed MH+ = 305; TRET = 1.86min.<br><br><br>
Intermediate 60 (0.255g, 0.84mmol), EDC (0.225g, 1.17mmol) and HOBT (0.136g,<br>
l.Ommol) in DMF (5ml) was stirred at 20 Â°C for 75 minutes. Pivalic acid hydrazide<br>
(0.107g, 0.92mmol) was added and stirring continued for 18 hours. The reaction mixture<br>
was concentrated in vacuo and the residue partitioned between DCM and water. The<br>
organic phase was washed with aqueous sodium hydrogen carbonate then evaporated in<br>
vacuo to afford Intermediate 61 as a white solid (0.27g).). LCMS showed MH+ = 403;<br>
TRET = 2.13min.<br><br>
Intermediate 60 (0.253g, 0.83mmol), EDC (0.223g, 1.17mmol) and HOBT (0.135g,<br>
l.Ommol) in DMF (5ml) was stirred at 20 Â°C for 30 minutes. t-Butyl carbazate (O.llOg,<br>
0.83mmol) was added and stirring continued for 18 hours. The reaction mixture was<br>
concentrated in vacuo and the residue dissolved in DMF (5ml) additional EDC (0.159g0)<br>
and HOBT (0.112g) added. After 30 minutes t-butyl carbazate (0.019g) was added and<br>
stirring continued for 18 hours. The reaction was concentrated in vacuo and the residue<br>
partitioned between DCM and water. The organic phase was washed with aqueous<br>
sodium hydrogen carbonate then evaporated in vacuo. The material was applied to a SPE<br>
cartridge (silica, lOg) and eluted with cyclohexane: ethyl acetate (1:1 followed by 2:1) to<br>
afford Intermediate 62 as a white solid (0.19g). LCMS showed MH+ = 419; TRET =<br>
2.35min.<br><br><br>
Intermediate 62 (0.19g, 0.46mmol) was dissolved in 4M hydrogen chloride in dioxane<br>
(5ml) and the reaction mixture stirred overnight at 20 Â°C. Concentration in vacuo<br>
afforded Intermediate 63 as a white solid (0.161g). LCMS showed MH+ = 319; TRBT =<br>
1.72min.<br><br>
Intermediate 30 (0.06g, 0.45mmol) and TBTU (0.146g, 0.45mmol) in DMF (5ml) was<br>
stirred at 20 Â°C for 30 minutes. A mixture of Intermediate 63 (0.16g, 0.45mmol) and<br>
diisopropylethylamine (0.32ml, 1.82mmol) in DMF (1ml) was added and the reaction<br>
mixture stirred overnight under nitrogen. The reaction was concentrated in vacuo and the<br>
residue partitioned between DCM and water. The phases were separated using a<br>
hydrophobic frit (Whatman PTFE Folter Media with Polypropylene Housing 5uM pore<br>
size) and the organic phase evaporated in vacuo. The residue was applied to an SPE<br>
cartridge (aminopropyl, lOg) and eluted with MeOH. Appropriate fractions were<br>
concentrated in vacuo then applied to an additional SPE cartridge (silica, 2g) which was<br>
eluted sequentially with a gradient of MeOH in DCM (i) 2%, (ii) 4%, (iii) 6% and (iv)<br>
10%. Fractions containing the desired material were combined and concentrated in vacuo<br>
to afford Intermediate 64 as a white solid (0.048g). LCMS showed MH+ = 431; TRET =<br>
1.87min.<br><br><br>
TBTU (0.050g, 0.15mmol) and diisopropylethylamine (0.04ml, 0.26 mmol) in DMF<br>
(0.5ml) was added to cyclobutylcarboxylic acid (RYCOOH, 0.015g, 0.15mmol). The<br>
reaction mixture was stirred for 40 minutes at 20 Â°C. A mixture of Intermediate 19<br>
(0.045g, 0.13rnmol) and diisopropylethylamine (0.04ml, 0.26mmol) in DMF (0.5ml) was<br>
added and the reaction mixture stirred for 18h. The solvent was removed in vacuo and<br>
the residue applied to a SPE cartridge (aminopropyl, 2g). The cartridge was eluted with<br>
methanol to afford Intermediate 65 (0.052g). LCMS showed MH+ = 387; TRET = 2.28min.<br>
Similarly prepared using the same or similar numbers of moles of reagents and/or<br>
volumes of solvents were the following:<br><br><br><br>
(4-Methyl-1-piperazinyl)acetonitrile (1.08g, 7.7mmol) (J. Med. Chem., 1999, 42,2870)<br>
was added to a suspension of potassium carbonate (3.2g, 23.1rnmol) and hydroxylamine<br>
hydrochloride (1.06g, 15.4mmol) in ethanol (10ml). The reaction mixture was heated at<br>
reflux for 9 hours then allowed to cool. The reaction was filtered and the solvent<br>
evaporated in vacuo to afford Intermediate 80 (1.53g). lH NMR (400MHz in d6-DMSO,<br>
27Â°C, Î´ppm) 9.02 (br s, 1H), 5.17 (br s, 2H), 2.78 (s, 2H), 2.31 (br s, 8H), 2.13 (s, 3H).<br><br><br>
Commercially available from Sigma-Aldrich, CAS (Chemical Abstracts) Registry<br>
Number 22179-78-8.<br><br>
Commercially available from the Maybridge Chemical Company, CAS (Chemical<br>
Abstracts) Registry Number 57399-51-6.<br>
Intermediates 83 and 84<br>
The structures of Intermediates 83 and 84 and their preparation are as follows:<br><br><br><br>
Anhydrous hydrogen chloride in dioxane (8ml, 4M solution) was added to Intemediate 84<br>
(0.807g, 1.88mol). The reaction mixture was stirred overnight at room temperature then<br>
evaporated in vacuo. The residue was suspended in ether and the mixture filtered to give<br>
Intermediate 83 as a brown solid (0.525g). LCMS showed MH+ = 373; TRET = 2.62min.<br><br>
Diisopropyethylarnine (8.3ml, 47.5mmol) was added to a mixture of Intermediate 17<br>
(2.76g, 9.5mmol), TBTU (3.050g, 9.5mmol) and hydroxybenzotriazole (1.28g, 9.5mmol)<br>
in N,N-dimethylformamide (40ml) at room temperature. After stirring for 10 minutes<br>
Intermediate 85 (2.318g, 13.3mmol) was added. The reaction mixture was srirred for 50<br>
minutes then l,r-carbonyldiimidazole (1.54g, 9.5mmol) was added and the reaction<br>
heated at 100 Â°C for 16 hours. The solvent was removed in vacuo and the residue<br>
partitioned between dichloromethane and water. The organic phase was washed with<br>
aqueous sodium hydrogen carbonate (5%) then dried (Na2SO4) and evaporated in vacuo.<br>
The residue was purified by chromaography using the Biotage system (100g, silica)<br>
eluting with cyclohexane:ethyl acetate (1:1). Intermediate 84 was obtained a brown solid<br>
(0.97g). LCMS showed MH+ = 429 TRET = 3.26min.<br><br><br><br>
A solution of sodium methoxide in methanol (50ml, O.SM) was added to hydroxylamine<br>
hydrochloride (1.78g, 25.62mmol) at room temperature. After stirring for 15 minutes the<br>
solution was filtered and the filtrate added to t-butyl cyanoacetate (3.0g, 21.25mmol,<br>
available from Aldrich). The solution was refluxed for 1.75 hours then cooled and<br>
evaporated in vacuo. The residue was partitioned between ethyl acetate and water. The<br>
aqueous phase was extracted with ethyl acetate and the combined organic phases washed<br>
with brine, dried (MgSO4) and evaporated in vacuo. The residue was suspended in<br>
cyclohexane: ether (1:1) then filtered to give Intermediate 85 as a white solid (1.883g).<br>
1H NMR (400MHZ in CDC13, 27Â°C, Î´ppm) 8.34 (br s, 1H), 5.05 (br s, 2H), 3.09 (s, 2H),<br>
1.47 (s, 9H).<br><br>
Intermediate 19 (0.1g, 0.29mmol), TBTU (0.094g, 0.29mmol) and diisopropylethylamine<br>
(0.204ml, 1.17mmol) in N,N-dimethylformamide (1ml) were stirred at room temperature<br>
for 1 hour. The solvent was evaporated in vacuo and the residue dissolved in methanol<br>
and applied to an SPE cartridge (aminopropyl, 5g). The cartridge was eluted with<br>
methanol and appropriate fractions evaporated in vacuo to give Intermediate 86 as a<br>
yellow solid (0.113g). LCMS showed MH+ = 403; TRET = 1.99min.<br><br><br><br>
To a solution of Intermediate 87 (6g, 32.4mmol) in dioxan (15ml) was added a solution<br>
of lithium hydroxide monohydrate (1.53g, 36.4mmol) in water (15ml). The mixture was<br>
stirred for 17h, then washed with diethyl ether (20ml), then with ethyl acetate (20ml) and<br>
acidified with concentrated hydrochloric acid under ethyl acetate (50ml). The combined<br>
aqueous phases were adjusted to pH 2.7 by addition of sodium bicarbonate and extracted<br>
with further ethyl acetate (2x50ml). The combined organic phases were washed with<br>
water (20ml) and saturated brine (20ml), then concentrated in vacuo to afford<br>
Intermediate 88 as a white solid (1.69g). 1H NMR (400MHz in CDC13,27Â°C, Î´ppm) 2.74<br>
(s, 3H), 3.85 (s, 2H), 5.8-6.2 (br, s, 1H), 7.02 (s, 1H).<br><br>
General Procedure for Intermediates 89 to 114:<br>
A mixture of carboxylic acid RYCO2H (0.2mmol), diisopropylethylamine (0.105ml,<br>
0.6mmol) and TBTU (0.071g, 0.22mmol) in N,N-dimethylformamide (0.5ml) was<br>
allowed to stand for 10 minutes. A mixture of Intermediate 19 (0.2mmol) and<br>
diisopropylethylamine (0.035ml, 0.2mmol) in N,N-dimethylformamide (0.5ml) was<br>
added. After agitation the reactions were allowed to stand for 16 hours. The solvent was<br>
removed in vacuo and residue was applied to an SPE cartridge (aminopropyl, 0.5g). The<br>
cartridge was eluted with chloroform, ethyl acetatexhloroform (1:1), ethyl acetate, ethyl<br>
acetate:methanol (9:1,2ml). Appropriate fractions were evaporated in vacuo to afford the<br>
Intermediates below.<br><br><br><br><br><br><br><br>
Prepared from commercially available N-(tert-Butoxycarbonyl)-2-aminoacetonitrile as<br>
decribed by M. Schwarz et. al, WO 02/102799.<br><br>
Diisopropylethylamine (6.0ml, 34.4mmol) was added to a stirred mixture of Intermediate<br>
17 (2.0g, 6.89mmol), TBTU (2.212g, 6.89mmol) and HOBT (0.931g, 6.89mmol) in dry<br>
dimethylformamide (45ml). After lOmin, the resulting clear solution was treated with<br>
Intermediate 116 (1.89g, lOmmol). The reaction mixture was stirred at room temperature<br>
for 2h. DBU (5.14ml, 34.5mmol) was added, and the reaction mixture was heated at<br>
80Â°C. After 3.5h at 80Â°C, the reaction mixture was evaporated in vacuo, and the residue<br>
was dissolved in dichloromethane (150ml) and washed successively with 5% sodium<br>
hydrogen carbonate (50ml) and water (50ml). The organic solution was dried over<br>
anhydrous sodium sulphate and evaporated to give the crude product. Purification by<br>
Biotage chromatography (silica, 100g) eluting with ethyl acetate-petroleum ether (1:1)<br>
afforded Intermediate 117 as a white solid (2.70g). LCMS showed MH+ =444, TRET =<br>
3.06min.<br><br>
Trifluoroacetic acid (5ml) was added to a stirred solution of Intermediate 117 (1.774g,<br>
4.0mmol) in dry dichloromethane (20ml) at 0Â°C. After 2h, the reaction mixture was<br>
neutralised by careful addition of 5% sodium hydrogen carbonate solution (150ml) and<br>
solid sodium hydrogen carbonate. The resulting mixture was extracted with chloroform (2<br>
x 100ml). The combined organic extracts were dried over anhydrous sodium sulphate and<br>
evaporated to afford Intermediate 118 as a white solid (1.358g). LCMS showed MH+<br>
=344, TRET = 1.95min.<br><br><br>
4-chlorobutanoyl chloride (0.12mmol) was added to a stirred solution of Intermediate 118<br>
(0.1mmol) and diisopropylethylarnine (0.3mmol) in chloroform (1ml) at room<br>
temperature. After stirring at room temperature for 16h, the reaction mixture was applied<br>
to a SPE cartridge (aminopropyl, 2g) and the cartridge was eluted sequentially with<br>
chlororm, ethyl acetate and methanol. Fractions containing the desired product were<br>
combined and blown down under nitrogen. The resulting residue was further purified on a<br>
SPE cartidge (silica, lg) eluting with a gradient of 30-100% ethyl acetate in petroleum<br>
ether to afford Intermediate 119 as a white solid (45mg). ). LCMS showed MH+ =448,<br>
TRET = 2.77min.<br><br>
5-cbloropentanoyl chloride (0.12mmol) was added to a stirred solution of Intermediate<br>
118 (0.1mmol) and diisopropylethylarnine (0.3mmol) in chloroform (1ml) at room<br>
temperature. After stirring at room temperature for 16h, the reaction mixture was applied<br>
to a SPE cartridge (aminopropyl, 2g) and the cartridge was eluted sequentially with<br>
chlororm, ethyl acetate and methanol. Fractions containing the desired product were<br>
combined and blown down under nitrogen. The resulting residue was further purified on a<br>
SPE cartidge (silica, lg) eluting with a gradient of 30-100% ethyl acetate in petroleum<br>
ether to afford Intermediate 120 as a white solid (46mg). LCMS showed MH+ =462, TRET<br>
= 2.86min.<br>
Intermediate 121: (1E/Z)-N-hydroxy-2-(4-morpholinyl)propanimidamide<br><br><br>
Prepared from a-metliyl-4-morpholineacetonitrile using a similar process to that<br>
described for any of Intermediates 9, 22 or 80 using similar or the same number of moles<br>
of reagents and/or volumes of solvents. 1H NMR (27 Â°C, d4-MeOH) 3.70-3.60 (m, 5H),<br>
3.13-3.07 (m, 2H), 2.83-2.76 (m, 2H), 1.84 (d, J = 5Hz, 3H)<br>
a-Methyl-4-morphoUneacetonitrile can be prepared according to the procedure described<br>
by H.R.Henze et. al. J. Am. Chem. Soc 1957,79,6230.<br><br>
Can be prepared from cyclohexylacetic acid (commercially available from e.g. Aldrich)<br>
according to the procedure described by T.R. Alessi et al. in US 4895860.<br><br>
Prepared from 1,1-dimethylethyl 4-(cyanomethyl)-1-piperidinecarboxylate using a<br>
similar process to that described for any of Intermediates 9, 22 or 80 using similar or the<br>
same number of moles of reagents and/or volumes of solvents.<br>
1,1-dimethylethyl 4-(cyanomethyl)-1-piperidinecarboxylate can be prepared from<br>
commercially available 1,1-dimethylethyl 4-oxo-1-piperidinecarboxylate according to the<br>
procedure described by A.M.Wilson in WO 00/006159.<br>
Intermediate 124: 1,1-Dimethylethyl 4-({5-[1-ethyl-4-(tetrahydro-2H-pyran-4-<br>
ylamino)-1H-pyrazolo[3,4-6]pyridm-5-yl]-l,2,4-oxadiazo1-3-yl}methyl)-1-<br>
piperidinecarboxylate<br><br><br>
A mixture of Intermediate 16 (0.064g, 0.2mmol), Intermediate 80 (0.257g, 1mmol), a<br>
solution of sodium ethoxide in EtOH (0.19ml, 21% solution) and powdered 4A molecular<br>
sieves (0.3 8g) in EtOH (2ml) were stirred at 82 Â°C under an atmosphere of nitrogen for<br>
18 hours. Additional sodium ethoxide in ethanol (0.19ml, 21% solution), molecular<br>
sieves (0.38g) and ethanol (4ml) were added and the reaction heated for a further 72<br>
hours. The reaction mixture was filtered, the solvent was evaporated in vacuo and the<br>
residue was applied to an SPE cartridge (silica, 2g). The cartridge was eluted with<br>
cyclohexane: ethyl acetate (4:1,2:1,1:1), then ethyl acetate to afford Intermediate 124 as<br>
a colourless oil (0.052g). LCMS showed MH+ = 512; TRET = 3.51min.<br><br>
A solution of hydrogen chloride in dioxane (1ml) was added to Intermediate 124 (0.052g,<br>
0. lmmol) and the reaction mixture stirred at 20 Â°C for 2 hours. The solution was<br>
evaporated in vacuo to afford Intermediate 125 as a yellow solid (0.047g). LCMS showed<br>
MH+ = 412; TRET = 2.21min.<br><br>
Prepared from 1-(phenylsulphonyl)cyclopropoanecarbonitrile (commercially available<br>
from Menai Organics Ltd, Menai Technology Centre, Deiniol Roas, Bangor, Gwynedd,<br>
Wales, LL57 UP, United Kingdom or described in Bull. Chem. Soc. Jpn. 1985 58(2),<br>
765) using a similar process to that described for any of Intermediates 9, 22 or 80 using<br>
similar or the same number of moles of reagents and/or volumes of solvents. LCMS<br>
showed MH+ = 241; TRET = 1 -7 lmin.<br><br>
Intermediate 127: (1E/Z)-N-Hydroxy-2-phenylethanimidamide<br><br>
Commercially available from Maybridge Chemical Company Ltd, Trevillett, Tintagel,<br>
Cornwall, PL34 OHW, United Kingdom.<br>
Intermediate 128: (1E/Z)-N-Hydroxy-2-phenylpropanimidamide<br><br>
Can be prepared from a-methylphenylacetonitirile according to the procedure described<br>
by J. Rheineimer EP 323864.<br>
Intermediate 129: (1E/Z)-N-Hydroxy-2-[4-(methyloxy)phenyl]ethanimidamide<br><br>
Commercially available from Exploratory Library, Ambinter, 46 quai Louis Bleriot,<br>
Paris, F-75016, France.<br>
Intermediate 130: (1E/Z)-N-Hydroxy-2-[3-(methyloxy)phenyl]ethanimidamide<br><br>
Can be prepared from according to the procedure described by S.Borg et. Al European<br>
J.Med Chem. 1993, 28(10,) 801.<br>
Intermediate 131: (1E/Z)-2-[4-(Dimethylamino)phenyl]-N-hydroxyethanimidamide<br><br>
Prepared from 4-(dimethylamino)benzeneacetonitrile (described by Borovicka et al.<br>
i Collect. Czech. Chem. Commun 1955, 20, 437) using a similar process to that described<br>
for any of Intermediates 9, 22 or 80 using similar or the same number of moles of<br>
reagents and/or volumes of solvents. LCMS showed MH+ = 194; TRET = 0.38min.<br>
Intermediate 132: (1E/Z)-2-[3-(Dimethylamino)phenyl]-N-hydroxyethanimidamide<br><br><br>
Prepared from 3-(dimethylamino)benzeneacetonitrile (described by M.L. Sznaidman et<br>
al. Bioorganic Medicinal Chemistry Letters 1996, 6(5), 565) using a similar process to<br>
that described for any of Intermediates 9, 22 or 80 using similar or the same number of<br>
moles of reagents and/or volumes of solvents. LCMS showed MH+ = 194; TRET =<br>
0.46min<br><br>
Prepared	from	5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyridine-3-acetonitrile<br>
(commercially available from hiterchim, 213 Avenue Kennedy, BP 1140, Montlucon,<br>
Cedex 03103, France or Exploratory Library, Ambinter, 46 quai Louis Bleriot, Paris, F-<br>
75016, France) using a similar process to that described for any of Intermediates 9, 22 or<br>
80 using similar or the same number of moles of reagents and/or volumes of solvents.<br>
LCMS showed MH+ = 198; TRET = 0.32min.<br><br>
Prepared from 4-phenyl-1-piperazineacetonitnle (commercially available from mterchim,<br>
213 Avenue Kennedy, BP 1140, Montlucon, Cedex 03103, France or Exploratory<br>
Library, Ambinter, 46 quai Louis Bleriot, Paris, F-75016, France) using a similar process<br>
to that described for any of Intermediates 9, 22 or 80 using similar or the same number of<br>
moles of reagents and/or volumes of solvents. LCMS showed MH+" = 235; TRET =<br>
1.09min.<br><br><br>
A solution of Intermediate 17 (3.263g, 11.25mmol) in tbionyl chloride (17ml) was heated<br>
at 60 Â°C for 2 hours. The solution was concentrated in vacuo and then co-evaporated<br>
with dichloromethane. The residue was suspended in a solution of ammonia in dioxane<br>
(45ml, 0,5M solution) and the resultant mixture stirred for 18 hours. After concentration<br>
in vacuo the residue was re-suspended in ammonia in dioxane (45ml, 0.5M) and stirred<br>
for a further 16 hours. The solvent was removed in vacuo and the solid suspended in a<br>
mixture of dichloromethane (40ml) and water (40ml). The solid was filtered, washed<br>
with water and dried in vacuo over P2O5 to afford Intermediate 136 as a cream solid<br>
(2.50g). LCMS showed MH+ = 290; TRET = 2.12min<br><br>
Burgess Reagent 4.53g, 19.0mmol) was added to a suspension of Intermediate 136 (5.0g,<br>
17.3mmol) in THF (80ml). The reaction mixture was stirred at room temperature for 18<br>
hours then a further portion of Burgess Reagent (0.9g, 1.8mmol) was added and stirring<br>
continued for 5 hours. The reaction mixture was concentrated in vacuo and the residue<br>
partitioned between dichloromethane and water. The organic phase was washed with<br>
water, dried and evaporated in vacuo to afford Intermediate 137 as an off-white solid<br>
(4.43g). LCMS showed MH+ = 272; TRET = 2.40min<br><br>
Intermediate 137 (3.50g, 12.9mmol), hydroxylamine hydrochloride (3.30g, 47.8mmol)<br>
and sodium hydrogencarbonate (4.0lg, 47.8mmol) in EtOH (45ml) were heated at 45 Â°C<br><br>
for 1.5 hours then at 50 Â°C for 2.5 hours. The suspension was concentrated in vacuo and<br>
the solid stirred in dichloromethane (80ml) for 0.5 hours. The mixture was filtered and<br>
the solid stirred in EtOH, the resultant mixture was filtered and the filtrate evaporated.<br>
The solid was then washed with dichloromethane three time to afford Intermediate 138 as<br>
a white solid (1.62g). LCMS showed MH+ = 305; TRET = 1.85min<br><br>
Intermediate 139 was prepared from Intermediate 17 and (4-arninotetrahydro-2H-pyran-<br>
4-yl)methanol (commercially available from PharmaCore Inc., 4170 Mendenhall Oaks<br>
Pkwy, Suite 140, High point, NC, USA) using an analogous method to that for<br>
Intermediate 42. LCMS showed MH+ = 404, TRET = 2.19min.<br><br>
Intermediate 141: (S)-(-)-3-Amino tetrahydrofuran 4-toluenesulphonate<br>
Commercially available from E. Merck, Germany; or from E. Merck (Merck Ltd), Hunter<br>
Boulevard, Magna Park, Lutterworth, Leicestershire LE17 4XN, United Kingdom (CAS<br>
104530-80-5)<br>
O -HQ-|-OH<br>
Intermediate 142: Tetrahvdro-2H-thiopyran-4-amine<br>
Prepared from commercially available tetrahydrothiopyran-4-one as described by<br>
Subramanian et. al., J. Org, Chem., 1981,46, 4376-4383. Subsequent preparation of the<br>
hydrochloride salt can be achieved by conventional means.<br><br><br><br>
Intermediate 143: Tetrahydro-3-thiopheneamine<br>
Prepared in an analogous manner to Intermediate 142 from commercially available<br>
tetrahydrothiophene-4-one. The oxime formation is described by Grigg et.al.,<br>
Tetrahedron, 1991,47,4477-4494 and the oxime reduction by Unterhalt et. al., Arch.<br>
Pharm., 1990, 317-318.<br><br>
Intermediate 144: Tetrahydro-3-thiopheneamine 1,1-dioxide hydrochloride<br>
Commercially available from Sigma Aldrich Library of Rare Chemicals (SALOR) (CAS-<br>
6338-70-1). Preparation of the hydrochloride salt of the amine can be achieved by<br>
conventional means.<br><br>
Intermediate 145: Tetrahydro-2H-thiopyran-4-amine-l,1-dioxide hydrochloride<br>
Prepared in an analogous manner to Intermediate 11 from commercially available<br>
tetrahydrothiophene-4-one. Oxidation to l,1-dioxo-tetrahydro-l?i,6-thiopyran-4-one is<br>
described by Rule et. al., in J. Org. Chem., 1995, 60,1665-1673. Oxime formation is<br>
described by Truce et.al., in J. Org. Chem., 1957, 617, 620 and oxime reduction by<br>
Barkenbus et. al., J. Am. Chem. Soc, 1955, 77, 3866. Subsequent preparation of the<br>
hydrochloride salt of the amine can be achieved by conventional means.<br><br>
Intermediate 146:1,1-DimethyIethyI (4,4-difluorocyclohexyl)carbamate<br><br><br>
(Diethylamino)sulphur trifluoride (DAST), (0.06ml, 0.47mmol), was added to a stirred<br>
solution of l,1-dimethylethyl(4-oxocyclohexyl)carbamate, (250mg, 1.17mmol,<br>
commercially available from AstaTech Inc., Philadelphia, USA) in anhydrous<br>
dichloromethane (5ml) and the mixture was stirred under nitrogen at 20Â°C. After 22h,<br>
the reaction mixture was cooled to 0Â°C, treated with saturated sodium hydrogen carbonate<br>
solution (4ml), and then allowed to warm to ambient temperature. The phases were<br>
separated by passage through a hydrophobic frit and the aqueous phase was further<br>
extracted with DCM (5ml). The combined organic phases were concentrated in vacuo to<br>
give an orange solid (369mg) which was further purified by chromatography using a SPE<br>
cartridge (silica, 10g), eluting with DCM to afford Intermediate 62 (140mg) containing<br>
20% of 1,1-dimethylethyl (4-fluoro-3-cyclohexen-1-yl)carbamate. 1H NMR (400MHz<br>
in CDC13,27Â°C, Î´ppm)<br>
Minor component: 55.11 (dm, 16Hz, 1H), 4.56 (br, 1H), 3.80 (br, 1H) 2.45-1.45 (m's,<br>
6H excess), 1.43 (s, 9H). Major component: 54.43 (br, 1H), 3.58 (br, 1H), 2.45-1.45<br>
(m's, 8H excess), 1.45 (s, 9H).<br><br>
A solution of hydrogen chloride in dioxane (4M, 1.6ml) was added at 20Â°C to a stirred<br>
solution of Intermediate 146 (140mg, 0.6mmol), in dioxane (1.6ml). After 3h, the<br>
reaction mixture was concentrated in vacuo to afford Intermediate 147 (96.5mg)<br>
containing 4-fluoro-3-cyclohexen-1-amme. lH NMR (400MHz in d6-DMSO, 27Â°C,<br>
8ppm) Minor component: 58.22 (br, 3H excess), 5.18 (dm, 16Hz, 1H), 3.28-3.13 (m, 1H<br>
excess), 2.41-1.53 (m's, 6H excess). Major component: 58.22 (br, 3H excess), 3.28-3.13<br>
(m, 1H excess), 2.41-1.53 (m's, 8H excess). Impurities are also present.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Intermediate 4 (0.043g) was dissolved in acetonitrile (2ml) then treated with phosphorous<br>
oxychloride (0.101g) and stirred under nitrogen and heated at 90Â°C for 2h. The mixture<br>
was concentrated in vacuo and the residue partitioned between DCM and saturated<br>
aqueous sodium bicarbonate solution. The organic layer was concentrated in vacuo and<br>
applied to an SPE cartridge (arninopropyl, lg), which was eluted with methanol.<br>
Concentration in vacuo afforded Example 1 (0.032g). LCMS showed MH+ = 313; TRET =<br>
3.13mm.<br><br>
Similarly prepared, for example without limitation using the same or similar number of<br>
moles of reagents and/or volumes of solvents, but with an extended reaction time (see<br>
table) was:<br><br>
Intermediate 10 was dissolved in acetonitrile (2ml) then treated with phosphorous<br>
oxychloride (0.101g) and stirred under nitrogen at 90Â°C for 3.5h. The mixture was<br>
concentrated in vacuo and the residue partitioned between DCM and saturated aqueous<br>
sodium bicarbonate solution. The organic layer was concentrated in vacuo and the residue<br>
applied to a SPE cartridge (silica, 5g), which was eluted with cyclohexane : Et2O (1:2).<br>
Fractions containing desired material were combined and concentrated in vacuo to afford<br>
Example 3 (0.034g). LCMS showed MH+ = 341; TRET = 3.39min.<br><br>
A solution of Intermediate 4 (0.09g) in acetonitrile (5ml) was stirred under nitrogen and<br>
treated with Lawesson's reagent (0.116g). The mixture was heated at 65Â°C for 16h, then<br>
concentrated in vacuo. The residue was applied to an SPE cartridge (silica, 5g) and eluted<br>
with a gradient of cyclohexane : Et2O (1:2 then 1:3, 1:4, 1:5, 0:1). Fractions containing<br>
desired material were combined and concentrated in vacuo. Further purification was<br>
achieved using mass directed autoprep HPLC to afford Example 4 (0.002g). LCMS<br>
showed MH+ = 339; TRET = 3.23min.<br><br><br>
A solution of Intermediate 5 (0.07g) in acetonitrile (3ml) was stirred under nitrogen and<br>
treated with Lawesson's reagent (0.085g). The mixture was heated at 65Â°C for 136h, then<br>
concentrated in vacuo. The residue was partitioned between DCM and water and the<br>
organic layer concentrated in vacuo. Further purification was achieved using mass<br>
directed autoprep HPLC to afford Example 5 (0.008g). LCMS showed MH+ = 407; TRET<br>
= 2.98min.<br><br>
Intermediate 10 was dissolved in acetonitrile (5ml) then treated with Lawesson's reagent<br>
(0.125g) and heated under nitrogen at 65Â°C for 66h. Volatiles were removed in vacuo and<br>
the residue was purified by mass directed autoprep HPLC to afford Example 6. LCMS<br>
showed MH+ = 357; TRET = 3.59min.<br><br>
A solution of Intermediate 6 (0.04g) in ethanol (1ml) was stirred over powdered 4A<br>
molecular sieves (0.290g) and treated with Intermediate 9 (0.045g), followed by sodium<br>
ethoxide (0.020g). The mixture was heated under reflux for 18h, then cooled and filtered.<br>
Following concentration of the filtrate in vacuo, the residue was applied to an SPE<br><br>
cartridge (silica, 5g) which was eluted with cyclohexane : Et2O (1:1). Fractions<br>
containing desired material were combined and concentrated in vacuo to afford Example<br>
7 (0.017g). LCMS showed MH+ = 339; TRET = 3.23min.<br><br>
A solution of Intermediate 7 (0.06g) in ethanol (2ml) was treated with triethylamine<br>
(0.101g), followed by methyl acetimidate hydrochloride (0.033g) and the mixture heated<br>
under reflux (80Â°C) for 42h. Reaction was incomplete so a further portion of methyl<br>
acetimidate hydrochloride (0.033 g) was added and stirring continued under reflux for 6<br>
days. The mixture was concentrated in vacuo and the residue partitioned between DCM<br>
and 2M aqueous HC1. The organic layer was concentrated in vacuo and purified by mass<br>
directed autoprep to afford Example 8 (0.003g). LCMS showed MH+ = 326; TRET =<br>
2.66min.<br><br>
Intermediate 13 (0.016g) was dissolved in anhydrous acetonitrile (1ml).<br>
4-Aminotetrahydropyran hydrochloride (Intermediate 21A, 0.008g) was then added,<br>
followed by diisopropylethyl amine (0.05ml) and the mixture was stirred under nitrogen<br>
at 75Â°C for 19h. A further portion of 4-aminotetrahydropyran (0.002g) was added and<br>
stirring continued at 85Â°C for 16h. The mixture was concentrated in vacuo and partitioned<br>
between DCM and water. The organic phase was concentrated in vacuo and applied to an<br>
SPE cartridge (silica, lg), which was eluted sequentially with a gradient of EtOAc:<br>
cyclohexane (i) 1:8, (ii) 1:4, (iii) 1:2, (iv) 1:1 and (v) 1:0. Fractions containing desired<br>
material were combined and concentrated in vacuo to afford Example 9 (0.013g). LCMS<br>
showed MH+ = 357; TRET = 2.89min.<br><br><br><br>
Intermediate 13 (0.016g, 0.055 mmol) was dissolved in anhydrous acetonitrile (1ml).<br>
Cyclobexyl amine (0.007ml, 0.061 mmol) was then added, followed by diisopropylethyl<br>
amine (0.05ml, 0.29 mmol) and the mixture was stirred under nitrogen at 75 Â°C for 16h.<br>
The mixture was concentrated in vacuo and partitioned between DCM and water. The<br>
organic phase was concentrated in vacuo and applied to an SPE cartridge (silica, lg),<br>
which was eluted sequentially with a gradient of EtOAc: cyclohexane (i) 1:16, (ii) 1:8,<br>
(Hi) 1:4, (iv) 1:2 and (v) 1:1. Fractions containing desired material were combined and<br>
concentrated in vacuo to afford Example 10 (0.015g). LCMS showed MH+ = 355; TRET =<br>
3.59min.<br>
Similarly prepared using the same or similar number of moles of reagents and volumes of<br>
solvents was the following:<br><br>
Intermediate 12 (0.026g, 0.1 mmol) was dissolved in ethanol (1.5ml) and treated with a<br>
solution of isobutylamine (0.007g, 0.1 mmol), also in ethanol (1ml). The mixture was<br>
then treated with diisopropylethyl amine (0.075 ml, 0.4 mmol, 4 mole equivalents) and<br>
stirred at 75Â°C for 16h. The mixture was concentrated in vacuo and applied to an SPE<br>
cartridge (silica, 0.5g) which was eluted sequentially with (i) chloroform, (ii) Et2O and<br>
(iii) methanol. Fractions containing desired material were combined and concentrated in<br>
vacuo to afford Example 12 (0.024g). LCMS showed MH+ = 301; TRET = 2.90min<br><br>
Similarly prepared using the same or similar number of moles of reagents and volumes of<br>
solvents were the following:<br><br><br><br>
An alternative method of preparing Example 14 is now described:<br>
An alternative method of preparing Example 17 is now described:<br>
EDC (0.823g, 5.3mmol) and HOBT (0.614g, 4.55mmol) were added to Intermediate 17<br>
(1.10g, 3.80mmol) in N,N'-dimethylformamide (10ml). The mixture was stirred for 1.5<br>
hours then acetic hydrazide (0.421g, 5.7mmol) (commercially available e.g. from<br>
Aldrich) was added and the reaction mixture stirred at 20 Â°C for 48 hours. The reaction<br>
mixture was evaporated and the residue partitioned between chloroform and water. The<br>
aqueous phase was extracted with chloroform and the combined organic phases were<br>
washed with saturated aqueous sodium chloride solution then dried (Na2SO4) and<br>
evaporated. Phosphorus oxychloride (10ml) was added to the residue and the mixture<br>
heated at 120 Â°C for 0.5 hours. The reaction mixture was evaporated in vacuo and the<br>
residue applied to an SPE cartridge (silica, 20g). The cartridge was eluted with<br>
dichloromethane, cyclohexanerethyl acetate (2:1 then 1:1), ethyl acetate,<br>
chloroform:methanol (19:1 followed by 9:1). Fractions containing the required<br>
compounds were combined and evaporated in vacuo. The residue was then<br>
chromatographed on the Biotage (silica, 50g) using cyclohexane:ethyl acetate (2:1 then<br>
1:1), ethyl acetate followed by ethyl acetate:ethanol (19:1, 9:1 then 9:2). The residue was<br>
partitioned between dichloromethane and aqueous sodium hydrogencarbonate solution.<br>
The oreanic nhase was dried (Na2SO4) and evaporated in vacuo to give Example 14 as a<br><br><br>
EDC (1.30g, 6.76mmol) and HOBT (0.782g, 5.80mmol) were added to Intermediate 17<br>
(1.40g, 4.83mmol) in N,N'-dimethylformamide (20ml). The mixture was stirred for 0.5<br>
hours then pivalic acid hydrazide (0.616g, 5.3mmol) (commercially available from<br>
Fluorochem Ltd, Wesley Stree, Glossop, Derbyshire SKI 3 9RY, United Kingdom or can<br>
be prepared according to the procedure by K. Ohmoto et al. in J. Med. Chem., 2001,<br>
44(8), 1268) was added and the reaction mixture stirred at 20 Â°C for 18 hours. The<br>
reaction mixture was evaporated and the residue partitioned between dichloromethane<br>
and water. The organic phase was washed with water, saturated aqueous sodium<br>
hydrogen carbonate solution followed by saturated aqueous sodium chloride solution then<br>
evaporated in vacuo. Phosphorus oxychloride (10ml) was added to the residue and the<br>
mixture heated at 120 Â°C for 3 hours. The reaction mixture was evaporated in vacuo and<br>
the residue partitioned between dichloromethane and water. The organic phase was<br>
washed with aqueous sodium hydrogen carbonate solution then dried and evaporated in<br>
vacuo. The residue was applied to an SPE cartridge and eluted with cyclohexane: ethyl<br>
acetate (3:1 followed by 7:3). The solvent was evaporated in vacuo to give Example 17<br><br>
A solution of Intermediate 16 (0.05g, 0.157 mmol) in ethanol (2ml) was stirred over<br>
powdered 4A molecular sieves (0.30g) and treated with a solution of Intermediate 9<br>
(0.059g, 0.8 mmol) and sodium ethoxide (0.027g, 0.4 mmol) in ethanol (1ml). The<br>
mixture was heated at reflux for 18h under nitrogen, then cooled and filtered. Following<br>
concentration of the filtrate in vacuo, the residue was applied to an SPE cartridge (silica,<br>
5g) which was eluted with cyclohexane : EtOAc (1:1). Fractions containing desired<br>
material were combined and concentrated in vacuo to afford Example 28 (0.024g). LCMS<br>
showed MH+ = 329; TRET = 2.86 min.<br>
Similarly prepared using the same or similar number of moles of reagents and volumes of<br>
solvents were the following:<br><br><br>
A solution of Intermediate 16 (0.05g) in ethanol (2ml) was stirred over powdered 4A<br>
molecular sieves (0.30g) and treated with a solution of Intermediate 23 (0.094g) and<br>
sodium ethoxide (0.027g) in ethanol (1ml). The mixture was heated at reflux for 18h<br>
under nitrogen, then cooled and filtered. Following concentration of the filtrate in vacuo,<br>
the residue was applied to an SPE cartridge (silica, 5g) which was eluted with 2-5%<br>
methanol in DCM. Fractions containing desired material were combined and<br>
concentrated in vacuo, then applied to a further SPE cartridge (aminopropyl, 1g) which<br>
was eluted with methanol to afford Example 30 (0.02g). LCMS showed MH+ = 372; TRET<br>
= 2.10min.<br><br>
A solution of Intermediate 16 (0.05g) in ethanol (2ml) was stirred over powdered 4A<br>
molecular sieves (0.30g) and treated with a solution of Intermediate 24 (0.128g) and<br>
sodium ethoxide (0.027g) in ethanol (1ml). The mixture was heated at reflux for 18h<br>
under nitrogen, then cooled and filtered. Following concentration of the filtrate in vacuo,<br>
the residue was applied to an SPE cartridge (silica, 5g) which was eluted with 2-5%<br>
methanol in DCM. Fractions containing desired material were combined and<br><br>
concentrated in vacuo to afford Example 31 (0.025g). LCMS showed MH+ = 415; TRET =<br>
2.46 min.<br><br>
A solution of Intermediate 20 (0.020g) in THF (0.2ml) was treated with Burgess reagent<br>
(0.026g) and heated in a microwave at 120Â°C (100W) for 5min. The mixture was<br>
concentrated by evaporation under a stream of nitrogen and the residue applied to an SPE<br>
cartridge (silica, lg) which was eluted with 2% methanol in DCM to afford Example 32<br>
as a white solid (0.014g). LCMS showed MH+ = 355; TRET = 2.78 min.<br><br>
Intermediate 12 (0.03g) was dissolved in acetonitrile (2ml) and treated with DIPEA<br>
(0.1ml) and Intermediate 25 (0.022g). The mixture was stirred at 85Â°C for 18h then<br>
concentrated in vacuo and partitioned between DCM and water. The layers were<br>
separated and the organic layer concentrated in vacuo, then purified by mass directed<br>
autoprep HPLC to afford Example 33 (0.01g). LCMS showed MH+ = 370; TRET =<br>
2.48rnin.<br><br><br>
A solution of Intennediate 19 (0.05g, 0.133 mmol), TBTU (0.045g, 0.14 mmol) and<br>
DIPEA (0.1ml, ca. 0.5 mmol) in DMF (1ml) is stirred at room temperature under nitrogen<br>
for 5 min. A solution of Intermediate 26 (0.024g, 0.21 mmol) in DMF (1ml) is then added<br>
and stirring continued for 18h. Reaction can be found to be incomplete after this time so a<br>
further portion of Intermediate 26 (0.012g, 0.10 mmol) is added and stirring continued<br>
under nitrogen for a further 18h. The mixture is concentrated in vacuo then the residue<br>
applied to an SPE cartridge (aminopropyl, 2g), which is eluted with methanol (2x3ml).<br>
Fractions containing desired material are concentrated in vacuo.<br>
The partially purified intermediate is taken forward without further<br>
characterisation and si dissolved in THF (0.5ml) then treated with Burgess reagent<br>
(0.025g, ca. 0.1 mmol). The mixture is heated under microwave conditions at 120Â°C<br>
(120W) for 5 min. The mixture is then concentrated in vacuo and purified by mass<br>
directed autoprep HPLC to afford Example 34.<br>
According to an alternative and more preferred embodiment, the reaction was performed<br>
as follows. A solution of carboxylic acid Intermediate 26 (0.024g, 0.21 mmol), TBTU<br>
(0.045g, 0.14 mmol) and DIPEA (0.1ml, ca. 0.5 mmol) in DMF (1ml) was stirred at room<br>
temperature under nitrogen for 5 min. A solution of Intermediate 19 (0.05g, 0.133 mmol)<br>
in DMF (1ml) was then added and stirring continued for 18h. Reaction was found to be<br>
incomplete after this time so a further portion of Intermediate 26 (0.012g, 0.10 mmol)<br>
was added and stirring continued under nitrogen for a further 18h. The mixture was<br>
concentrated in vacuo then the residue applied to an SPE cartridge (aminopropyl, 2g),<br>
which was eluted with methanol (2x3ml). Fractions containing desired material were<br>
concentrated in vacuo. The partially purified intermediate was taken forward without<br>
further characterisation and was dissolved in THF (0.5ml) then treated with Burgess<br>
reagent (0.025g, ca. 0.1 mmol). The mixture was heated under microwave conditions at<br>
120Â°C (120W) for 5 min. The mixture was then concentrated in vacuo and purified by<br>
mass directed autoprep HPLC to afford Example 34 (0.006g). LCMS showed MH+ =<br>
385; TRET = 2.65min.<br>
Similarly prepared, via the original or alternative embodiment described above, and using<br>
the same or similar number of moles of reagents and volumes of solvents, were the<br>
following:<br><br><br><br>
An alternative method of preparing Example 35 is now described:<br>
A solution of Intermediate 27 (0.463g, 2.93mmol), TBTU (0.941g, 2.93mmol) and<br>
DIPEA (1.53ml, 8.79mmol) in dry dimethylformamide (7ml) was stirred at room<br>
temperature for 15min. A solution of Intermediate 19 (1.0g, 2.93mmol) in dry<br>
dimethylformamide (5ml) was then added and stirring was continued for lh. The mixture<br>
was concentrated in vacuo, and the residue was dissolved in methanol (5ml) and applied<br>
equally to two SPE cartridges (aminopropyl, 10g). The cartridges were eluted with<br>
methanol. The product-containing fractions were combined and evaporated to give a<br>
yellow oil (1.56g) which was dissolved in dichloromethane (10ml) and applied to a SPE<br>
cartridge (silica, 10g). The cartridge was eluted with chloroform-methano1-triethylamine<br>
(9/0.2/0.1). Fractions containing the desired product were combined and evaporated to<br>
give a pale yellow foam (1.17g). This product was suspended in dry tetrahydrofuran<br>
(45ml) and treated with Burgess reagent (1.244g, 5.22mmol) at room temperature under<br>
nitrogen. The resulting solution was heated at 70Â°C. After 2h, the reaction mixture was<br>
evaporated and the residual oil was dissolved in dichloromethane (5ml) and applied to a<br>
SPE cartridge (silica, 20g). The cartridge was eluted with chloroform-methano1-<br>
triethylamine (9/0.2/0.1). Fractions containing the desired material were combined and<br>
evaporated to give a cream solid. Further purification by passage through a SCX cartridge<br>
(20g) eluting with methanol followed by 10% ammonia in methanol afforded Example 35<br><br><br><br>
A solution of Intermediate 19 (0.05g, 0.133 mmol), TBTU (0.045g, 0.14 mmol) and<br>
DIPEA (0.1ml, ca. 0.5 mmol) in DMF (1ml) is stirred at room temperature under nitrogen<br>
for 5 min. A solution of Intermediate 30 (0.018g, 0.14 mmol) in DMF (1ml) is then added<br>
and stirring continued for 18h. Reaction can be found to be incomplete after this time so a<br>
further portion of Intermediate 30 (0.009g, 0.07 mmol) is added and stirring continued<br>
under nitrogen for a further 18h. The mixture is concentrated in vacuo then the residue<br>
applied to an SPE cartridge (aminopropyl, 2g), which is eluted with methanol (2x3ml).<br>
Fractions containing desired material are concentrated in vacuo. The partially purified<br>
intermediate is taken forward without further characterisation and is dissolved in THF<br>
(0.5ml) then treated with Burgess reagent (0.025g, ca. 0.1 mmol). The mixture is heated<br>
under microwave conditions at 120Â°C (120W) for 5 min. Reaction can appear incomplete<br>
so a further portion of Burgess Reagent (0.012g, ca. 0.05 mmol) is added and the mixture<br>
heated under microwave conditions at 140Â°C (120W) for a further 10 min. The mixture<br>
is then concentrated in vacuo and purified by mass directed autoprep HPLC to afford<br>
Example 38.<br>
According to an alternative and more preferred embodiment, the reaction was performed<br>
as follows. A solution of carboxylic acid Intermediate 30 (0.018g, 0.14 mmol), TBTU<br>
(0.045g, 0.14 mmol) and DIPEA (0.1ml, ca. 0.5 mmol) in DMF (1ml) was stirred at room<br>
temperature under nitrogen for 5 min. A solution of Intermediate 19 (0.05g, 0.133 mmol)<br>
in DMF (1ml) was then added and stirring continued for 18h. Reaction was found to be<br>
incomplete after this time so a further portion of Intermediate 30 (0.009g, 0.07 mmol)<br>
was added and stirring continued under nitrogen for a further 18h. The mixture was<br>
concentrated in vacuo then the residue applied to an SPE cartridge (aminopropyl, 2g),<br>
which was eluted with methanol (2x3ml). Fractions containing desired material were<br>
concentrated in vacuo. The partially purified intermediate was taken forward without<br>
further characterisation and was dissolved in THF (0.5ml) then treated with Burgess<br>
reagent (0.025g, ca. 0.1 mmol). The mixture was heated under microwave conditions at<br>
120Â°C (120W) for 5 min. Reaction appeared incomplete so a further portion of Burgess<br>
Reagent (0.012g, ca. 0.05 mmol) is added and the mixture heated under microwave<br>
conditions at 140Â°C (120W) for a further 10 min. The mixture was then concentrated in<br>
vacuo and purified by mass directed autoprep HPLC to afford Example 38 (0.006g).<br>
LCMS showed MH+ = 399; TRET = 2.64min.<br><br>
Similarly prepared, via the original or alternative embodiment described above, and using<br>
the same or similar number of moles of reagents and volumes of solvents, were the<br>
following:<br><br>
An alternative method of preparing Example 38 is now described:<br>
A mixture of Intermediate 30 (0.325g, 2.5mmol), TBTU (0.803g, 2.5mmol) and DDPEA<br>
(1.75ml, 10.04mmol) in N,N-dimethylformamide (10ml) was stirred at 20 Â°C for 20<br>
minutes. A suspension of Intermediate 19 (1.024g, 3.00mmol) in N,N-<br>
dimethylformamide was added and the reaction mixture stirred for 18 hours. The solvent<br>
was evaporated and the residue applied to SPE cartridges (2 x 50g, aminopropyl). The<br>
cartridges were eluted with dichloromethane:memanol (0 - 100% methanol over 17<br>
minutes at 25ml/min). Appropriate fractions were evaporated in vacuo and the residue<br>
dissolved in tetrahydrofuran (10ml). Burgess Reagent (0.746g, 3.13mmol) was added<br>
and the reaction mixture was heated at reflux for 2.5 hours. Additional Burgess Reagent<br>
(0.284g) was added and heating continued for 1.5 hours. The solvent was evaporated in<br>
vacuo. The residue was applied to an SPE cartridge (silica, lOOg) and eluted with<br>
cyclohexane:ethyl acteate (gradient of 0 to 100% ethyl acetate over 25 minutes at<br>
25ml/min) followed by ethyl acetate then ethyl acetate:methanol (4:1). Appropriate<br>
fractions were combined and evaporated to give Example 38 as a white solid (0.503g).<br>
LCMS showed MH+ = 399, TRET = 2.67min. 1H NMR (400MHz in CDC13, 27Â°C, Î´ppm)<br><br><br>
Intermediate 33 (0.055g, 0.14mmol) and Burgess reagent (0.037g, 0.16mmol) were<br>
suspended in THF (2ml) and heated at reflux for 4 hours. Solvents were removed in<br>
vacuo and the residue applied to an SPE cartridge (silica, 2g), which was eluted with<br>
cyclohexane:ethyl acetate (1:2). Concentration in vacuo afforded Example 40A (0.03g).<br>
LCMS showed MH+ = 374, TRET = 2.78min.<br><br>
The compound of Example 41 was synthesised using the following route, reagents and<br>
solvents:<br><br><br>
In one embodiment, a suitable detailed procedure for the first two steps is given above in<br>
"Intermediate 33" and "Example 40A". In one embodiment, a suitable detailed procedure<br>
for synthesising Example 41 from Example 40A is as follows:<br>
Example 40A (0.023g, 0.062mmol) and DBU (0.028g, 0.18mmol) were dissolved in<br>
carbon tetrachloride/acetonitrile/pyridine (2:3:3, 1.6ml) and stirred at room temperature<br>
under nitrogen for 48 hours. Solvents were removed in vacuo and the residue was<br>
purified by mass directed autoprep HPLC to afford Example 41 (0.0017g). LCMS<br>
showed MH+ = 372, TRET = 9.24min.<br><br><br>
Intermediate 34 (0.095g, 0.27mmol) and Burgess reagent (0.071g, 0.30mmol) were<br>
dissolved in THF (2ml) and heated at reflux for 4 hours. Solvents were removed in vacuo<br>
and the residue applied to an SPE (silica, 5g), which was eluted with ethyl acetate to<br>
afford Example 42 (0.045g). LCMS showed MH+ = 330, TRJET= 2.84min.<br><br>
Example 43 was synthesised according to the following reaction scheme:<br><br><br>
Detailed conditions which can be used for the first six reactions from Intermediate 1 to<br>
Intermediate 40 are given in the "Intermediate" syntheses hereinabove for Intermediates<br>
35,36, 37, 38, 39 and 40.<br><br>
Example 43 can be made from Intermediate 40 using a similar process to mat described<br>
for Example 1,2, 3, using a similar or the same number of moles of reagents and/or<br>
volumes of solvents. LCMS showed MH+ = 343, TRET = 2.70min.<br><br>
A solution of Tetrahydro-2-furoic acid = 2-(tetrahydrofuran)carboxylic acid<br>
(commercially available from Sigma-Aldrich) (0.012ml, 0.12mmol), TBTU (0.039g,<br>
0.12mmol) and DIPEA (0;084ml, 0.48mmol) in DMF (2ml) was stirred at room<br>
temperature under nitrogen. Intermediate 19 (0.045g, 0.12mmol) was added and the<br>
reaction stirred for 2 days. The mixture was concentrated in vacuo then the residue<br>
applied to an SPE cartridge (aminopropyl, 5g), which was eluted with methanol.<br>
Fractions containing the desired material were concentrated in vacuo. Half of the<br>
partially purified material was dissolved in THF (0.1ml) and treated with Burgess reagent<br>
(0.015g, 0.06mmol). The mixture was heated under microwave conditions at 120 Â°C<br>
(100W) for 5 minutes. The mixture was then concentrated in vacuo and applied to an<br>
SPE cartridge (silica, 0.5g). The cartridge was eluted with dichloromethane: methanol<br>
(19:1), fractions containing the desired material were concentrated in vacuo. The sample<br>
was then partitioned between dichloromethane and water, the organic phase was<br>
evaporated to give Example 44 (0.0065g). LCMS showed MH+ =385, TRET = 2.69rnin.<br><br>
Intermediate 86 (0.113g, 0.28mmol) and Burgess Reagent (0.133g, 0.56mmol) in THF<br>
(lml) were heated in the microwave 5 minutes at 120 Â°C SmithCreator Microwave. The<br><br>
sample was evaporated in vacuo and the residue purified by mass directed autoprep<br>
HPLC...LCMS showed MH+ = 358; TRET = 2.57min<br><br>
A solution of the Intermediate 19 (0.1g, 0.29mmol), diisopropylethylamine (0.3ml,<br>
1.74rmnol) and methyl acetimidate hydrochloride (0.095g, 0.87mmol, commercially<br>
available from Aldrich) in ethanol (3ml) was heated under reflux. After 17h, the reaction<br>
mixture was evaporated to an oily residue which was partitioned between<br>
dichloromethane (10ml) and water (2ml). The phases were separated and the organic<br>
phase was dried over anhydrous sodium sulphate and evaporated to a waxy solid<br>
(0.053g). Purification of a portion of this solid (0.025 g) by mass directed autoprep HPLC<br>
afforded Example 46 (0.005g). LCMS showed MH+ = 328; TRET = 2.25min.<br><br>
A mixture of Intermediate 41 (0.049mg, 0.14mmol), Intermediate 9 (0.051g, 0.68mmol),<br>
sodium ethoxide (0.13ml, 21% solution in ethanol, commercially available from Aldrich)<br>
and powdered 4A molecular sieves (0.3g) in ethanol (2ml) were heated at 80 Â°C for 16<br>
hours under nitrogen. The mixture was cooled and filtered and the filtrate concentrated in<br>
vacuo. The residue was applied to an SPE cartridge (silica, 5g) and eluted with<br>
cyclohexane, cyclohexane: ethyl acetate (1:1) and then ethyl acetate. The desired<br>
fractions were combined and evaporated to give Example 47 (0.005g). LCMS showed<br>
MH+ = 370; TRET = 2.77min<br><br><br>
Example 48 was prepared from Intermediate 41 and Intermediate 24 using an analogous<br>
method to that for Example 47. LCMS showed MH+ = 455; TRET = 2.59mm.<br><br>
Burgess reagent (0.189g, 0.79mmol) was added portionwise, over 3min, to a stirred<br>
solution of Intermediate 42 (0.293g, 0.72mmol) in dry tetrahydrofuran (13ml) at room<br>
temperature under nitrogen. The resulting solution was heated at 70Â°C under nitrogen for<br>
4h. The reaction mixture was evaporated to give an off-white solid which was dissolved<br>
in dichloromethane (5ml) and applied to a SPE cartridge (silica, lOg). The cartridge was<br>
eluted sequentially with a gradient of ethyl acetate-petroleum ether (1:8,1:4,1:2,1:1,<br>
1:0). Fractions containing the desired product were combined and evaporated to afford<br>
Example 49 as a white crystalline solid (0.169g). LCMS showed MH+ = 392; TRET =<br>
3.31min.<br><br><br><br>
Example 50 was prepared from Intermediate 43 using an analogous method to that for<br>
Example 49. LCMS showed MH+ = 392; TRET = 3.32min.<br><br>
Example 51 was prepared from Intermediate 44 using an analogous method to that for<br>
Example 49. LCMS showed MH+ = 406; TRET = 3.38min<br><br>
Example 52 was prepared from Intermediate 45 using an analogous method to that for<br>
Example 49. LCMS showed MH+ = 406; TRET = 3.38min.<br><br><br>
Example 53 was prepared from Intermediate 46 using an analogous method to that for<br>
Example 49. LCMS showed MH+ = 406; TRET = 3.37min.<br><br>
Example 54 was prepared from Intermediate 47 using an analogous method to that for<br>
Example 49. LCMS showed MH+ - 392; TRET = 3.29min.<br><br><br>
Example 55 was prepared from Intermediate 48 using an analogous method to that for<br>
Example 49. LCMS showed MH+ = 392; TRET = 3.29min.<br><br>
Example 56 was prepared from Intermediate 49 using an analogous method to that for<br>
Example 49. LCMS showed MH+ = 344; TRET = 2.95min.<br><br>
A solution of lithium hydroxide (0.12g, 5.2mmol) in water (6ml) was added to a<br>
suspension of Example 41 (0.48g, 1.3mmol) in methanol (20ml) and the resultant mixture<br>
heated at 50 Â°C for 2 hours. The solvent was evaporated in vacuo and the residue<br>
dissolved in water (50ml), cooled in an ice bath and acidified to pH 3 by the addition of<br>
aqueous hydrochloric acid. The precipitate was filtered, washed with water and dried in<br>
vacuo at 40 Â°C to give Example 57 as a white solid (0.3g). LCMS showed MH+ = 358;<br>
TRBT = 2.62min<br><br><br>
A mixture of Example 57 (0.05g, 0.14mmol), HOBT (0.023g, 0.17mmol), EDC (0.038g,<br>
0.2mmol) in DMF (2ml) were stirred at 20 Â°C for 20 minutes. isopropylamine (0.013ml,<br>
0.15mmol) was added and the reaction mixture stirred overnight. The solvent was<br>
concentrated in vacuo and the residue dissolved in DCM. The organic phase was washed<br>
with water then aqueous sodium hydrogen carbonate solution. The aqueous phases were<br>
extracted with DCM and the combined organic phases concentrated in vacuo. The<br>
residue was applied to an SPE cartridge (aminopropyl, 2g) and eluted with MeOH,<br>
appropriate fractions were combined and evaporated in vacuo. The residue was further<br>
purified by chromatography on SPE (silica, 0.5g) eluting with cyclohexane-.ethyl acetate<br>
(2:1 followed by 1:1) to give Example 58 as a white solid (0.012g). LCMS showed MH+<br>
= 399; TRET = 2.78min<br>
Similarly prepared using the same or similar numbers of moles of reagents and/or<br>
volumes of solvents was the following:<br><br>
Intermediate 53 (0.076g, 0.21mmol) in phosphorous oxychloride (3ml) was heated at 120<br>
Â°C for 3 hours then evaporated in vacuo. The residue was partitioned between DCM and<br><br>
water and the organic phase concentrated in vacuo. The residue was purified by mass<br>
directed autoprep HPLC to afford Example 60 (0.027g). LCMS showed MH+ = 343; TRET<br>
= 2.34min<br><br>
Intermediate 54 (0.072g, 0.63mmol), Intermediate 12 (0.150g, 0.57mmol) and<br>
diisopropylethylamine (0.51ml) in acetonitrile (3ml) were heated at 85 Â°C for 18 hours<br>
then evaporated in vacuo. The residue was partitioned between DCM and water and the<br>
organic phase concentrated in vacuo. The residue was purified by mass directed autoprep<br>
HPLC to afford Example 61 (0.004g). LCMS showed MH+ = 343; TRET = 2.48min<br>
Similarly prepared using the same or similar numbers of moles of reagents and/or<br>
volumes of solvents were the following:<br><br><br>
Intermediate 61 (0.266g, 0.56mmol) in phosphorous oxychloride (10ml) was heated at<br>
120 Â°C for 1.5 hours then evaporated in vacuo. The residue was partitioned between<br>
DCM and water and the organic phase concentrated in vacuo. The residue was purified<br>
on an SPE cartridge (silica, 5g) eluting with cyclohexane: ethyl acetate (2:1,1:1 then 2:3)<br>
to afford Example 65 (0.042g). LCMS showed MH+ = 385; TRET = 3.05min.<br><br>
Intermediate 64 (0.05g, 0.1 lmol) and Burgess Reagent (0.053g, 0.22mol) in a mixture of<br>
THF / DMF (1ml, 1:1) were heated under microwave conditions at 120 Â°C (120W) for 5<br>
minutes. The reaction mixtures were heated at 150 Â°C for four 10 minutes intervals with<br>
an additional portion of Burgess reagent (0.025g) being added after the first and third<br>
period of additional microwave heating. The reaction mixture was concentrated in vacuo<br>
and purified by SPE (silica, 0.5g) eluting with cyclohexane, cyclohexane: ethyl acetate<br>
(2:3 then 1:4) then ethyl acetate. Fractions containing the desired material were<br>
evaporated in vacuo to afford Example 66 (O.OlOg). LCMS showed MH+ = 413; TRET =<br>
2.63min.<br><br>
Intermediate 65 (0.05g, 0.13mmol) and Burgess Reagent (0.07g, 0.3mmol) in THF (2ml)<br>
was heated at 80 Â°C for 7 hours. The reaction mixture was concentrated in vacuo and a<br>
further portion of Burgess Reagent (0.07g, 0.3mmol) in THF (0.5ml) was added and the<br>
reaction mixture refiuxed for 18 hours. The reaction was concentrated in vacuo and<br>
partitioned between DCM and water. The phases were separated using a hydrophobic frit<br>
(Whatman PTFE Filter Media with Polypropylene Housing 5ÂµM pore size). The organic<br><br>
phase was concentrated in vacuo and the residue purified by mass directed autoprep<br>
HPLC to afford Example 67 (0.018g). LCMS showed MH+ = 369; TRET = 3.03min.<br>
Similarly prepared using the same or similar numbers of moles of reagents and/or<br>
volumes of solvents were the following:<br><br><br><br>
Alternative Procedure:<br>
Burgess Reagent (0.168g, 0.74mmol) was added to a solution of Intermediate 75 (0.141g,<br>
0.33mmol) in tetrahydrofuran (2ml). The reaction mixture was heated at reflux for 1.5<br>
hours then evaporated. The residue was applied to an SPE cartridge (silica, 10g) and<br>
eluted with cyclohexane:ethyl acteate (gradient of 0 to 100% ethyl acetate over 15<br>
minutes at 15ml/min) followed by ethyl acetate then ethyl acetate:methanol (4:1).<br>
Appropriate fractions were combined and evaporated to give Example 77 as a white solid<br><br>
Intermediate 79 (0.18mmol) and Burgess Reagent (0.14g, 0.6mmol) in THF (0.75ml) was<br>
heated at 80 Â°C under an atmosphere of nitrogen for 16 hours. The reaction was<br>
concentrated using a stream of nitrogen and the residue dissolved in DCM (8ml). The<br>
solution was stirred with water and the phases separated using a hydrophobic frit<br>
(Whatman). The organic phase was concentrated in vacuo and the material was purified<br>
by mass directed auotprep HPLC to afford Example 81 (0.005g). LCMS showed MH4" =<br>
440; TRET = 2.52min.<br><br><br>
A mixture of Intermediate 16 (0.064g, 0.2mmol), Intermediate 80 (0.172g, lmmol), a<br>
solution of sodium ethoxide in EtOH (0.19ml, 21% solution) and powdered 4A molecular<br>
sieves (0.3 8g) in EtOH (2ml) were stirred at 82 Â°C under an atmosphere of nitrogen for<br>
18 hours. The reaction mixture was filtered, the solvent was evaporated in vacuo and the<br>
residue was applied to an SPE cartridge (silica, 2g). The cartridge was eluted with (i)<br>
cyclohexane, (ii) cyclohexane: ethyl acetate (4:1, 3:2,1:1,2:3,1:4), (iii) EtOAc, (iv)<br>
MeOH and (v) 10% aqueous NH3 solution in MeOH to afford Example 82 as a white<br>
solid (0.038g). LCMS showed MH+ = 427; TRET = 2.10min.<br>
Similarly prepared from Intermediate 16, using the same or similar numbers of moles of<br>
reagents and/or volumes of solvents, were the following:<br><br><br>
Examples 85 to 96 - various 5-{3-[substituted]-l,2,4-oxadiazol-5-yl}-1-ethyl-N-<br>
(tetrahydro-2H-pyran-4-yI)-1H-pyrazolo[3,4-b]pyridin-4-amines<br>
Examples 85 to 96 can be prepared from Intermediate 16 using a similar processes to<br>
those described for any of Examples 28-31 or 82-84, using a similar or the same number<br>
of moles of reagents and/or volumes of solvents.<br>
Alternatively, Examples 85 to 90 and Examples 95 to 96 (all amides) can be prepared<br>
from the corresponding carboxylic acid compound Intermediate 83, by activating the<br>
carboxylic acid moiety (e.g. using a coupling agent such as EDC, HATU or more<br>
preferably TBTU) and reacting the activated carboxylic acid with the appropriate amine<br>
R10R11NH. This reaction, preferred reagents, and the structure of Intermediate 83 is<br>
shown in the following scheme (Intermediate 83 has the same structure as Example 84<br>
but the 1,2,4-oxadiazole side-chain Rx is -CH2-C(O)OH):<br><br>
As shown in the scheme above, Intermediate 83 can be prepared by hydrolysis of the<br>
corresponding t-butyl ester compound Intermediate 84 (wherein the 1,2,4-oxadiazole<br>
side-chain R.X is -CH2-C(O)-0-tBu). Intermediate 84 can be prepared from Intermediate<br>
17 and Intermediate 85 as shown in the scheme above. The preparation of Intermediate<br>
85 has been shown earlier.<br><br>
In an alternative embodiment, Examples 85 to 90 and Examples 95 to 96 can be prepared<br>
from reaction of carboxylic acid Intermediate 83 with R10R11NH as shown above, but<br>
the Intermediate 83 (wherein the 1,2,4-oxadiazole side-chain Rx is -CH2-C(O)OH)<br>
might be preparable from Example 84, by hydrolysing the amide bond within Rx in<br>
Example 84 to form the carboxylic acid Intermediate 83.<br>
The example numbers and corresponding structures of Examples 85 to 96 are as follows:<br><br>
N,N-Dimethylformamide (0.1ml) was added dropwise to a stirred mixture of Intermediate<br>
83 (0.525g, 1.40mmol) and oxalyl chloride (0.18ml, 2.1mmol) in dichloromethane (15ml)<br>
at 0 Â°C under an atmosphere of nitrogen. The resultant mixture was stirred at 0 Â°C for 1<br>
hour.<br>
An aliquot of the above solution (1.1ml) was added to a solution of the amine<br>
(0.6mmol) in dichloromethane (0.5ml). The reaction mixture was allowed to stand at<br>
room temperature for 2 hours then applied to an SPE cartridge (aminopropyl, 2g). The<br>
cartridge was eluted with chloroform then ethyl acetate / methanol (9:1). Fractions<br>
containing the product were concentrated and the residue purified by SPE cartridge<br>
(silica, 5g) eluting with dichloromethane, ether, ethyl acetate then ethyl acetate /<br>
methanol (9:1). The desired fractions were concentrated to afford the examples given<br>
below.<br><br><br>
A mixture of Intermediate 16 (0.059g, 0.2mmol), Intermediate 121 (0.161g, 1.54mmol), a<br>
solution of sodium ethoxide in EtOH (0.21ml, 21% solution) and powdered 4A molecular<br>
sieves (0.43g) in EtOH (1.5ml) were stirred at 82 Â°C under an atmosphere of nitrogen for<br>
18 hours. The reaction mixture was filtered and the residue purified by mass directed<br>
autoprep HPLC to afford Example 92 (0.007g). LCMS showed MH+ = 428; TRET =<br>
2.46min.<br><br><br>
A mixture of Intermediate 16 (0.098g, 0.31mmol), Intermediate 122 (0.24g, 0.93mmol), a<br>
solution of sodium ethoxide in EtOH (0.21ml, 21 % solution) and powdered 4A molecular<br>
sieves (0.43 g) in EtOH (1.5ml) were stirred at 82 Â°C under an atmosphere of nitrogen for<br>
18 hours. The reaction mixture was filtered and the residue purified by mass directed<br>
autoprep HPLC to afford Example 93 (0.079g). LCMS showed MH+ = 411; TRET =<br>
3.80min.<br><br>
General Procedure for Example 95 to 96:<br>
N,N-Dimethylformamide (0.1ml) was added dropwise to a stirred mixture of Intermediate<br>
83 (0.525g, 1.40mmol) and oxalyl chloride (0.18ml, 2.1mmol) in dichloromethane (15ml)<br>
at 0 Â°C under an atmosphere of nitrogen. The resultant mixture was stirred at 0 Â°C for 1<br>
hour.<br>
An aliquot of the above solution (1.1ml) was added to a solution of the R10R11NH amine<br>
(0.6mmol) in dichloromethane (0.5ml). The reaction mixture was allowed to stand at<br>
room temperature for 2 hours then applied to an SPE cartridge (aminopropyl, 2g). The<br>
cartridge was eluted with chloroform then ethyl acetate / methanol (9:1). Fractions<br>
containing the product were concentrated and the residue purified by SPE cartridge<br>
(silica, 5g) eluting with dichloromethane, ether, ethyl acetate then ethyl acetate /<br><br><br><br>
Examples 97 to 125 -various 5-{5-[substituted]-l,3,4-oxadiazo1-2-yl}-1-ethyl-N-<br>
(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amines<br>
Examples 97 to 125 can be made using processes similar to those described for any of<br>
Examples 9,14, 32-40,44-45,60-64, 65-66, and 67-81, using a similar or the same<br>
number of moles of reagents and/or volumes of solvents.<br>
ExajmjpjeJ7:1-Ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(lH-l,2,3-triazo1-1-<br>
ylmethyI)-l,3,4-oxadiazo1-2-yI]-1H-pyrazolo[3,4-6]pyridin-4-amine<br><br>
General Procedure for preparation of Examples 97 to 125:<br>
A mixture of diacyl hydrazide Intermediate (one of Intermediates 89-114) and Burgess<br>
Reagent (2 equivalents) in N,N-dimethylformamide (1ml) was heated in a microwave for<br>
10 minutes at 120 Â°C at 150 Watts. The resultant solution was concentrated in vacuo and<br>
partitioned between chloroform and water. The organic phase was separated using a<br>
hydrophobic frit (Whatman PTFE Filter Media with Polypropylene Housing 5pM pore<br>
size) then concentrated. The residue was purified by mass directed auto-prep HPLC.<br>
As either formic acid or trifluoroacetic acid are used in the solvents in the mass directed<br>
auto-prep HPLC procedure (see "Machine Methods section hereinbefore), some of the<br>
Examples were isolated as the formate salt or trifluoroacetate salt as shown below.<br>
The example numbers and corresponding structures of Examples 97 to 125 are as<br>
follows:<br><br><br><br><br><br>
Examples 126 to 147-various 5-{4-[substituted]-oxazoI-2-yl}-1-ethyl-N-(tetrahydro-<br>
2H-pyran-4-yl)-1H-pyrazoIo[3,4-b]pyridin-4-amines<br>
Examples 126 to 147 (all amides) can be prepared by reacting Example 57 and the<br>
appropriate amine to form the amide bond using a process similar to that described for<br>
Example 58, except mat HATU is preferably used instead of EDC as coupling agent, and<br>
using a similar or the same number of moles of reagents andVor volumes of solvents as in<br>
Example 58.<br>
Example 126: 2-[1-Ethv1-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-<br>
6]pyridin-5-yl]-N-(phenylmethyl)-l,3-oxazole-4-carboxamide<br><br>
General Procedure for Examples 126 to 147:<br>
A mixture of Example 57 (0.014g, 0.04mmol), diisopropylethylamine (0.0017ml,<br>
0.096mmol) and HATU (0.016g, 0.042mmol) in N,N-dimethylformamide (0.4ml) was<br>
allowed to stand for 10 minutes. The resultant solution was added to the appropriate<br>
amine R10R11NH (0.05mmol) and mixture agitated by sonication. After standing for 18<br>
hours the solvent was removed in vacuo. The residue was applied to an SPE cartridge<br>
(aminopropyl, 0.5g) and the cartridge eluted with chloroform (1.5ml) followed by ethyl<br>
acetate : methanol (9:1,2ml). Appropriate fractions were evaporated in vacuo and the<br>
residue purified by mass directed auto-prep HPLC<br>
The example numbers and corresponding structures of Examples 126 to 147 are as<br>
follows:<br><br><br><br><br><br>
N,N-Dimethylformamide (0.1ml) was added dropwise to a stirred mixture of Intermediate<br>
83 and oxalyl chloride (0.18ml, 2.1mmol) in dichloromethane (15ml) at 0 Â°C under an<br>
atmosphere of nitrogen. The resultant mixture was stirred at 0 Â°C for 1 hour.<br>
An aliquot of the above solution (1.1ml) was added to a solution of the amine<br>
(0.6mmol) in dichloromethane (0.5ml). The reaction mixture was allowed to stand at<br>
room temperature for 2 hours then applied to an SPE cartridge (aminopropyl, 2g). The<br>
cartridge was eluted with chloroform then ethyl acetate / methanol (9:1). Fractions<br>
containing the product were concentrated and the residue purified by SPE cartridge<br>
(silica, 5g) eluting with dichloromethane, ether, ethyl acetate then ethyl acetate /<br>
methanol (9:1). The desired fractions were concentrated to afford the examples given<br>
below.<br><br><br><br>
General Procedure for Examples 157 to 158:<br>
A mixture of diacyl hydrazide Intermediate 104 or 105 and Burgess Reagent (2<br>
equivalents) in N,N-dimethylformamide (lml) was heated in a microwave for 10 minutes<br>
at 120 Â°C at 150 Watts. The resultant solution was concentrated in vacuo and partitioned<br>
between chloroform and water. The organic phase was separated using a hydrophobic frit<br>
(Whatman PTFE Filter Media with Polypropylene Housing 5yM pore size) then<br>
concentrated. The residue was purified by mass directed auto-prep HPLC<br><br><br><br>
General Procedure for Examples 159 to 165:<br>
The appropriate carboxylic acid chloride R17C(O)Cl (0.12mmol) was added to a stirred<br>
solution of amine Intermediate 118 (0.1mmol) and diisopropylethylamine (0.3mmol) in<br>
chloroform (1ml) at room temperature. After stirring at room temperature for 16h, the<br>
reaction mixture was applied to a SPE cartridge (aminopropyl, 2g) and the cartridge was<br>
eluted sequentially with chlororm, ethyl acetate and methanol. Fractions containing the<br>
desired product were combined and blown down under nitrogen. The resulting residue<br>
was further purified on a SPE cartidge (silica, 1g) eluting with a gradient of 30-100%<br>
ethyl acetate in petroleum ether. Appropriate fractions were combined and the solvents<br>
were evaporated to afford the product.<br><br><br><br>
General Procedure for Examples 166 to 172:<br>
The appropriate sulphonyl chloride R18S(O)2C1 (0.12mmol) was added to a stirred<br>
solution of amine Intermediate 118 (0.1mmol) and pyridine (0.2mrnol) in chloroform<br>
(1ml) at room temperature. After stirring at room temperature for 16h, the reaction<br>
mixture was applied to a SPE cartridge (aminopropyl, 2g,) and the cartridge was eluted<br>
sequentially with chlororm, ethyl acetate and methanol. Fractions containing the desired<br>
product were combined and blown down under nitrogen. The resulting residue was<br>
further purified on a SPE cartidge (silica, 1g) eluting with a gradient of 30-100% ethyl<br>
acetate in petroleum ether. Appropriate fractions were combined and the solvents were<br>
evaporated to afford the product.<br><br><br><br>
A solution of Intermediate 119 (45mg, 0.1mmol) in dry dimethylformamide (2ml) was<br>
added to sodium hydride (60% dispersion in mineral oil, 4.4mg, 0.11mmol), and the<br>
resulting mixture was stirred at room temperature. After 16h, the reaction mixture was<br>
diluted with water (2ml) and extracted with chloroform (3 x 5ml). The combined organic<br>
extracts were dried over anhydrous sodium sulphate and evaporated to give the crude<br>
product. Purification of the crude product on a SPE cartridge (silica, 2g) using a gradient<br>
of ethyl acetate in petroleum ether afforded Example 173. LCMS showed MH+ =412,<br>
TRET = 2.59min.<br><br><br>
A solution of Intermediate 120 (46mg, 0.1mmol) in dry dimethylformamide (2ml) was<br>
added to sodium hydride (60% dispersion in mineral oil, 4.4mg, 0.11mmol), and the<br>
resulting mixture was stirred at room temperature. After 16h, the reaction mixture was<br>
diluted with water (2ml) and extracted with chloroform (3 x 5ml). The combined organic<br>
extracts were dried over anhydrous sodium sulphate and evaporated to give the crude<br>
product. Purification of the crude product on a SPE cartridge (silica, 2g) using a gradient<br>
of ethyl acetate in petroleum ether afforded Example 174. LCMS showed MH+ =426,<br>
TRET = 2.66min.<br><br>
Acetyl chloride (0.04mmol) was added to a stirred solution of Intermediate 125<br>
(0.033mmol) and diisopropylethylamine (0.1mmol) in chloroform (1ml) at room<br>
temperature. After stirring at room temperature for 1.5h, a further quantity of acetyl<br>
chloride (0.04mmol) and diisopropylethylamine (0.1mmol) were added to the reaction<br>
mixture. After 3.5h the reaction mixture was applied to a SPE cartridge (aminopropyl,<br>
lg,) and the cartridge was eluted sequentially with chlororm, ethyl acetate and methanol.<br>
Fractions containing the desired product were combined and blown down under nitrogen,<br>
the resulting residue was further purified on a SPE cartridge (silica, lg) eluting with a<br>
gradient of 30-100% ethyl acetate in petroleum ether to afford Example 175 LCMS<br>
showed MH+ = 454, TRET = 2.79min.<br><br>
isovaleryl chloride (0.04mmol) was added to a stirred solution of Intermediate 125<br>
(0.033mmol) and diisopropylemylamine (0.1mmol) in chloroform (1ml) at room<br>
temperature. After stirring at room temperature for 1.5h, the reaction mixture was applied<br><br>
to a SPE cartridge (arninopropyl, 1g,) and the cartridge was eluted sequentially with<br>
chloroform, ethyl acetate and methanol. Fractions containing the desired product were<br>
combined and blown down under nitrogen. The resulting residue was further purified on a<br>
SPE cartridge (silica, lg) eluting with a gradient of 30-100% ethyl acetate in petroleum<br>
ether to afford Example 176. LCMS showed MH+ = 496, TRET = 3.17min.<br><br>
Methanesulphonyl chloride (1.16mmol) was added to a stirred solution of Intermediate<br>
125 (0.033mmol) and pyridine (0.5ml) in chloroform (1ml) at room temperature. After<br>
stirring at room temperature for 31h, the reaction mixture was applied to a SPE cartridge<br>
(aminopropyl, 5g) and the cartridge was eluted sequentially with chloroform, ethyl<br>
acetate and methanol. Fractions containing the desired product were evaporated in vacuo.<br>
The resulting residue was further purified on a SPE cartridge (silica, 1g) eluting with a<br>
gradient of 30-100% ethyl acetate in petroleum ether to afford Example 176. LCMS<br>
showed MH+ = 490, TRET = 2.97min.<br><br>
A mixture of Intermediate 16 (0.067g, 0.26mmol), amidoxime Intermediate 126 (0.255g,<br>
1.06mmol), a solution of sodium ethoxide in EtOH (0.87ml, 21% solution) and powdered<br>
4A molecular sieves (0.68g) in EtOH (2ml) were stirred at 82 Â°C under an atmosphere of<br>
nitrogen for 12 hours. The reaction mixture was filtered and the solvent was evaporated<br>
in vacuo. The residue was applied to an SPE cartridge (silica, 5g) and eluted with ethyl<br>
acetate: cyclohexane (0 to 70% in 10% increments). Appropriate fractions were<br>
combined and evaporated, the residue was purified further by mass directed auto prep<br>
HPLC to give Example 178 (0.011g) LCMS showed MH+ = 495; TRBT = 3.2min.<br><br>
Similarly prepared using the same or similar numbers of moles of reagents and/or<br>
volumes of solvents were the following:<br><br><br><br>
Propionic anhydride (0.015ml, 0.12mmol) was added to Intermediate 138 (0.030g,<br>
O.lmmol) in glacial acetic acid (1.5ml). The reaction mixture was stirred at room<br>
temperature for 2 hours then heated at 80 Â°C for 5 hours. The solvent was concentrated in<br>
vacuo and the residue applied to an SPE cartridge (silica, 1g). The cartridge was eluted<br>
with cyclohexane then cyclohexane:ethyl acetate (7:3). Appropriate fractions were<br>
combined and evaporated to give Example 188 as a white solid (0.015g). LCMS showed<br>
MH+ = 343; TRET - 2.92min<br><br>
4-(Dimethylamino)phenylacetic acid (0.09g, 0.504mmol) and 1-(3-<br>
dimemylarnmopropyl)-3-emylcarbodiimide hydrochloride (0.097g, 0.51mmol) in<br>
dichloromethane (1ml) were stirred at room temperature for 3 hours. The reaction<br>
mixture was concentrated then Intermediate 138 (0.07g, 0.23mmol) and diglyme (1ml)<br>
were added. After stirring at 20 C for 18 hour glacial acetic acid (0.07ml) and additional<br>
diglyme (0.5ml) were added and the mixture heated at 60 Â°C for 2 hours then at 75 Â°C for<br>
4 hours. The reaction mixture was applied to an SPE cartridge (SCX, 2g) and the<br>
cartridge eluted with methanol then 10% ammonia in methanol. The methanolic<br><br>
ammonia fractions were evaporated in vacuo and the residue purified by mass directed<br>
autoprep HPLC to afford Example 189 as a beige solid (0.004g). LCMS showed MH+ -<br>
448; TRET = 3.24min.<br><br>
Prepared from Intermediate 138 and 4-methoxyphenylacetic acid using a similar process<br>
to that described for Example 189 using similar or the same number of moles of reagents<br>
and/or volumes of solvents. LCMS showed MH+ = 435; TRET = 3.26rnin<br><br>
Example 191 was prepared from Intermediate 139 using an analogous method to that for<br>
Example 49. LCMS showed MH+ 386, TRET = 2.71min.<br><br><br>
CLAIMS<br>
A compound of formula (I) or a salt thereof:<br>
wherein:<br>
R1 is C1-3 alkyl, C1-2 fluoroalkyl or -(CH2)2OH;<br>
R2 is a hydrogen atom (H), methyl or C1 fluoroalkyl;<br>
R3 is unsubstituted branched C3-6alkyl, optionally substituted C3-8cycloalkyl, or an<br>
optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc):<br><br>
in which n1 and n2 independently are 1 or 2; and Y is O, S, SO2, or NR4; where R4 is a<br>
hydrogen atom (H), C1-2alkyl, C1-2fluoroalkyl, C(O)NH2, C(O)-C1-2alkyl, or<br>
C(O)-C1 fluoroalkyl;<br>
wherein in R3 the unsubstituted branched C3-8alkyl is isobutyl, sec-butyl, t-butyl or 3-<br>
methylbutan-2-yl;<br>
wherein in R3 the C3-8cycloalkyl is optionally substituted with one or two substituents<br>
independently being oxo (=O); OH; Cialkoxy; C1fluoroalkoxy; NHR21 wherein R21 is a<br>
hydrogen atom (H); C1-2alkyl; C1fluoroalkyl; -CH2OH; -CH2NHR22 wherein R22 is H;<br>
-C(O)OR23 wherein R23 is H; -C(O)NHR24 wherein R24 is H; -C(O)R25 wherein R25<br>
is methyl; fluoro; hydroxyimino (=N-OH); or (C1-2alkoxy)imino (=N-OR26 where R26<br>
is C1-2alkyl); and wherein any OH, alkoxy, fluoroalkoxy or NHR21 substituent is not<br>
substituted at the R3 ring carbon attached (bonded) to the -NH- group of formula (I);<br><br>
and wherein in R3 the heterocyclic group of sub-formula (aa), (bb) or (cc) is optionally<br>
substituted with one or two substituents being oxo (=O);<br>
and R3a is a hydrogen atom (H) or methyl;<br>
provided that when R3a is methyl then R3 is tetrahydro-2H-pyran-4-yl, cyclohexyl (i.e.<br>
unsubstituted), 3-hydroxy-cyclohexyl, 4-oxo-cyclohexyl or 4-(hydroxyimino)cyclohexyl;<br>
and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v):<br><br>
wherein:<br>
W1, W2, W4 and W5 are N; and W3 is NRW;<br>
X1, X3 and X4 are N or CRX; X2 is O, S or NRX; and X5 is CRX1RX2 or CRX3RX4;<br>
Y1, Y2 and Y3 are CRY or N; Y4 is O, S or NRY; and Y$ is CRY1RY2;<br>
Z1 and Z5 are O, S or NRZ; and Z2, Z3 and Z4 are N or CRZ;<br>
wherein:<br>
RW is a hydrogen atom (H);<br>
Rx, Rx2, RY and RY2 independently are:<br>
a hydrogen atom (H);<br>
Ci-galkyl;<br>
C3-6cycloalkyl optionally substituted by one or two C1-2alkyl groups and/or by one<br>
oxo (=O) group;<br>
-(CH2)n2a-C3-6cycloalkyl optionally substituted, in the -(CH2)n2a- moiety or in<br>
the C3-6cycloalkyl moiety, by a C1-2alkyl group, or optionally substituted in<br>
the C3-8cycloalkyl moiety by a -CH2C(O)NHC1-2alkyl group, wherein n2a is<br>
1,2 or 3;<br><br>
-(CH2)n3-S(O)2-R5, -CH(C1-2alkyl)-S(O)2-R5, -CMe2-S(O)2-R5, or<br>
C~3-5cycloalkyl substituted at the connecting carbon atom by -S(O)2-R5,<br>
wherein n3 is 1 or 2;<br>
and R5 is C1-2alkyl, -NR15R16, phenyl, carbon-linked-pyridinyl or<br>
benzyl (wherein the phenyl and benzyl are independently optionally<br>
substituted on the aromatic ring by one or two substituents independently<br>
being fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy, C1fluoroalkoxy<br>
or OH, and wherein the pyridinyl is optionally substituted by one methyl,<br>
methoxy or OH (including any tautomer thereof));<br>
wherein R15 is H, C1-2alkyl, phenyl, benzyl (wherein the phenyl and<br>
benzyl are independently optionally substituted on the aromatic ring by one or<br>
two substituents independently being fluoro, chloro, C1-2alkyl, C1fluoroalkyl,<br>
C1-2alkoxy or C1fluoroalkoxy), CH(Me)Ph, or carbon-linked-pyridinyl<br>
optionally substituted by one methyl, methoxy or OH (including any tautomer<br>
thereof);<br>
and R16 is H or C1-2alkyl;<br>
or wherein R15 and R16 together are -(CH2)n3a-X3a-(CH2)n3b- in which<br>
n3a and n3b independently are 2 or 3 and X3a is a bond, -CH2-, O, or NR^a<br>
wherein R8a is H or C1-2alkyl, acetyl, -S(O)2Me or phenyl, and wherein the<br>
ring formed by NR15R16 is optionally substituted on a ring carbon by one or<br>
two substituents independently being methyl or oxo (=O);<br>
-(CH2)n4-NR6R7, -CH(C1-2alkyl)-NR6R7, -CMe2-NR6R7, or C~3-5cycloalkyl<br>
substituted at the connecting carbon atom by -NR6R7, wherein n4 is 0,1, 2 or<br>
3;<br>
and R6 and R7 independently are H, C1-2alkyl, C3-6cycloalkyl,<br>
-CH2-C3-6cycloalkyl, -C(O)R17, -S(O)2R18, phenyl, benzyl (wherein the<br>
phenyl and benzyl are independently optionally substituted on the aromatic<br>
ring by one or two substituents independently being fluoro, chloro, C1-2alkyl,<br>
C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy), or carbon-linked-pyridinyl<br>
optionally substituted by one methyl, methoxy or OH (including any tautomer<br>
thereof);<br>
and wherein R17 and R18 independently are C1-6alkyl, C3-6cycloalkyl,<br>
optionally substituted 5-membered heteroaryl being furyl (furanyl) or 1,3-<br>
oxazolyl or isoxazolyl or oxadiazolyl or thienyl or 1,3-thiazolyl or isothiazolyl<br>
or pyrrolyl or imidazolyl or pyrazolyl (all independently optionally substituted<br>
by one oxo and/or one or two methyl), or phenyl or benzyl (wherein the<br>
phenyl and benzyl are independently optionally substituted on the aromatic<br>
ring by one or two substituents independently being fluoro, chloro, C1-2alkyl,<br>
C1fluoroalkyl, C1-2alkoxy, C1fluoroalkoxy or OH), or carbon-linked-<br><br>
pyridinyl optionally substituted by one methyl, methoxy or OH (including any<br>
tautomer thereof);<br>
or R6 and R7 together are -(CH2)n5-X5-(CH2)n6- in which n5 and nÂ°<br>
independently are 2 or 3 and X5 is a bond, -CH2-, O, or NR8 wherein R8 is H,<br>
C1-2alkyl, acetyl, -S(O)2Me or phenyl, and wherein the ring formed by<br>
NR6R7 is optionally substituted on a ring carbon by one or two substituents<br>
independently being methyl or oxo (=O);<br>
-(CH2)n7-0-R9; wherein n7 is 0,1, 2 or 3 and R9 is H, C1-6alkyl, C3-6cycloalkyl,<br>
-CH2-C3-6cycloalkyl, -C(O)R17, phenyl, or benzyl (wherein the phenyl and<br>
benzyl are independently optionally substituted on the aromatic ring by one or<br>
two of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or<br>
C1fluoroalkoxy); wherein n7 is 0 only when the -(CH2)n7-O-R9 is bonded to<br>
a carbon atom in the Het ring; and wherein n7 is not 0 when Het is of sub-<br>
formula (v) (i.e. n7 is not 0 for RX2 and for RY2);<br>
-(CH2)n1 C(O)-NR10R11, -CH(C1-2alkyl)-C(O)-NR10R11,<br>
-CMe2-C(O)-NR10R11, or C~3-5cycloalkyl substituted at the connecting<br>
carbon atom by -C(O)-NR10R11, wherein n11 is 0,1 or 2;<br>
and wherein R10 and R11 independently are H; C1-6alkyl;<br>
C1fluoroalkyl; C2-4alkyl substituted by one OH or -OC1-2alkyl other than<br>
at the connection point; C3-8cycloalkyl optionally substituted by one or two<br>
methyl groups; -CH2-C3-6cycloalkyl optionally substituted by one methyl,<br>
NH2 or NHMe group; -(CH2)n17-Het2; carbon-linked-pyridinyl optionally<br>
substituted by one methyl, methoxy or OH (including any tautomer thereof);<br>
phenyl; benzyl; or -CH(C1-2alkyl)Ph [wherein the phenyl, benzyl and<br>
-CH(C1-2alkyl)Ph are independently optionally substituted on the aromatic<br>
ring by one or two substituents independently being: fluoro, chloro,<br>
C1-2alkyl, C1fluoroalkyl, C1-2alkoxy, C1fluoroalkoxy, OH, -NR10aR10b<br>
(wherein R10a is H or C1-2alkyl and R10b is H C1-2alkyl, -C(O)-C1-2alkyl<br>
or -S(O)2-C1-2alkyl), -C(O)-NRl0cR10d (wherein R10c and R10d<br>
independently are H or C1-2alkyl), or -S(O)2-R10e (wherein R10e is<br>
C1-2alkyl, NH2, NHMe or NMe2)];<br>
wherein n17 is 0, 1 or 2 and wherein Het2 is a 4-, 5- or 6- membered<br>
saturated heterocyclic ring containing one O or S ring atom or one NR27 ring<br>
group wherein R27 is H, C1-2alkyl, -C(O)Me, or -S(O)2Me, wherein the Het2<br>
ring is optionally substituted on a ring carbon by one or two substituents<br>
independently being methyl or oxo (=O);<br>
and wherein when n17 is 2 then the Het2 ring can optionally contain one<br>
additional ring N atom at the Het2 ring position bonded to the -(CH2)n17-<br><br>
moiety; provided that, when Het2 contains one O or S or NR27 ring<br>
atom/group and one additional ring N atom, then the O/S/NR27 ring<br>
atom/group and the one additional ring N atom are not directly bonded to each<br>
other, and are separated by more than one carbon atom;<br>
or R10 and R11 together are -(CH2)n8-X6-(CH2)n9- in which n8 and n9<br>
independently are 2 or 3 and X6 is a bond, -CH2-, O, or NR12 wherein R12 is<br>
H, C1-2alkyl, acetyl, -S(O)2Me or phenyl, and wherein the ring formed by<br>
NR10R11 is optionally substituted on a ring carbon by one or two substituents<br>
independently being methyl or oxo (=O);<br>
-(CH2)n12-C(O)-OR13 wherein n12 is 0,1 or 2; and wherein R13 is H, C1-2alkyl,<br>
C3-6cycloalkyl, -CH2-C3-6cycloalkyl, phenyl, or benzyl (wherein the phenyl<br>
and benzyl are independently optionally substituted on the aromatic ring by<br>
one or two of (independently) fluoro, chloro, C1-2alkyl, C]fluoroalkyl,<br>
C1-2alkoxy or C1fluoroalkoxy);<br>
-(CH2)n13-C(O)-R13a wherein n13 is 0,1 or 2; and wherein R13a is a hydrogen<br>
atom (H), C1-6alkyl, C1-2ffuoroalkyl, C3-6cycloalkyl, -CH2-C3-6cycloalkyl,<br>
benzyl, or phenyl; wherein the phenyl and benzyl are independently optionally<br>
substituted on the aromatic ring by one or two of (independently) fluoro,<br>
chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy;<br>
-(CH2)n14-Het1, -CHtC1-2alkyl)-Het1, -CMe2-Het1, or C~3-5cycloalkyl<br>
substituted at the connecting carbon atom by Het1, wherein n14 is 0, 1 or 2<br>
and wherein Het1 is a 4-, 5-, 6- or 7-membered saturated heterocyclic ring;<br>
wherein said heterocyclic ring Het1 contains one O or S ring atom and/or<br>
one NR14 ring group wherein R14 is H, C1-4alkyl, C3-6cycloalkyl, benzyl,<br>
phenyl, -C(O)Rl9, or -S(O)2R19;<br>
wherein R19, independent of any other R19, is C1-6alkyl, C3-6cycloalkyl,<br>
thienyl, furyl (furanyl), or phenyl or benzyl; wherein the phenyl and benzyl<br>
are independently optionally substituted by one or two of (independently)<br>
fluoro, methyl or methoxy;<br>
and wherein said heterocyclic ring Het1 is optionally substituted (at a<br>
position or positions other than any NR14 position) by one or two oxo (=O)<br>
and/or one C1-4alkyl substituents;<br>
provided that, when the heterocyclic ring Het1 contains one O or S ring<br>
atom and one NR14 ring group then: (a) the O/S ring atom and the NR14 ring<br>
group are not directly bonded to each other, and (b) the O/S ring atom and the<br>
NR14 ring group are separated by more than one carbon atom unless Het1<br>
contains an -NR14-C(O)-O or -NR14-C(O)-S- moiety as part of the ring; or<br>
-(CH2)n10-Ar, -CH(C1-2alkyl)-Ar, -CMe2-Ar, or C~3-5cycloalkyl substituted at the<br>
connecting carbon atom by Ar, wherein n10 is 0, 1 or 2 and<br><br>
(i) Ar is phenyl optionally substituted by one or two substituents<br>
independently being fluoro, chloro, bromo, C1-2alkyl, C1-2fluoroalkyl,<br>
C1-2alkoxy, C1-2fluoroalkoxy, OH, -NR1laR11b (wherein R1la is H or<br>
C1-2alkyl and R1lb is H, C1-2alkyl, -C(O)-C1-2alkyl or -S(O)2-C1-2alkyl),<br>
cyano, -C(O)-NR11CR11d (wherein R1lc and R1ld independently are H or<br>
C1-2alkyl), -C(O)-OR1le wherein R1le is H or C1-2alkyl, or -S(O)2-R1lf<br>
(wherein R1lf is C1-2alkyl, NH2, NHMe or NMe2); or the phenyl Ar is<br>
optionally substituted at two adjacent Ar ring atoms by the two ends of a chain<br>
which is: -(CH2)4-, -(CH2)3-, or -CH=CH-CH=CH-; or<br>
(ii) Ar is an optionally substituted 5- or 6-membered heterocyclic aromatic<br>
ring containing 1, 2, 3 or 4 heteroatoms selected from O, N or S; and wherein<br>
when the heterocyclic aromatic ring Ar contains 2, 3 or 4 heteroatoms, one is<br>
selected from O, N and S and the remaining heteroatom(s) are N; and wherein<br>
the heterocyclic aromatic ring Ar is optionally substituted by one or two<br>
groups independently being C1-4alkyl or OH (including any keto tautomer of<br>
an OH-substituted aromatic ring), or the heterocyclic aromatic ring Ar is<br>
optionally substituted at two adjacent Ar ring atoms by the two ends of a chain<br>
which is: -(CH2)4-, -(CH2)3-, or -CH=CH-CH=CH-;<br>
RX1 and RY1 independently are a hydrogen atom (H), C1-2alkyl or C1fluoroalkyl;<br>
RX3 and RX4 together are -(CH2)n15-X7-(CH2)n16- wherein n15 and n16<br>
independently are 1 or 2 and X7 is a bond, -CH2-, O, or NRX5 wherein RX5 is H,<br>
C1-2alkyl, acetyl or -S(O)2Me; and<br>
RZ is a hydrogen atom (H);<br>
provided that:<br>
when R3 is the heterocyclic group of sub-formula (bb), nl is 1, and Y is NR4, then R4 is<br>
not C1-2alkyl or C1-2fluoroalkyl;<br>
when R3 is the heterocyclic group of sub-formula (aa) and Y is NR4, then R4 is not<br>
C(O)NH2, C(O)-C1-2alkyl or C(O)-C1fluoroalkyl;<br>
provided that: when R3 is the heterocyclic group of sub-formula (cc), then NR3R3a is of<br>
sub-formula (L), (m), (ml) or (m2), wherein the -NH- connection point of the NR3R3a<br>
group to the 4-position of the pyrazolopyridine of formula (I) is underlined:<br><br><br>
and provided that:<br>
where R3 is optionally substituted C3-8cycloalkyl, then any OH, alkoxy, fluoroalkoxy,<br>
-CH2OH, -CH2NHR22, -C(O)OR23, -C(O)NHR24, -C(O)R25 or fluoro substituent is at<br>
the 3-, 4- or 5-position of the R3 cycloalkyl ring (wherein, in this connection, the 1-<br>
position of the R3 cycloalkyl ring is deemed to be the connection point to the -NH- in<br>
formula (I)).<br>
2. A compound of formula (IA) or a salt thereof:<br><br>
wherein:<br>
R1 is C1-3alkyl, C1-2fluoroalkyl or -(CH2)2OH;<br>
R2 is a hydrogen atom (H), methyl or C1fluoroalkyl;<br>
R3 is unsubstituted branched C3-6alkyl, optionally substituted C3-8cycloalkyl, or an<br>
optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc):<br><br>
in which n1 and n2 independently are 1 or 2; and Y is O, S, SO2, or NR4; where R4 is a<br>
hydrogen atom (H), C1-2alkyl, C1-2fluoroalkyl, C(O)NH2, C(O)-C1-2alkyl, or<br>
C(O)-C1fluoroalkyl;<br><br>
wherein in R3 the unsubstituted branched C3-6alkyl is isobutyl, sec-butyl, t-butyl or 3-<br>
methylbutan-2-yl;<br>
wherein in R3 the C3-8cycloalkyl is optionally substituted with one or two substituents<br>
being oxo (=O), OH, C1alkoxy, C1fluoroalkoxy, or C1-2alkyl; and wherein any OH,<br>
alkoxy or fluoroalkoxy substituent is not substituted at the R3 ring carbon attached<br>
(bonded) to the -NH- group of formula (IA);<br>
and wherein in R3 the heterocyclic group of sub-formula (aa), (bb) or (cc) is optionally<br>
substituted with one or two substituents being oxo (=O);<br>
and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v):<br><br>
wherein:<br>
W1, W2, W4 and W5 are N; and W3 is NRW;<br>
X1, X3 and X4 are N or CRX; X2 is O, S or NRX ; and X5 is CRX1RX2;<br>
Y1, Y2 and Y3 are CRY or N; Y4 is O, S or NRY ; and Y5 is CRY1RY2;<br>
Z1 and Z5 are O, S or NRZ; and Z2, Z3 and Z4 are N or CRZ;<br>
wherein:<br>
RW is a hydrogen atom (H);<br>
Rx, RX2, RY and RY2 independently are:<br>
a hydrogen atom (H);<br>
C1-8alkyl;<br>
C3-6cycloalkyl optionally substituted by a C1-2alkyl group;<br>
-(CH2)n2a-C3-6cycloalkyl optionally substituted, in the -(CH2)n2a- moiety or in<br>
the C3-6cycloalkyl moiety, by a C1-2^alkyl group, wherein n2a is 1, 2 or 3;<br>
-(CH2)n3-SO2-R5 wherein n3 is 1 or 2 and R5 is C1-3alkyl or -NH-C1-2alkyl or<br>
phenyl;<br><br>
-(CH2)n4-NR6R7 wherein n4 is 0,1, 2 or 3, and R6 and R7 independently are H,<br>
C1-2galkyl, C3-6cycloalkyl, -CH2-C3-6cycloalkyl, -C(O)-C1-2alkyl, -SO2-C1-<br>
2alkyl, phenyl, or benzyl (wherein the phenyl or benzyl are independently<br>
optionally substituted on the aromatic ring by one of fluoro, chloro, C1-2alkyl,<br>
C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy); or R6 and R7 together are<br>
-(CH2)n5-X5-(CH2)n6- in which n5 and n6 independently are 2 or 3 and X5<br>
is a bond, -CH2-, O, or NR8 wherein R8 is H or C1-2alkyl;<br>
-(CH2)n7-0-R^; wherein n7 is 0, 1, 2 or 3 and R9 is H or C1-6alkyl; wherein n7 is<br>
0 only when the -(CH2)n7-O-R9 is bonded to a carbon atom in the Het ring;<br>
and wherein n7 is not 0 when Het is of sub-formula (v) (i.e. n7 is not 0 for<br>
RX2andforRY2);<br>
-C(O)-NR10R11 wherein R10 and R11 independently are H, C1-6alkyl,<br>
C3-6cycloalkyl, -CH2-C3-8cycloalkyl, phenyl, or benzyl (wherein the phenyl<br>
or benzyl are independently optionally substituted on the aromatic ring by one<br>
of fluoro, chloro, C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy);<br>
or R10 and R11 together are -(CH2)n8-X6-(CH2)n9- in which n8 and n9<br>
independently are 2 or 3 and X6 is a bond, -CH2-, O, or NR12 wherein R12 is<br>
HorC1-2alkyl;<br>
-C(O)-OR13 wherein R13 is H, C1-6alkyl, C3-6cycloalkyl, -CH2-C3-6cycloalkyl,<br>
phenyl, or benzyl (wherein the phenyl or benzyl are independently optionally<br>
substituted on the aromatic ring by one of fluoro, chloro, C1-2alkyl,<br>
C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy);<br>
-C(O)-Rl3a wherein R13a is hydrogen atom (H), C1-6alkyl, C1fluoroalkyl,<br>
C3-6cycloalkyl, -CH2-C3-6cycloalkyl, benzyl, or phenyl; wherein the phenyl<br>
or benzyl are independently optionally substituted on the aromatic ring by one<br>
of fluoro, chloro, C1-2alkyl, C1 fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy;<br>
a 4-, 5-, 6- or 7-membered saturated heterocyclic ring containing one O ring atom or<br>
one NR14 ring group wherein R14 is H or C1-2alkyl, said heterocyclic ring<br>
being optionally substituted (at a position or positions other than any NR14<br>
position) by one oxo (=O) and/or one C1-4alkyl substituent; or<br>
-(CH2)n10-Ar wherein n10 is 0, 1 or 2 and<br>
(i) Ar is phenyl optionally substituted by one or two substituents being fluoro,<br>
chloro, C1-2alkyl, C1-2fluoroalkyl, C1-2alkoxy, C1fluoroalkoxy or cyano;<br>
or<br>
(ii) Ar is an optionally substituted 5- or 6-membered heterocyclic aromatic<br>
ring containing 1, 2 or 3 heteroatoms selected from O, N or S; and wherein<br>
when the heterocyclic aromatic ring Ar contains 2 or 3 heteroatoms, one is<br>
selected from O, N and S and the remaining heteroatom(s) are N; and wherein<br><br>
the heterocyclic aromatic ring Ar is optionally substituted by one or two<br>
C1-4alkyl groups;<br>
RX1 and RY1 independently are a hydrogen atom (H), C1-2alkyl or C1fluoroalkyl; and<br>
RZ is a hydrogen atom (H);<br>
provided that:<br>
when R3 is the heterocyclic group of sub-formula (bb), n1 is 1, and Y is NR4, then R4 is<br>
not C1-2alkyl or C1-2fluoroalkyl;<br>
when R3 is the heterocyclic group of sub-formula (aa) and Y is NR4, then R4 is not<br>
C(O)NH2, C(O)-C1-2alkyl or C(O)-C1fluoroalkyl;<br>
provided that: when R3 is the heterocyclic group of sub-formula (cc), then NHR3 is of<br>
sub-formula (L), (m) or (ml), wherein the -NH- connection point of the NHR3 group to<br>
the 4-position of the pyrazolopyridine of formula (IA) is underlined:<br><br>
and provided that:<br>
where R3 is optionally substituted C3-8 cycloalkyl, then any OH, alkoxy or fluoroalkoxy<br>
substituent is at the 3-, 4- or 5-position of the R3 cycloalkyl ring (wherein, in this<br>
connection, the 1-position of the R3 cycloalkyl ring is deemed to be the connection point<br>
to the -NH- in formula (IA)).<br>
3.	A compound or salt as claimed in claim 1, wherein R3a is a hydrogen atom (H).<br>
4.	A compound or salt as claimed in claim 1, 2 or 3, wherein R^ is a hydrogen atom<br>
(H) or methyl.<br>
5.	A compound or salt as claimed in claim 1, 2, 3 or 4, wherein R1 is C2-3alkyl,<br>
C2fluoroalkyl or -(CH2)2OH.<br>
6.	A compound or salt as claimed in any preceding claim, wherein R1 is ethyl,<br>
n-propyl, C2fluoroalkyl or -CH2CH2OH.<br>
7.	A compound or salt as claimed in any preceding claim, wherein R1 is ethyl.<br><br>
8.	A compound or salt as claimed in any preceding claim, wherein in R3 there is one<br>
substituent or no substituent.<br>
9.	A compound or salt as claimed in any preceding claim, wherein, where R3 is<br>
unsubstituted branched C3-6alkyl, then R3 is (R)-3-methylbutan-2-yl or (S)-3-<br>
methylbutan-2 -yl.<br>
10.	A compound or salt as claimed in any preceding claim, wherein R3 is optionally<br>
substituted C3-8cycloalkyl or the optionally substituted heterocyclic group of sub-<br>
formula (aa), (bb) or (cc).<br>
11.	A compound or salt as claimed in any preceding claim, wherein, where R3 is<br>
optionally substituted C3-8cycloalkyl, then R3 is optionally substituted C6-8cycloalkyl.<br>
12.	A compound or salt as claimed in claim 11, wherein, where R3 is optionally<br>
substituted C3-8cycloalkyl, then R3 is optionally substituted cyclohexyl.<br>
13.	A compound or salt as claimed in any preceding claim, wherein, where R3 is<br>
optionally substituted C3-8cycloalkyl, then the one or two optional substituents is or<br>
independently are: oxo (=O); OH; NHR21 wherein R21 is a hydrogen atom (H); methyl;<br>
-CH2F; -CHF2; -C(O)OR23 wherein R23 is H; fluoro; hydroxyimino (=N-OH); or<br>
(C1-2alkoxy)imino (=N-OR26 where R26 is C1-2alkyl).<br>
14.	A compound or salt as claimed in any preceding claim, wherein, where R3 is<br>
optionally substituted C3-8cycloalkyl, then the one or two optional substituents is or<br>
independently are OH, oxo (=O) or hydroxyimino (=N-OH).<br>
15.	A compound or salt as claimed in any preceding claim, wherein, where R3 is<br>
optionally substituted C3-8cycloalkyl, then the one or two optional substituents if present<br>
is or are substituent(s) at the 3-, 4- or 5- position(s) of the R3 cycloalkyl ring, (wherein<br>
the 1-position of the R3 cycloalkyl ring is deemed to be the connection point to the -NH-<br>
in formula (I) or (IA)).<br>
16.	A compound or salt as claimed in any preceding claim, wherein, where R3 is<br>
optionally substituted C6cycloalkyl, then R3 is cyclohexyl (i.e. unsubstituted), 3-<br>
hydroxy-cyclohexyl (i.e. 3-hydroxycyclohexan-1-yl), 4-oxo-cyclohexyl (i.e. 4-<br>
oxocyclohexan-1-yl), 4-(hydroxyimino)cyclohexyl (i.e. 4-(hydroxyimino)cyclohexan-1-<br>
yl), 4-(C1-2alkoxyimino)cyclohexyl, 1-methylcyclohexyl or 3-methylcyclohexyl.<br><br>
17.	A compound or salt as claimed in any preceding claim, wherein R.4 is a hydrogen<br>
atom (H), C1-2alkyl, C(O)NH2, C(O)-Me or C(O)-CF3.<br>
18.	A compound or salt as claimed in any preceding claim, wherein R.4 is a hydrogen<br>
atom (H) or C(O)-Me.<br>
19.	A compound or salt as claimed in any preceding claim, wherein, where R.3 is the<br>
heterocyclic group of sub-formula (aa), (bb) or (cc), then Y is O.<br>
20.	A compound or salt as claimed in any preceding claim, wherein where R.3 is the<br>
heterocyclic group of sub-formula (aa), (bb) or (cc), then Ry is the heterocyclic group of<br>
sub-formula (bb) and n^ is 1.<br>
21.	A compound or salt as claimed in any preceding claim, wherein, in R3, the<br>
heterocyclic group of sub-formula (aa), (bb) or (cc) is unsubstiruted (wherein, where Y is<br>
NR4, R4 is not classified as a substituent).<br>
22.	A compound or salt as claimed in any preceding claim, wherein<br>
when R3 is the heterocyclic group of sub-formula (aa), then Y is not NR4, and<br>
when R3 is the heterocyclic group of sub-formula (bb) and Y is NR4, then R4 is<br>
not C1-2alkyl or C1-2fluoroalkyl.<br>
23.	A compound or salt as claimed in any preceding claim, wherein NHR3 or<br><br><br><br><br>
A compound or salt as claimed in claim 23, wherein NHR3 or NR3R3a is of sub-<br>
formula (c), (cl), (c 4), (c 5), (h), (i), (j), (k), (ml), (m.2), (n), (o), (o2), (o3), (p2), (p5),<br>
(r),(s)or(tl).<br>
25.	A compound or salt as claimed in claim 23, wherein NHR3 or NR3R3a is of sub-<br>
formula (c), (h), (k), (n), (o), (o2) or (s).<br>
26.	A compound or salt as claimed in claim 23, wherein NHR3 or NR3R3a is of sub-<br>
formula (c), (h), (k), (n), (o) or (s).<br>
27.	A compound or salt as claimed in claim 23, wherein<br>
NHR3 or NR3R3a is of sub-formula (h):<br><br>
28.	A compound or salt as claimed in claim 27, wherein R1 is ethyl.<br>
29.	A compound or salt as claimed in any preceding claim, wherein Het is of sub-<br>
formula (i), (ii) or (v).<br>
30.	A compound or salt as claimed in claim 29, wherein Z1 and Z5 are O.<br>
31.	A compound or salt as claimed in claim 29 or 30, wherein Het is of sub-formula<br>
(ia), (ib), (ic), (id), (ie), (if), (ig), (va), (vb) or (iia):<br><br><br>
32.	A compound or salt as claimed in claim 31, wherein Het is of sub-formula (ia),<br>
(ib),(ic),(id),(ir),(ig),(va)or(iia).<br>
33.	A compound or salt as claimed in claim 31, wherein Het is of sub-formula (ia),<br>
(ic) or (id).<br>
34.	A compound or salt as claimed in any preceding claim, wherein RW and RZ are a<br>
hydrogen atom (H).<br>
35.	A compound or salt as claimed in any preceding claim, wherein for the Het group,<br>
one of RX and RY (or RX2 and RY2) is as defined herein and the other of RX and RY<br>
(or RX2 and RY2)<br>
is a hydrogen atom (H).<br>
36.	A compound or salt as claimed in any preceding claim, wherein RX, RX2, RY<br>
and RY2 independently are:<br>
a hydrogen atom (H);<br>
C1-8alkyl;<br>
optionally substituted C3-6cycloalkyl;<br>
optionally substituted -(CH2)n2a-C3-6 cycloalkyl;<br><br>
-(CH2)n3-S(O)2-R5, -CH(Me)-S(O)2-R5, or C3cycloalkyl substituted at the<br>
connecting carbon atom by -S(O)2-R5;<br>
-(CH2)n4-NR6R7 or -CH(Me)-NR6R7;<br>
-(CH2)n7-O-R9;<br>
-(CH2)n11-C(O)-NR10R11 or-CH(Me)-C(O)-NR10R11;<br>
-(CH2)n12-C(O)-ORl3;<br>
-(CH2)n13-C(O)-Rl3a;<br>
-(CH2)n14-Het1 or-CH(Me)-Het1; or<br>
-(CH2)n10-Ar or -CH(Me)-Ar.<br>
37.	A compound or salt as claimed in any preceding claim, wherein one of RX and<br>
RY, and for Het of sub-formula (v) one of RX2 and RY2, IS:<br>
-(CH2)n4-NR6R7, -CH(Me)-NR6R7, -(CH2)n11-C(O)-NR10R11, -(CH2)n14-Het1, or<br>
-(CH2)n10-Ar.<br>
38.	A compound or salt as claimed in any preceding claim, wherein RX, RX2, RY<br>
and RY2 independently are:<br>
C1-6alkyl;<br>
optionally substituted C3-8cycloalkyl;<br>
-(CH2)n2a-C3-8cycloalkyl optionally substituted by a C1-2alkyl group; wherein<br>
n2a is 1;<br>
-(CH2)n3-S(O)2-R5 or C3cycloalkyl substituted at the connecting carbon atom by<br>
-S(O)2-Ph, wherein n3 is 1 and R5 is C1-2alkyl, -NR15R16, optionally substituted<br>
phenyl or optionally substituted benzyl; wherein R16 is H or methyl and R15 is H,<br>
C1-4alkyl or optionally substituted phenyl; or R15 and R16 together are<br>
-(CH2)n3a-X3a.(CH2)n3b- wherein n3a and n3b are 2 and X3a is a bond, -CH2-, O, or<br>
NR8a wherein R8a is C1-2alkyl or acetyl; and the ring formed by NR15R16 is not<br>
substituted on a ring carbon or is substituted on a ring carbon by one methyl or oxo (=O)<br>
substiruent;<br>
-(CH2)n4-NR6R7, -CH(Me)-NR6R7 or -CMe2-NR6R7 wherein n4 is 0 (when the<br>
-(CH2)n4-NR6R7 is bonded to a carbon atom in the Het ring) or wherein n4 is 1; and<br>
wherein R6 is H or C1-4alkyl and R7 is H, C1-4alkyl, -C(O)R17 or -S(O)2R18; or R6<br><br>
and R? together are -(CH2)n5-X5-(CH2)n6- in which n5 and n6 are 2 and X5 is a bond,<br>
-CH2-, O, or NR8, and wherein the ring formed by NR6R7 is not substituted on a ring<br>
carbon or is substituted on a ring carbon by one methyl or oxo (=O) substiruent;<br>
-(CH2)n7-O-R9, wherein n7 is 1 or 2 and R9 is H, C1-4alkyl or phenyl;<br>
-(CH2)nn-C(O)-NR10R11 ,-CH(Me)-C(O)-NR10R11 or<br>
-CMe2-C(O)-NR10R11, wherein n11 is 0 or 1,<br>
and R10 is H or C1-2alkyl,<br>
and R11 is: H; C1-6alkyl; C3-6cycloalkyl optionally substituted by one or two<br>
methyl groups; -CH2-C3-6cycloalkyl (unsubstituted); -(CH2)n17-Het2; optionally<br>
substituted carbon-linked-pyridinyl; optionally substituted phenyl, optionally substituted<br>
benzyl; or optionally substituted -CH(C1-2alkyl)Ph; wherein the phenyl, the benzyl and<br>
the -CH(C1-2alkyl)Ph are independently optionally substituted on the aromatic ring by<br>
one or two substituents independently being: fluoro, chloro, C1-2alkyl, C1fluoroalkyl,<br>
C1-2alkoxy, C1fluoroalkoxy, -NR10aR10b (wherein R10a is H or methyl and R10b is H,<br>
C1-2alkyl, -C(O)Me or -S(O)2Me), -C(O)-NR10cR10d (wherein R10c and R10d<br>
independently are H or C1-2alkyl), or -S(O)2-R10e (wherein R10e is C1-2alkyl, NH2,<br>
NHMe or NMe2); and wherein the carbon-linked-pyridinyl is preferably optionally<br>
substituted by one OH (including any keto tautomer thereof);<br>
or R10 and R11 together are -(CH2)n8-X6-(CH2)n9- in which n8 and n9 are 2<br>
and X6 is a bond, -CH2-, O, or NR12; and wherein the ring formed by NR10R11 is not<br>
substituted on a ring carbon or is substituted on a ring carbon by one methyl or oxo (=O)<br>
substiruent;<br>
-(CH2)n12-C(O)-OR13 , wherein n12 is 0 or 1, and R13 is H or C1-2alkyl;<br>
-(CH2)n13-C(O)-R13a, n13 is 0 or 1, and R13a is C1-6alkyl, C1-2fluoroalkyl,<br>
C1-2cycloalkyl, -CH2-C3-6cycloalkyl, benzyl, or phenyl (wherein the phenyl and benzyl<br>
are independently optionally substituted on the aromatic ring by one of fluoro, chloro,<br>
C1-2alkyl, C1fluoroalkyl, C1-2alkoxy or C1fluoroalkoxy);<br>
-(CH2)n14-Het1, -CH(Me)-Het1, or -CMe2-Het1, wherein n14 is 0 or 1, and Het1<br>
is 4-, 5- or 6-membered heterocyclic ring, and R14 is C1-2alkyl, C(O)R19 or S(O)2R19<br>
wherein R19 is C1-4alkyl, C3-6cycloalkyl, 2-thienyl, furan-2-yl, phenyl (unsubstituted)<br>
or benzyl (unsubstituted);<br>
or<br><br>
-(CH2)n10-Ar wherein n10 is 0 or 1.<br>
39.	A compound or salt as claimed in claim 33, or claim 34 or 38 as dependent on<br>
claim 33, wherein, for the Het group, one of RX and RY is:<br>
C1-8alkyl;<br>
optionally substituted C3-6cycloalkyl;<br>
-(CH2)n3-S(O)2-R5, -CH(C1-2alkyl)-S(O)2-R5, -CMe2-S(O)2-R5, or<br>
C~3-5cycloalkyl substituted at the connecting carbon atom by -S(O)2-R5;<br>
-(CH2)n4-NR6R7, -CH(C1-2alkyl)-NR6R7, -CMe2-NR6R7, or C~3-5cycloalkyl<br>
substituted at the connecting carbon atom by -NR6R7;<br>
-(CH2)n11-C(O)-NR10R11,-CH(C1-2alkyl)-C(O)-NR10R11,<br>
-CMe2-C(O)-NR10R11, or C~3-5cycloalkyl substituted at the connecting<br>
carbon atom by -C(O)-NR10R11;<br>
-(CH2)n14-Het1, -CH(C1-2alkyl)-Hetl, -CMe2-Het1, or C~3-5cycloalkyl substituted<br>
at the connecting carbon atom by Hetl;<br>
-(CH2)n10-Ar, -CH(C1-2alkyl)-Ar, -CMe2-Ar, or C~3-5cycloalkyl substituted at the<br>
connecting carbon atom by Ar;<br>
(i) wherein Ar is optionally substituted phenyl, or (ii) wherein Ar is an<br>
optionally substituted 5- or 6-membered heterocyclic aromatic ring;<br>
and the other of RX and RY is a hydrogen atom (H).<br>
40.	A compound or salt as claimed in claim 39, wherein, for the Het group, one of RX<br>
and RY is:<br>
-(CH2)n4-NR6R7, -CH(C1-2alkyl)-NR6R7, -CMe2-NR6R7, or C~3-5cycloalkyl<br>
substituted at the connecting carbon atom by -NR6R7;<br>
-(CH2)n11-C(O)-NRl0R11, -CH(C1-2alkyl)-C(O)-NR10R11,<br>
-CMe2-C(O)-NR10R11, or C~3-5cycloalkyl substituted at the connecting<br>
carbon atom by -C1-2-NR10R11;<br>
-(CH2)n14-Het1, -CH(C1-2alkyl)-Het1, -CMe2-Het1, or C~3-5cycloalkyl substituted<br>
at the connecting carbon atom by Hetl; or<br>
-(CH2)n10-Ar, -CH(C1-2alkyl)-Ar, -CMe2-Ar, or C~3-5cycloalkyl substituted at the<br>
connecting carbon atom by Ar;<br>
and wherein Ar is (ii) the optionally substituted 5- or 6-membered heterocyclic<br>
aromatic ring;<br><br>
and the other of RX and RY is a hydrogen atom (H).<br>
41. A compound or salt as claimed in claim 40, wherein:<br><br><br><br><br>
when RX or RY is -(CH2)n14-Het1, -CH(C1-2alkyl)-Het1, or -CMe2-Het1, then<br>
the 4-, 5-, 6- or 7-membered optionally substituted saturated heterocyclic ring Het1 is:<br>
tetrahydro-2H-pyran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl,<br><br><br><br>
Ar is an optionally substituted 5- or 6-membered heterocyclic aromatic ring being<br>
optionally substituted: furyl, thienyl, pyrrolyl, 1,3-oxazolyl, 1,3-thiazolyl, imidazolyl,<br>
oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, tetrazolyl, triazinyl, pyridazyl, pyrimidinyl,<br>
pyrazolyl, isothiazolyl (1,2-thiazolyl), or isoxazolyl (1,2-oxazolyl);<br>
wherein the Ar ring is optionally substituted by one or two independent C1-2alkyl<br>
groups or by one OH group (including any keto tautoraer thereof).<br>
42. A compound or salt as claimed in claim 40 or 41, wherein:<br>
Rl is ethyl; and<br><br>
NHR3 or NR3R3a is of sub-formula (h):<br><br>
(h) .<br><br>
43. A compound or salt as claimed in any preceding claim, which is:<br>
N-Cyclopentyl-1-ethyl-5-(5-methyl-l,3,4-oxadiazo1-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,<br>
N-Cyclopentyl-1 -ethyl-5 - {5 -[(methylsulfonyl)methyl] -1,3,4-oxadiazo1-2-yl} -1 H-pyrazolo [3,4-<br>
b]pyridin-4-amine,<br>
N-Cyclopentyl-1-ethyl-5-(5-isopropyl-l,3,4-oxadiazo1-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine,<br><br><br><br><br><br>
or a salt thereof.<br>
45. A compound or salt as claimed in any of claims 1 to 42, which is:<br><br><br><br>
or a salt thereof.<br>
46. A compound or salt as claimed in any of claims 1 to 42, which is:<br><br><br><br><br><br><br><br><br><br><br><br>
or a salt thereof.<br>
47. A compound or salt as claimed in any of claims 1 to 42, which is:<br><br><br><br>
or a salt thereof.<br>
48.	A compound or salt as claimed any preceding claim, which is the compound or a<br>
pharmaceutically acceptable salt thereof.<br>
49.	A compound or salt as claimed in any preceding claim, which is in a particle-size-<br>
reduced form, wherein the particle size (D50 value) of the size-reduced compound or salt<br>
is 0.5 to 10 microns.<br>
50.	A compound or salt as claimed in any preceding claim, for use as an active<br>
therapeutic substance in a mammal such as a human.<br>
51.	A pharmaceutical composition comprising a compound of formula (I) or (IA), as<br>
defined in any of claims 1 to 49, or a pharmaceutically acceptable salt thereof, and one or<br>
more pharmaceutically acceptable carriers and/or excipients.<br>
52.	A pharmaceutical composition as claimed in claim 51 which is suitable for and/or<br>
adapted for inhaled administration.<br>
53.	A pharmaceutical composition as claimed in claim 51 which is suitable for and/or<br>
adapted for oral administration.<br>
54.	A pharmaceutical composition as claimed in claim 51, 52 or 53, for the treatment<br>
and/or prophylaxis of an inflammatory and/or allergic disease, or of cognitive impairment<br>
in a neurological disorder, in a mammal such as a human.<br>
55.	The use of a compound of formula (I) or (IA), as defined in any of claims 1 to 49,<br>
or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the<br>
treatment and/or prophylaxis of an inflammatory and/or allergic disease, or of cognitive<br>
impairment in a neurological disorder, in a mammal such as a human.<br>
56.	A composition or the use as claimed in claim 54 or 55, wherein the composition<br>
or medicament is for the treatment and/or prophylaxis of chronic obstructive pulmonary<br><br>
disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis in a mammal such as a<br>
human.<br>
57.	A composition or the use as claimed in claim 56, wherein the composition or<br>
medicament is for the treatment and/or prophylaxis of chronic obstructive pulmonary<br>
disease (COPD) in a mammal such as a human.<br>
58.	A composition or the use as claimed in any of claims 54 to 57, wherein the<br>
composition or medicament is for oral administration and is a pharmaceutical<br>
composition as defined in claim 53.<br>
59.	The use of a compound of formula (I) or a pharmaceutically acceptable salt<br>
thereof, as defined in any of claims 1 to 49, in the manufacture of a medicament for the<br>
treatment and/or prophylaxis of: asthma, chronic obstructive pulmonary disease (COPD),<br>
atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis,<br>
eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis,<br>
Crohn's disease, reperfusion injury of the myocardium and brain, chronic<br>
glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, multiple<br>
sclerosis, cognitive impairment in a neurological disorder, depression, or pain; in a<br>
mammal such as a human.<br>
60.	A pharmaceutical composition as claimed in claim 51, 52 or 53, for use in the<br>
treatment and/or prophylaxis of: asthma, chronic obstructive pulmonary disease (COPD),<br>
atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis,<br>
eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis,<br>
Crohn's disease, reperfusion injury of the myocardium and brain, chronic<br>
glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, multiple<br>
sclerosis, cognitive impairment in a neurological disorder, depression, or pain; in a<br>
mammal such as a human.<br><br>
The invention relates to a compound of formula (I) or a salt thereof: Formula (I) wherein: Rl is C1-4alkyl, C1-3fluo-<br>
roalkyl or -(CH2)2OH; R2 is a hydrogen atom (H), methyl or C1fluoroalkyl; R3a is a hydrogen atom (H) or C1-3alkyl; R3 is optionally<br>
substituted branched C3-6alkyl, optionally substituted C3-8cycloalkyl, optionally substituted mono-unsaturated-C5-7cycloalkenyl, op<br>
tionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), or (bb) or (cc) in which nl and n2<br>
independently are 1 or 2; and Y is O, S, SO2, or NR4; and wherein Het is of sub-formula (i), or (ii), or (iii), or (iv) or (v). The com-<br>
pounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula<br>
(I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an<br>
inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD),<br>
asthma, or allergic rhinitis.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1LT0xOUC0yMDA1LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">1207-KOLNP-2005-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1LT0xOUC0yMDA1LUZPUk0gMjctMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1207-KOLNP-2005-FORM 27-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1LT0xOUC0yMDA1LUZPUk0gMjcucGRm" target="_blank" style="word-wrap:break-word;">1207-KOLNP-2005-FORM 27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1LT0xOUC0yMDA1LUZPUk0tMjcucGRm" target="_blank" style="word-wrap:break-word;">1207-KOLNP-2005-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtY29ycmVzcG9uZGVuY2UucGRm" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtZGVzY3JpcHRpb24gKGNvbXBsZXRlKS5wZGY=" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSAxMy5wZGY=" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSAxOC5wZGY=" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSAzLnBkZg==" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtZm9ybSA1LnBkZg==" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtZ3BhLnBkZg==" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtcmVwbHkgdG8gZXhhbWluYXRpb24gcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1LWdyYW50ZWQtc3BlY2lmaWNhdGlvbi5wZGY=" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005-granted-specification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1Z3JhbnRlZC1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1Z3JhbnRlZC1hc3NpZ25tZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005granted-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTIwNy1rb2xucC0yMDA1Z3JhbnRlZC1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">1207-kolnp-2005granted-claims.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="228088-an-immunogenic-analogue-of-a-human-tnf-protein.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="228090-modulation-of-the-transcription-of-pro-inflammatory-gene-products.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>228089</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1207/KOLNP/2005</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>05/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>30-Jan-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>28-Jan-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>22-Jun-2005</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>GLAXO GROUP LIMITED</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>GLAXO WELLCOME HOUSE, BERKELEY AVENUE, GREEEFORD, MIDDLESEX</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>EDLIN CHRISTOPHER DAVID</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>2</td>
											<td>HAMBLIN JULIE NICOLE</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>3</td>
											<td>JOHNSON MARTIN REDPATH</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>4</td>
											<td>JONES PAUL SPENCER</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>5</td>
											<td>LINDVALL MIKA KRISTIAN</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>6</td>
											<td>MITCHELL CHARLOTTE JANE</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>7</td>
											<td>REDGRAVE ALISON JUDITH</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>8</td>
											<td>ALLEN DAVID GEORGE</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>9</td>
											<td>COE DIANE MARY</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>10</td>
											<td>COOK CAROLINE MARY</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>11</td>
											<td>COOPER ANTHONY WILLIAM JAMES</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
										<tr>
											<td>12</td>
											<td>DOWLE MICHAEL DENNIS</td>
											<td>GLAXOSMITHKLINE, GUNNELS WOOD ROAD, STEVENAGE, HERTFORDSHIRE, SG1 2NY</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 471/04</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2003/014867</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-12-19</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>0230165.3</td>
									<td>2002-12-24</td>
								    <td>U.K.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>0230045.7</td>
									<td>2002-12-23</td>
								    <td>U.K.</td>
								</tr>
								<tr>
									<td>3</td>
									<td>0307998.5</td>
									<td>2003-04-07</td>
								    <td>U.K.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/228089-pyrazolo-3-4-b-pyridine-compounds-and-their-use-as-phosphodiesterase-inhibitors by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 08:39:30 GMT -->
</html>
